肺癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT00706862 / NCI-2009-01425

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

AI 简述这是一项III期试验，研究他拉克替醇联合标准化疗用于非小细胞肺癌。

?

适用疾病: Stage IV Non-Small Cell Lung Cancer；Stage IIIA Non-Small Cell Lung Cancer；Stage IIIB Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Agennix

正在招募 Phase 3

NCI NCT00246727 / NCI-2017-01022

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

AI 简述这是一项III期试验，研究蔬菜草药混合物的效果用于晚期非小细胞肺癌，在美国开展。

?

适用疾病: Non-Small Cell Squamous Lung Cancer；Stage IV Non-Small Cell Lung Cancer；Stage IIIB Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Sun Farm Corporation

正在招募 Phase 3

NCI NCT04267848 / NCI-2020-00751

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

AI 简述这是一项III期试验，在非小细胞肺癌标准化疗中加入免疫治疗药物。

?

适用疾病: Non-Small Cell Squamous Lung Cancer；Non-Squamous Non-Small Cell Lung Cancer；Stage II Lung Cancer
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 2, Phase 3

NCI NCT04093167 / NCI-2020-07404

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

AI 简述这是一项II/III期试验，研究ctDNA指导的免疫化疗用于肺癌。

?

适用疾病: Stage IIIB Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Canadian Cancer Trials Group

正在招募 Phase 3

NCI NCT05624996 / NCI-2022-08263

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

AI 简述这是一项III期试验，研究在常规治疗基础上增加高剂量定向放疗用于局部晚期不可手术非小细胞肺癌，在美国和加拿大开展。

?

适用疾病: Stage IIB Lung Cancer；Stage III Lung Cancer；Locally Advanced Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States，Canada
申办方: NRG Oncology

正在招募 Phase 3

NCI NCT06096844 / NCI-2023-08628

Chemotherapy Combined with Immunotherapy versus Immunotherapy alone for Older Adults with Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

AI 简述这是一项III期试验，在美国比较化疗联合免疫疗法与免疫疗法单用用于IIIB-IV期肺癌老年人。

?

适用疾病: Stage IIIB Lung Cancer；Stage IIIC Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: ECOG-ACRIN Cancer Research Group

正在招募 Phase 3

NCI NCT06265285 / NCI-2024-00637

Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

AI 简述这是一项III期试验，比较Nivolumab在家与在诊所给药用于多种癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Florida

正在招募 Phase 3

NCI NCT06498635 / NCI-2024-05588

Immunotherapy after Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

AI 简述这是一项III期试验，研究早期非小细胞肺癌术后免疫治疗。在美国等地开展。

?

适用疾病: Stage II Lung Cancer；Stage IIIA Lung Cancer；Stage IIIB Lung Cancer
干预: 未列出
地点: United States
申办方: SWOG

正在招募 Phase 3

NCI NCT06362395 / NCI-2025-05948

Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

AI 简述这是一项III期试验，研究超高剂量立体定向放疗用于肝转移，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Toronto Western Hospital

正在招募 Phase 2, Phase 3 放疗

ClinicalTrials.gov NCT02448992

Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer

AI 简述这是一项II/III期试验，研究海马保护性全脑放疗用于淋巴结阳性非小细胞肺癌脑转移预防。

?

适用疾病: Non-Small-Cell Lung Cancer (NSCLC)；Brain Metastasis
干预: hippocampal-sparing WBRT
地点: Taiwan
申办方: Chang Gung Memorial Hospital

正在招募 Phase 3 手术/操作放疗

ClinicalTrials.gov / NCI NCT02468024 / NCI-2015-01676

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

AI 简述这是一项III期试验，比较亚肺叶切除与立体定向消融放疗用于早期非小细胞肺癌，在美国、澳大利亚、加拿大、英国等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Stage IA Non-Small Cell Lung Cancer；Stage IB Non-Small Cell Lung Cancer
干预: Lung Surgery，Radiation therapy
地点: United States，Australia，Canada，United Kingdom
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT04181060 / NCI-2019-07941

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

AI 简述这是一项III期试验，研究奥希替尼联合或不联合贝伐珠单抗用于EGFR突变晚期非鳞非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Squamous Non-Small Cell Carcinoma；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: Bevacizumab，Biospecimen Collection，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2, Phase 3 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT04402788 / NCI-2020-03472

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

AI 简述这是一项II/III期试验，研究放疗联合Atezolizumab用于广泛期小细胞肺癌，在美国开展。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Extensive Stage Small Cell Lung Cancer
干预: Atezolizumab，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 器械药物

ClinicalTrials.gov / NCI NCT04585490 / NCI-2021-09500

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

AI 简述这是一项III期试验，研究放化疗和免疫治疗后个体化巩固治疗用于III期NSCLC，在美国开展。

?

适用疾病: Non Small Cell Lung Cancer；NSCLC, Stage III；Nsclc
干预: Durvalumab，Carboplatin，Pemetrexed，Paclitaxel
地点: United States
申办方: Maximilian Diehn

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05085028

A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项III期试验，比较降低频率的Pembrolizumab与标准方案用于晚期非小细胞肺癌一线治疗。

?

适用疾病: Lung Cancer, Nonsmall Cell
干预: Pembrolizumab 25 MG/ML [Keytruda]
地点: United Kingdom
申办方: Imperial College London

正在招募 Phase 3 药物其他

ClinicalTrials.gov / NCI NCT05211895 / NCI-2023-06450

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

AI 简述这是一项III期试验，研究Durvalumab联合Domvanalimab用于放化疗后不可切除III期非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage III Lung Cancer
干预: Durvalumab，Domvanalimab，Placebo
地点: United States，Belgium，Brazil，Canada 等 24 个
申办方: AstraZeneca

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT05236946

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

AI 简述这是一项III期试验，比较观察与颅脑放疗用于驱动基因突变非小细胞肺癌伴无症状脑转移。在印度开展。

?

适用疾病: Asymptomatic Brain Metastases；Driver Mutation Positive Non-small Cell Lung Cancer
干预: Stereotactic radiosurgery/whole brain radiotherapy，Tyrosine kinase inhibitor
地点: India
申办方: Tata Memorial Hospital

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT05255302

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

AI 简述这是一项II/III期试验，评估IV期肺癌患者化疗免疫诱导后免疫维持的降阶梯治疗。

?

适用疾病: Metastatic NSCLC
干预: Pembrolizumab before randomization，Chemotherapy，Pemetrexed，Pembrolizumab after randomization
地点: France
申办方: Intergroupe Francophone de Cancerologie Thoracique

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT05278052

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

AI 简述这是一项III期试验，比较标准维持治疗联合局部巩固放疗与单用标准维持治疗用于寡转移非小细胞肺癌，在印度开展。

?

适用疾病: Oligometastatic Disease；Metastatic Non Small Cell Lung Cancer
干预: Local consolidative radiation therapy，Standard maintenance therapy as decided by the treating medical oncologist
地点: India
申办方: Tata Memorial Hospital

正在招募 Phase 3 器械药物

ClinicalTrials.gov / NCI NCT05317858 / NCI-2022-09483

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

AI 简述这是一项3期试验，在美国、加拿大和韩国研究Exablate聚焦超声开放血脑屏障联合标准治疗用于非小细胞肺癌脑转移。

?

适用疾病: Brain Tumor；Non Small Cell Lung Cancer；Stage IV Lung Cancer
干预: Blood Brain Barrier Opening - Oncology，Pembrolizumab，Atezolizumab，Cemiplimab
地点: United States，Canada，South Korea
申办方: InSightec

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT05445791

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

AI 简述这是一项III期试验，研究二甲双胍联合酪氨酸激酶抑制剂用于EGFR突变非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Metformin Hydrochloride，Placebo
地点: Mexico
申办方: Instituto Nacional de Cancerologia de Mexico

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT05522660

Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

AI 简述这是一项III期试验，研究立体定向放射手术联合免疫检查点抑制剂用于黑色素瘤或非小细胞肺癌脑转移，在意大利、荷兰等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Melanoma
干预: Stereotactic radiosurgery，Immune checkpoint inhibitor
地点: Italy，Netherlands，Spain，Switzerland 等 1 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05654454

A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

AI 简述这是一项III期试验，贝伐珠单抗联合紫杉醇和卡铂对比Avastin用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Bevacizumab，Paclitaxel，Carboplatin
地点: Russia
申办方: Mabscale, LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05668650

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

AI 简述这是一项III期试验，比较Pembrolizumab生物类似药MB12与Keytruda用于IV期非小细胞肺癌，在阿根廷等地开展。

?

适用疾病: Non Small Cell Lung Cancer Metastatic
干预: Pembrolizumab，Pembrolizumab biosimilar
地点: Argentina
申办方: Laboratorio Elea Phoenix S.A.

正在招募 Phase 3 联合产品

ClinicalTrials.gov NCT05852990

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

AI 简述这是一项3期试验，研究谷氨酰胺加罗伊氏乳杆菌预防EGFR突变NSCLC靶向治疗相关腹泻。

?

适用疾病: Non-Small Cell Lung Cancer With EGFR Mutation
干预: Glutamine plus L. reuteri
地点: Mexico
申办方: Instituto Nacional de Cancerologia de Mexico

正在招募 Phase 3 生物制剂其他

ClinicalTrials.gov / NCI NCT06077760 / NCI-2023-09110

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

AI 简述这是一项III期试验，比较Intismeran autogene联合Pembrolizumab与安慰剂联合Pembrolizumab用于非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Non-Small Cell Squamous Lung Cancer；Non-Squamous Non-Small Cell Lung Cancer
干预: Intismeran autogene，Pembrolizumab，Placebo
地点: United States，Argentina，Australia，Belgium 等 29 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT06141070

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease

AI 简述这是一项III期试验，研究标准治疗加放疗用于寡转移非小细胞肺癌，在瑞典开展。

?

适用疾病: Non Small Cell Lung Cancer
干预: Standard systemic therapy + radiotherapy，Standard systemic therapy
地点: Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 3 器械药物

ClinicalTrials.gov / NCI NCT06216301 / NCI-2025-01328

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

AI 简述这是一项III期试验，研究TTFields联合Pembrolizumab和铂类化疗用于转移性非小细胞肺癌。

?

适用疾病: Metastatic Non-small Cell Lung Cancer；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: NovoTTF-200T，Pembrolizumab，Platinum based chemotherapy
地点: United States，Austria，Belgium，Czechia 等 12 个
申办方: NovoCure GmbH

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT06236438 / NCI-2024-06526

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项2/3期试验，研究Livmoniplimab联合Budigalimab加化疗对比帕博利珠单抗加化疗用于未经治疗的转移性非鳞非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: Livmoniplimab，Budigalimab，Pembrolizumab，Pemetrexed
地点: United States，Australia，Belgium，Chile 等 8 个
申办方: AbbVie

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06284317

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

AI 简述这是一项III期试验，评估在化疗、Durvalumab和手术后增加Durvalumab用于早期非小细胞肺癌的获益。

?

适用疾病: Non Small Cell Lung Cancer
干预: Adjuvant durvalumab
地点: Australia，Austria，Belgium，Estonia 等 6 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06431633

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

AI 简述这是一项III期试验，研究Sacituzumab和Zimberelimab用于术后胸部局限的非小细胞肺癌患者，在西班牙开展。

?

适用疾病: Lung Diseases；Carcinoma, Non-Small-Cell Lung；Resectable Lung Non-Small Cell Carcinoma
干预: Zimberelimab，Sacituzumab govitecan，Cisplatin，Carboplatin
地点: Spain
申办方: Fundación GECP

正在招募 Phase 3 器械药物

ClinicalTrials.gov / NCI NCT06472245 / NCI-2025-04308

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

AI 简述这是一项III期试验，比较OSE2101与多西他赛用于非小细胞肺癌，在美国、比利时等多国开展。

?

适用疾病: Patients With Non-Small Cell Lung Cancer；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: OSE2101，Docetaxel，NGS HLAA2 assay
地点: United States，Belgium，Canada，France 等 10 个
申办方: OSE Immunotherapeutics

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06486142

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

AI 简述这是一项III期试验，比较Afatinib/Dacomitinib与Osimertinib用于EGFR突变非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Afatinib/Dacomitinib，Osimertinib
地点: Sweden
申办方: Region Skane

正在招募 Phase 3 手术/操作放疗

ClinicalTrials.gov NCT06500455

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

AI 简述这是一项III期试验，比较长疗程放疗与常规放疗用于脑转移瘤，在美国、加拿大等地开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Digestive System Carcinoma
干预: Computed Tomography，Fractionated Stereotactic Radiation Therapy，Magnetic Resonance Imaging，Stereotactic Radiosurgery
地点: United States，Canada，Hong Kong，Ireland
申办方: NRG Oncology

正在招募 Phase 3 其他手术/操作放疗

ClinicalTrials.gov / NCI NCT06500481 / NCI-2024-04895

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

AI 简述这是一项III期试验，比较质子全脑全脊髓放疗与常规放疗用于柔脑膜转移，在美国开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Computed Tomography，Involved-Field Radiation Therapy，Lumbar Puncture
地点: United States
申办方: NRG Oncology

正在招募 Phase 2, Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06616584 / NCI-2024-06444

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

AI 简述这是一项II/III期试验，在既往铂类化疗和免疫治疗后的晚期非小细胞肺癌中添加Cemiplimab。

?

适用疾病: Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Advanced Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Cemiplimab，Computed Tomography，Dexamethasone
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 3 生物制剂药物其他

ClinicalTrials.gov / NCI NCT06623422 / NCI-2025-00146

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

AI 简述这是一项III期试验，研究Pembrolizumab联合或不联合Intismeran Autogene用于非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: Pembrolizumab，Cisplatin，Carboplatin，Pemetrexed
地点: United States，Argentina，Australia，Belgium 等 27 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT06632327 / NCI-2024-06356

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

AI 简述这是一项III期试验，比较手术前后治疗对II-IIIB期可切除非小细胞肺癌的影响。

?

适用疾病: Resectable Lung Non-Small Cell Carcinoma；Stage II Lung Cancer AJCC v8；Stage IIIA Lung Cancer AJCC v8
干预: Surgical Procedure，Cisplatin，Carboplatin，Pemetrexed
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3 其他放疗

ClinicalTrials.gov / NCI NCT06686771 / NCI-2024-09093

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

AI 简述这是一项III期试验，研究放疗用于阻断转移性非小细胞肺癌的寡进展。在美国、加拿大等地开展。

?

适用疾病: Non-small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: SBRT，First or second-line standard of care therapy
地点: United States，Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06687369

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

AI 简述这是一项III期试验，比较MB12与Keytruda用于非鳞状非小细胞肺癌。在亚美尼亚、波黑、格鲁吉亚、希腊等地开展。

?

适用疾病: Non Squamous Non Small Cell Lung Cancer
干预: MB12 (Proposed Pembrolizumab Biosimilar)，EU-sourced Keytruda®，US-sourced Keytruda®，Pemetrexed
地点: Armenia，Bosnia and Herzegovina，Georgia，Greece 等 19 个
申办方: mAbxience Research S.L.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06745908 / NCI-2025-03038

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

AI 简述这是一项III期试验，比较N-803联合替雷利珠单抗或多西他赛与多西他赛单药用于免疫检查点抑制剂耐药的非小细胞肺癌。

?

适用疾病: NSCLC Stage IV；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: N-803，Tislelizumab，Docetaxel，Prior failed checkpoint inhibitor
地点: United States
申办方: ImmunityBio, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06765109 / NCI-2025-02510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

AI 简述这是一项III期试验，比较Neladalkib与Alectinib用于初治ALK阳性非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Anaplastic Lymphoma Kinase-positive；Stage III Lung Cancer
干预: Neladalkib (NVL-655)，Alectinib
地点: United States，Argentina，Australia，Austria 等 25 个
申办方: Nuvalent Inc.

正在招募 Phase 3 药物放疗

ClinicalTrials.gov NCT06840782

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

AI 简述这是一项III期试验，在法国比较局部消融治疗联合免疫治疗与单独免疫治疗用于寡转移非小细胞肺癌。

?

适用疾病: Oligometastatic Non-small Cell Lung Cancer (NSCLC)
干预: Radical local treatment，SoC-based immunotherapy (+/- chemotherapy)
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06881784 / NCI-2025-02939

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

AI 简述这是一项III期试验，比较Daraxonrasib与多西他赛用于RAS突变非小细胞肺癌。

?

适用疾病: NSCLC (Non-small Cell Lung Cancer)；Non-Small Cell Lung Cancer；NSCLC
干预: daraxonrasib，docetaxel
地点: United States，Australia，Belgium，France 等 15 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06908993

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

AI 简述这是一项III期试验，比较Tepotinib与标准化疗用于MET外显子14突变非小细胞肺癌，在法国开展。

?

适用疾病: Advanced Non Small Cell Lung Cancer；MET Exon 14 Mutation
干预: Tepotinib，Pemetrexed (Alimta)，Vinorelbine，Gemcitabine alone
地点: France
申办方: Intergroupe Francophone de Cancerologie Thoracique

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06931717

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

AI 简述这是一项III期试验，研究Cemiplimab辅助免疫治疗用于未接受化疗的可手术非小细胞肺癌，在欧洲多国开展。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Cemiplimab
地点: Austria，Estonia，France，Germany 等 5 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06992609

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

AI 简述这是一项三期试验，研究Durvalumab用于局限期小细胞肺癌放化疗后。在西班牙开展。

?

适用疾病: Small Cell Lung Carcinoma
干预: Durvalumab
地点: Spain
申办方: AstraZeneca

正在招募 Phase 3 放疗

ClinicalTrials.gov NCT07015892

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

AI 简述这是一项III期试验，比较不同剂量放疗方案用于局限期小细胞肺癌，在西班牙开展。

?

适用疾病: Small Cell Lung Carcinoma
干预: Thoracic Radiotherapy 45 Gy BID，Thoracic Radiotherapy 60 Gy BID，Thoracic Radiotherapy SIB 45-54 Gy BID
地点: Spain
申办方: Instituto de Investigación Biomédica de Salamanca

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07185997 / NCI-2025-07337

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

AI 简述这是一项III期试验，比较Firmonertinib与研究者选择的EGFR-TKI用于晚期非小细胞肺癌伴EGFR PACC罕见突变。在美国、澳大利亚等地开展。

?

适用疾病: Non-Small-Cell Lung Cancer；Metastatic Non-Small-Cell Lung Cancer；Advanced Non-Small-Cell Lung Cancer
干预: Firmonertinib，EGFR-TKI inhibitor based on investigator's choice
地点: United States，Australia，Canada，France 等 11 个
申办方: ArriVent BioPharma, Inc.

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov / NCI NCT07365319 / NCI-2026-03378

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

AI 简述这是一项II/III期试验，研究EIK1001联合帕博利珠单抗和化疗用于4期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer (Squamous or Non Squamous)；Stage 4 NSCLC；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: EIK1001，Pembrolizumab (KEYTRUDA®)，Placebo，Paclitaxel + Carboplatin
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 3 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT07388524 / NCI-2026-00505

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

AI 简述这是一项III期试验，研究Atezolizumab用于早期非小细胞肺癌术后预防复发。在美国等地开展。

?

适用疾病: Lung Non-Small Cell Carcinoma；Non-Small Cell Lung Cancer
干预: Atezolizumab，Atezolizumab and Recombinant Human Hyaluronidase，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 生物制剂其他

ClinicalTrials.gov / NCI NCT07513376 / NCI-2026-03478

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

AI 简述这是一项III期试验，研究Intismeran联合或不联合Pembrolizumab辅助治疗高风险I期非小细胞肺癌。在美国等地开展。

?

适用疾病: Non-small Cell Lung Cancer；Stage I Lung Cancer；Non-Small Cell Lung Cancer
干预: Intismeran，Pembrolizumab coformulated with berahyaluronidase alfa，Placebo
地点: United States，Australia，Canada，Netherlands 等 2 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 生物制剂药物其他

ClinicalTrials.gov NCT07554339

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

AI 简述这是一项III期试验，研究Calderasib联合Durvalumab用于非小细胞肺癌，在美国、荷兰、韩国、西班牙等地开展。

?

适用疾病: Non-small Cell Lung Cancer
干预: Calderasib，Durvalumab，Placebo to MK-1084
地点: United States，Netherlands，South Korea，Spain 等 2 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07566052 / NCI-2026-04238

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

AI 简述这是一项III期试验，比较Setidegrasib与Docetaxel用于KRAS G12D突变非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Setidegrasib，Docetaxel
地点: United States，Japan
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT07660094 / NCI-2026-04789

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

AI 简述这是一项III期试验，比较Aglatimagene Besadenovec联合prodrug和pembrolizumab与docetaxel用于IV期非鳞状非小细胞肺癌。

?

适用疾病: Non-squamous, Non-Small Cell Lung Cancer；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: Aglatimagene Besadenovec，Valacyclovir，Pembrolizumab，Docetaxel
地点: United States
申办方: Candel Therapeutics, Inc.

正在招募 Phase 2

NCI NCT02259621 / NCI-2015-00243

Neoadjuvant Immunotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

AI 简述这是一项II期试验，研究新辅助免疫治疗用于可切除的IB-IIIA期非小细胞肺癌，在美国、加拿大开展。

?

适用疾病: Non-Small Cell Squamous Lung Cancer；Non-Squamous Non-Small Cell Lung Cancer；Stage IB Non-Small Cell Lung Cancer
干预: 未列出
地点: United States，Canada
申办方: Johns Hopkins University/Sidney Kimmel Cancer Center

正在招募 Phase 2

NCI NCT03259867 / NCI-2017-01862

Combination of TATE and PD-1 Inhibitor in Liver Cancer

AI 简述这是一项II期试验，研究Nivolumab联合肝动脉栓塞用于肝癌和胃癌。

?

适用疾病: BCLC Stage C Hepatocellular Cancer；Metastatic Gastric Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Teclison Ltd.

正在招募 Phase 1, Phase 2

NCI NCT03190941 / NCI-2018-03522

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

AI 简述这是一项I/II期试验，研究输注靶向KRAS G12V的T细胞用于HLA-A*11:01阳性的胰腺癌、胃癌等患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 2

NCI NCT03290534 / NCI-2019-02116

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

AI 简述这是一项II期试验，研究CivaSheet植入治疗用于I期肺癌。

?

适用疾病: Stage I Lung Cancer；Stage IA1 Lung Cancer；Stage IA2 Lung Cancer
干预: 未列出
地点: United States
申办方: CivaTech Oncology

正在招募 Phase 1, Phase 2

NCI NCT04143789 / NCI-2019-07561

Evaluation of AP-002 in Patients With Solid Tumors

AI 简述这是一项I/II期试验，评估AP-002用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Altum Pharmaceuticals Inc

正在招募 Phase 2

NCI NCT04253964 / NCI-2020-03137

Immunotherapy with or without Chemotherapy for the Treatment of Metastatic or Unresectable Non-small Cell Lung Cancer

AI 简述这是一项II期试验，在美国研究免疫治疗联合或不联合化疗用于转移性或不可切除非小细胞肺癌。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Unresectable Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Wake Forest University Health Sciences

正在招募 Phase 1, Phase 2

NCI NCT04145622 / NCI-2020-03139

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2

NCI NCT04219254 / NCI-2020-05456

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BI-1206联合Pembrolizumab用于晚期实体瘤，包括肺癌和黑色素瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: BioInvent International AB

正在招募 Phase 1, Phase 2

NCI NCT04300556 / NCI-2020-06147

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

AI 简述这是一项I/II期试验，研究MORAb-202用于多种实体瘤，包括卵巢癌和肺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eisai Inc

正在招募 Phase 2

NCI NCT04114136 / NCI-2020-11521

Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors

AI 简述这是一项II期试验，研究PD-1抑制剂联合二甲双胍、罗格列酮用于多种实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04370587 / NCI-2020-11850

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究T3011单药及联合帕博利珠单抗用于晚期实体瘤，在美国和澳大利亚开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Immvira Compan Limited

正在招募 Phase 1, Phase 2

NCI NCT04665206 / NCI-2021-03566

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究VT3989用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Vivace Therapeutics, Inc

正在招募 Phase 2

NCI NCT04892953 / NCI-2021-03777

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC after Chemoradiation and Anti-PD-L1 Therapy

AI 简述这是一项II期试验，研究局部巩固治疗联合Durvalumab用于III期非小细胞肺癌。

?

适用疾病: Stage III Lung Cancer；Stage IIIA Lung Cancer；Stage IIIB Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04939610 / NCI-2021-07632

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-FAP-2286用于晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Novartis Pharmaceuticals Corporation

正在招募 Phase 1, Phase 2

NCI NCT05068024 / NCI-2021-11191

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer

AI 简述这是一项1/2期试验，研究FWD1509用于非小细胞肺癌，在美国开展。

?

适用疾病: Stage IIIB Lung Cancer；Stage IIIC Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Forward Pharmaceuticals Co., Ltd.

正在招募 Phase 2

NCI NCT05064280 / NCI-2021-11329

Pembrolizumab and Lenvatinib for the Treatment of Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, and Other Tumors with Brain Metastases

AI 简述这是一项2期试验，研究Pembrolizumab和Lenvatinib用于三阴性乳腺癌、非小细胞肺癌等脑转移实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Lung Cancer；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05118789 / NCI-2021-13611

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

AI 简述这是一项I/II期试验，研究Zidesamtinib用于ROS1重排的晚期非小细胞肺癌等实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Nuvalent Inc.

正在招募 Phase 2

NCI NCT05358548 / NCI-2022-02746

Alternating Chemoimmunotherapy and Immunotherapy Treatment Plans for the Treatment of Stage IV Lung Cancer or Head and Neck Cancers, The ATATcH Study

AI 简述这是一项II期试验，研究交替化疗免疫治疗和免疫治疗用于IV期肺癌或头颈癌。

?

适用疾病: Stage IV Lip and Oral Cavity Cancer；Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer；Stage IV Hypopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05384626 / NCI-2022-05419

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

AI 简述这是一项I/II期试验，研究Neladalkib (NVL-655)用于ALK重排或突变的晚期非小细胞肺癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Nuvalent Inc.

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 1, Phase 2

NCI NCT05533697 / NCI-2022-07826

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究mRNA-4359单用或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: ModernaTX, Inc.

正在招募 Phase 1, Phase 2

NCI NCT04903873 / NCI-2022-08794

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，评估一种研究药物用于晚期实体瘤，包括结直肠癌等。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eutilex

正在招募 Phase 2

NCI NCT04991025 / NCI-2022-09613

Nivolumab + Platinum-based Chemotherapy + Certolizumab for the Treatment of Resectable Stages II-III Non-Small Cell Lung Cancers

AI 简述这是一项II期试验，研究Nivolumab联合化疗和Certolizumab用于可切除II-III期非小细胞肺癌。

?

适用疾病: Stage II Lung Cancer；Stage III Lung Cancer；Resectable Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05394103 / NCI-2022-10300

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CDK7抑制剂Q901用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Qurient Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05443126 / NCI-2022-10316

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

AI 简述这是一项I/II期试验，研究EP0031（Lunbotinib）用于晚期RET改变的恶性肿瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Ellipses Pharma

正在招募 Phase 1, Phase 2

NCI NCT05592626 / NCI-2023-00103

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05519293 / NCI-2023-00135

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

AI 简述这是一项I/IIa期试验，研究H002用于携带活性EGFR突变的非小细胞肺癌，在美国开展。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Unresectable Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: RedCloud Bio

正在招募 Phase 1, Phase 2

NCI NCT05268666 / NCI-2023-00374

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究口服JBI-802用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jubilant Therapeutics Inc.

正在招募 Phase 1, Phase 2

NCI NCT05200559 / NCI-2023-00563

E7777 and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Cancer

AI 简述这是一项I/II期试验，研究E7777联合帕博利珠单抗用于复发或转移性实体瘤。在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT05584670 / NCI-2023-00867

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，首次人体研究SAR445877用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sanofi Aventis

正在招募 Phase 2

NCI NCT05830058 / NCI-2023-02155

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

AI 简述这是一项II期试验，研究PET引导的立体定向放疗用于寡进展的非小细胞肺癌、黑色素瘤和肾细胞癌。

?

适用疾病: Malignant Solid Tumor；Non-Small Cell Lung Cancer；Melanoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05696782 / NCI-2023-02411

Quick Start Durvalumab Following Chemoradiation for the Treatment of Stage II or III Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究放化疗后快速开始Durvalumab用于II或III期非小细胞肺癌，在美国开展。

?

适用疾病: Stage II Lung Cancer；Stage III Lung Cancer；Unresectable Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Wake Forest University Health Sciences

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 2

NCI NCT06014827 / NCI-2023-06041

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Oligoprogressive Non-small Cell Lung Carcinoma

AI 简述这是一项II期试验，在美国研究生物引导放疗和立体定向体部放疗用于寡进展非小细胞肺癌。

?

适用疾病: Stage IV Lung Cancer；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05785741 / NCI-2023-06649

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究DB-1310用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT05636618 / NCI-2023-06702

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

AI 简述这是一项I/II期试验，研究靶向α粒子疗法用于SSTR2阳性神经内分泌肿瘤。

?

适用疾病: Locally Advanced Paraganglioma；Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8；Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8
干预: 未列出
地点: United States
申办方: Perspective Therapeutics

正在招募 Phase 2

NCI NCT05541822 / NCI-2023-07070

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

AI 简述这是一项II期试验，研究ABN401用于c-MET失调的晚期非小细胞肺癌。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Non-Squamous Non-Small Cell Lung Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Abion Inc

正在招募 Phase 1, Phase 2

NCI NCT05987644 / NCI-2023-07526

Alectinib Alone or in Combination with Stereotactic Radiosurgery for Controlling Disease in Patients with Stage IV Non-small Cell Lung Cancer and Brain Metastases

AI 简述这是一项I/II期试验，研究Alectinib单用或联合立体定向放射外科用于IV期非小细胞肺癌伴脑转移，在美国开展。

?

适用疾病: Stage IV Lung Cancer；Non-Small Cell Lung Cancer；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06140407 / NCI-2023-09018

Pembrolizumab after Radiation Therapy and Chemotherapy in Treating Patients with Limited Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Pembrolizumab用于局限期小细胞肺癌放化疗后，在美国开展。

?

适用疾病: Stage I Lung Cancer；Stage II Lung Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Vanderbilt University/Ingram Cancer Center

正在招募 Phase 2

NCI NCT06103682 / NCI-2023-09053

Local Ablative Therapy for the Treatment of Oligoprogression in Patients Undergoing Systemic Therapy for Lung Cancer, OBLITERATE Trial

AI 简述这是一项II期试验，研究局部消融治疗用于肺癌系统治疗期间寡进展的患者，在美国开展。

?

适用疾病: Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma；Metastatic Lung Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT05746481 / NCI-2023-09259

Tiragolumab with Carboplatin, Pemetrexed, and Atezolizumab for the Treatment of Non-squamous Non-small Cell Lung Cancer and Untreated Brain Metastases

AI 简述这是一项II期试验，研究Tiragolumab联合卡铂、培美曲塞和阿替利珠单抗用于非鳞非小细胞肺癌及未经治疗的脑转移，在美国开展。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 1, Phase 2

NCI NCT04752826 / NCI-2023-10441

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

AI 简述这是一项1/2期试验，研究BI-1808单药或联合帕博利珠单抗用于晚期恶性肿瘤，包括卵巢癌、T细胞淋巴瘤等。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: BioInvent International AB

正在招募 Phase 2

NCI NCT06496659 / NCI-2024-00048

Segmentectomy for Treating Patients with Non-Small Cell Lung Cancer Treated with Neoadjuvant Therapy, SAINT Trial

AI 简述这是一项2期试验，研究肺段切除术用于新辅助治疗后的非小细胞肺癌，在美国开展。

?

适用疾病: Stage IA1 Lung Cancer；Stage IA2 Lung Cancer；Stage IA3 Lung Cancer
干预: 未列出
地点: United States
申办方: Northwestern University

正在招募 Phase 1, Phase 2

NCI NCT06014658 / NCI-2024-00437

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究MBRC-101用于晚期难治性实体瘤。

?

适用疾病: Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Hormone Receptor Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06219174 / NCI-2024-00864

Difluoromethylornithine in Combination with Pembrolizumab For the Treatment of STK11-Mutant Advanced or Metastatic Non-small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究Difluoromethylornithine联合Pembrolizumab用于STK11突变晚期或转移性非小细胞肺癌，在美国开展。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 2

NCI NCT05456256 / NCI-2024-00960

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

AI 简述这是一项II期试验，研究LP-300联合卡铂和培美曲塞用于不吸烟的晚期肺腺癌。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Adenocarcinoma
干预: 未列出
地点: United States
申办方: Lantern Pharma Inc.

正在招募 Phase 1, Phase 2

NCI NCT05914116 / NCI-2024-01206

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/IIa期试验，在美国研究DB-1311/BNT324用于晚期/转移性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT06015724 / NCI-2024-01588

Daratumumab in Combination with KRAS Vaccine and Nivolumab in Treating Refractory Pancreatic Ductal Cancer and Advanced Refractory Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，在美国研究Daratumumab联合KRAS疫苗和Nivolumab用于难治性胰腺癌和晚期非小细胞肺癌。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Refractory Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: MedStar Georgetown University Hospital

正在招募 Phase 1, Phase 2

NCI NCT05877430 / NCI-2024-01737

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

AI 简述这是一项I/II期试验，研究CJRB-101联合Pembrolizumab用于晚期或转移性实体瘤，包括非小细胞肺癌、头颈癌等。

?

适用疾病: Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer；Recurrent Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: CJ Bioscience, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05886920 / NCI-2024-03452

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

AI 简述这是一项I/II期试验，研究D3S-002单药或联合治疗用于MAPK通路突变的晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: D3 Bio (Wuxi) Co., Ltd

正在招募 Phase 1, Phase 2

NCI NCT06385925 / NCI-2024-04303

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

AI 简述这是一项I/II期试验，研究TSN1611用于KRAS G12D突变晚期实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Tyligand Pharmaceuticals (Suzhou) Limited

正在招募 Phase 2

NCI NCT06518057 / NCI-2024-05661

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases from Breast Cancer or Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究海马保护性全脑脊髓放疗用于乳腺癌或非小细胞肺癌的软脑膜转移。在美国开展。

?

适用疾病: Stage IV Lung Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT06425926 / NCI-2024-05762

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究GIM-531单独或联合抗PD-1抗体用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Georgiamune Inc

正在招募 Phase 1, Phase 2

NCI NCT06526819 / NCI-2024-06528

SMP-3124LP in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国开展，研究SMP-3124LP用于晚期实体瘤。

?

适用疾病: Recurrent Endometrial Serous Adenocarcinoma；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sumitomo Pharma America, Inc.

正在招募 Phase 1, Phase 2

NCI NCT06598371 / NCI-2024-07763

Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究基因工程肿瘤浸润淋巴细胞KSQ-004EX用于多种晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06651593 / NCI-2024-08852

Biomarkers for Predicting Response to SAR444881 in Combination with Cemiplimab in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, or Ovarian Cancer

AI 简述这是一项II期试验，在美国研究SAR444881联合Cemiplimab用于晚期非小细胞肺癌、结直肠癌或卵巢癌。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06385262 / NCI-2024-09342

Chemotherapy and Cemiplimab with or without Alirocumab before Surgery for the Treatment of Lung Cancer in Patients with Stage IB-IIIA Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究化疗和Cemiplimab联合或不联合Alirocumab术前治疗用于IB-IIIA期非小细胞肺癌，在美国开展。

?

适用疾病: Stage IB Lung Cancer；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募 Phase 2

NCI NCT06910761 / NCI-2025-02015

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究光子颅脊髓照射用于乳腺癌或非小细胞肺癌软脑膜转移。在美国开展。

?

适用疾病: Stage IV Lung Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06657222 / NCI-2025-02229

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究TUB-030用于晚期实体瘤。在美国、加拿大、罗马尼亚、西班牙等地开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tubulis GmbH

正在招募 Phase 1, Phase 2

NCI NCT06730750 / NCI-2025-02617

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986490联合或不联合贝伐珠单抗用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 1, Phase 2

NCI NCT06669117 / NCI-2025-06714

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

AI 简述这是一项I/II期试验，研究VERT-002用于MET改变的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Pierre Fabre

正在招募 Phase 1, Phase 2

NCI NCT06459973 / NCI-2025-07430

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL205用于晚期实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT07197827 / NCI-2025-07559

A Study of YL242 in Subjects With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL242用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT07160725 / NCI-2025-08065

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究BMS-986517用于晚期实体瘤和头颈部鳞状细胞癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2

NCI NCT07205718 / NCI-2025-08225

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-188用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Lip and Oral Cavity Cancer
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT06725758 / NCI-2025-08359

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

AI 简述这是一项I/II期试验，在美国开展，研究ODM-212用于晚期实体瘤。

?

适用疾病: Metastatic Head and Neck Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Orion Corporation, Orion Pharma

正在招募 Phase 2

NCI NCT07323641 / NCI-2025-09155

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Telisotuzumab Vedotin联合Osimertinib用于进展性非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT07423585 / NCI-2026-00832

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

AI 简述这是一项II期试验，在美国开展，研究塔拉妥单抗用于广泛期小细胞肺癌。

?

适用疾病: Recurrent Extensive Stage Lung Small Cell Carcinoma；Recurrent Limited Stage Lung Small Cell Carcinoma；Limited Stage Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07287995 / NCI-2026-02678

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

AI 简述这是一项I/II期试验，研究ASP2998单用及联合标准疗法用于实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2

NCI NCT07415031 / NCI-2026-02775

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

AI 简述这是一项II期试验，用于既往参与adagrasib研究的晚期实体瘤患者长期治疗，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Lung Cancer；Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Mirati Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT07436728 / NCI-2026-03048

A Study of TAK-505 in Adults With Solid Tumors

AI 简述这是一项I/II期试验，研究TAK-505用于晚期实体瘤，包括头颈癌、非小细胞肺癌等。在美国开展。

?

适用疾病: Metastatic Head and Neck Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Takeda

正在招募 Phase 1, Phase 2

NCI NCT07335497 / NCI-2026-03444

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究CR-001用于局部晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Crescent Biopharma, Inc.

正在招募 Phase 1, Phase 2

NCI NCT06914128 / NCI-2026-04077

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

AI 简述这是一项I/II期试验，研究PRMT5抑制剂BAY 3713372用于MTAP缺失的实体瘤。

?

适用疾病: Malignant Solid Tumor；Non-Small Cell Lung Cancer；Glioblastoma
干预: 未列出
地点: United States
申办方: Bayer Corporation

正在招募 Phase 1, Phase 2

NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT01639508 / NCI-2012-01187

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

AI 简述这是一项II期试验，研究Cabozantinib用于RET融合阳性非小细胞肺癌等。

?

适用疾病: Non-Small Cell Lung Cancer；Unresectable Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Cabozantinib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT01720836 / NCI-2013-00081

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究MUC1肽疫苗用于非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Stage 0 Lung Cancer；Stage I Lung Cancer
干预: Vaccine + PolyICLC
地点: United States
申办方: Olivera Finn

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT01803542

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

AI 简述这是一项II期试验，研究立体定向放疗用于肺转移，在加拿大开展。

?

适用疾病: Non-small Cell Lung Cancer；Metastasis From Other Cancers
干预: Stereotactic Radiation
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02133196 / NCI-2018-02265

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

AI 简述这是一项2期试验，研究T细胞受体免疫治疗用于转移性非小细胞肺癌，在美国开展。

?

适用疾病: Advanced Non-Small Cell Lung Cancer；Squamous Cell Carcinoma；Advanced NSCLC
干预: Aldesleukin，Fludarabine，Cyclophosphamide，Young TIL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT03175224 / NCI-2017-01648

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

AI 简述这是一项II期试验，研究APL-101用于c-Met外显子14跳跃突变的非小细胞肺癌和晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Solid Tumors；Advanced Cancer；Renal Cancer
干预: APL-101 Oral Capsules
地点: United States，Australia，Canada，France 等 7 个
申办方: Apollomics Inc.

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT03191149 / NCI-2017-01017

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

AI 简述这是一项II期试验，研究奥希替尼用于EGFR外显子20插入突变的晚期非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma；Stage IIIB Lung Non-Small Cell Cancer AJCC v7
干预: Biospecimen Collection，Computed Tomography with Contrast，Echocardiography Test，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03412877 / NCI-2018-03627

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

AI 简述这是一项II期试验，研究基因工程T细胞用于多种转移性癌症。

?

适用疾病: Endocrine Tumors；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Individual Patient TCR-Transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

AI 简述这是一项I/II期试验，研究VMD-928单药或联合Pembrolizumab用于TrkA过表达的实体瘤或淋巴瘤。

?

适用疾病: Head and Neck Carcinoma；Adenoid Cystic Carcinoma；Lung Cancer
干预: VMD-928 100 mg Tablet，VMD-928 Tablet and Pembrolizumab (200 mg)
地点: United States，Puerto Rico
申办方: VM Oncology, LLC

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT03808337 / NCI-2019-00436

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

AI 简述这是一项II期试验，研究立体定向体部放疗联合标准治疗用于转移性实体瘤。在美国开展。

?

适用疾病: Triple Negative Breast Cancer；Non Small Cell Lung Cancer；Metastatic Breast Cancer
干预: Stereotactic Body Radiotherapy/SBRT，Systemic Therapy/Standard of Care
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

AI 简述这是一项II期试验，研究Atezolizumab联合BDB001和放疗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

正在招募 Phase 1, Phase 2 器械药物

ClinicalTrials.gov NCT03953144

Synapse 3D With Intravascular Indocyanine Green

AI 简述这是一项I/II期试验，研究Synapse 3D肺建模联合吲哚菁绿用于非小细胞肺癌，在加拿大开展。

?

适用疾病: Non-small Cell Lung Cancer；Primary Neoplasm
干预: Synapse 3D Lung Modelling，IC-Green (ICG)
地点: Canada
申办方: St. Joseph's Healthcare Hamilton

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04077099 / NCI-2019-08522

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究REGN5093用于MET改变的晚期非小细胞肺癌。

?

适用疾病: NSCLC；Stage III Lung Cancer；Stage IIIA Lung Cancer
干预: REGN5093
地点: United States，France，South Korea
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT04105270 / NCI-2020-07398

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

AI 简述这是一项II期试验，比较RMT联合Durvalumab+化疗与安慰剂用于晚期肺腺癌。

?

适用疾病: Adenocarcinoma of Lung；Lung Cancer；Stage IIIB Lung Cancer
干预: Oral Restorative Microbiota Therapy (RMT) Capsules，Durvalumab 1500 mg IV，Cisplatin/pemetrexed or Carboplatin/pemetrexed，Placebo
地点: United States
申办方: Masonic Cancer Center, University of Minnesota

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04165070 / NCI-2020-03338

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

AI 简述这是一项I/II期试验，在美国等国研究Pembrolizumab联合化疗用于初治IV期非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Non-Small Cell Squamous Lung Cancer；Non-Squamous Non-Small Cell Lung Cancer
干预: Pembrolizumab，Carboplatin，Paclitaxel，Pemetrexed
地点: United States，Hungary，Israel，Italy 等 5 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 放疗

ClinicalTrials.gov / NCI NCT04210492 / NCI-2020-02511

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

AI 简述这是一项I/II期试验，研究剂量递减的3次立体定向体部放疗用于中央型肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Non-Small Cell Lung Cancer；Lung Neoplasm
干预: 45 Gray (Gy) regimen
地点: United States
申办方: Yale University

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04302025 / NCI-2020-01859

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，研究多种靶向药物用于可切除的IB-III期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage IB Lung Cancer；Stage II Lung Cancer
干预: Alectinib，Entrectinib，Vemurafenib，Cobimetinib
地点: United States
申办方: Genentech, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04317534 / NCI-2020-04538

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

AI 简述这是一项II期试验，研究帕博利珠单抗用于I期非小细胞肺癌根治术后治疗。

?

适用疾病: NSCLC, Stage I；Non-Small Cell Squamous Lung Cancer；Non-Squamous Non-Small Cell Lung Cancer
干预: Pembrolizumab
地点: United States
申办方: Greg Durm, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04332367 / NCI-2020-13703

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

AI 简述这是一项II期试验，研究卡铂、紫杉醇联合雷莫芦单抗用于晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage IV Lung Cancer；Non-Small Cell Lung Cancer
干预: Carboplatin，Paclitaxel，Ramucirumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04335292

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

AI 简述这是一项II期试验，研究奥希替尼序贯化疗再挑战奥希替尼用于EGFR突变肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Osimertinib First-Line，Platinum + Pemetrexed Chemotherapy Second-Line，Osimertinib Third-Line
地点: Canada
申办方: Mark Vincent

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT04375904

'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)

AI 简述这是一项II期试验，研究立体定向消融放疗用于中央型肺肿瘤。

?

适用疾病: NSCLC/Oligometastatic Cancer (Single Lung Lesion)
干预: Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
地点: Ireland
申办方: Cancer Trials Ireland

正在招募 Phase 2 其他放疗

ClinicalTrials.gov NCT04405401

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

AI 简述这是一项II期试验，研究立体定向消融放疗用于寡进展非小细胞肺癌，在加拿大开展。

?

适用疾病: Lung Cancer Metastatic
干预: SABR，Standard of care
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04410796 / NCI-2020-04069

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

AI 简述这是一项II期试验，研究Osimertinib单药或联合化疗用于EGFR突变肺癌，在美国开展。

?

适用疾病: Metastatic Non-small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Osimertinib，Carboplatin，Pemetrexed
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04467723 / NCI-2020-13239

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

AI 简述这是一项I/II期试验，研究阿替利珠单抗联合吡非尼酮用于晚期非小细胞肺癌，在美国开展。

?

适用疾病: NSCLC Stage IV；NSCLC, Recurrent；Stage I Lung Cancer
干预: Atezolizumab
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04486833 / NCI-2025-08549

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

AI 简述这是一项I/II期试验，研究Quaratusugene Ozeplasmid联合Osimertinib用于奥希替尼进展的晚期肺癌。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Stage III Lung Cancer；Stage IV Lung Cancer
干预: quaratusugene ozeplasmid，osimertinib，Platinum-Based Chemotherapy
地点: United States
申办方: Genprex, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04499053 / NCI-2022-01292

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究Durvalumab和Tremelimumab联合化疗用于HIV感染的非小细胞肺癌。在美国开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Stage IV Lung Cancer；Stage IVA Lung Cancer
干预: Durvalumab，Tremelimumab
地点: United States
申办方: Georgetown University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

AI 简述这是一项I/II期试验，研究rezatapopt用于TP53 Y220C突变晚期实体瘤，在美澳法德开展。

?

适用疾病: Advanced Solid Tumor；Advanced Malignant Neoplasm；Metastatic Cancer
干预: rezatapopt，pembrolizumab
地点: United States，Australia，France，Germany 等 5 个
申办方: PMV Pharmaceuticals, Inc

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04591002

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

AI 简述这是一项II期试验，研究Osimertinib用于EGFR突变阳性肺结节。

?

适用疾病: Lung Cancer
干预: Osimertinib 80 MG
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04614103 / NCI-2020-11568

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

AI 简述这是一项2期试验，研究LN-145用于转移性非小细胞肺癌，在美国、澳大利亚、加拿大、法国等地开展。

?

适用疾病: Metastatic Non Small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: LN-145
地点: United States，Australia，Canada，France 等 8 个
申办方: Iovance Biotherapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT04616209

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

AI 简述这是一项I/II期试验，研究供体来源的自然杀伤细胞输注用于非小细胞肺癌，在台湾开展。

?

适用疾病: Non-small Cell Lung Cancer
干预: donor-derived NK cell infusion
地点: Taiwan
申办方: Precision Biotech Taiwan Corp.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04683250 / NCI-2020-14193

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

AI 简述这是一项I/II期试验，研究RET抑制剂TAS0953/HM06用于RET基因异常的晚期实体瘤。在美国、日本、韩国等地开展。

?

适用疾病: RET-altered Non Small Cell Lung Cancer；RET-altered Solid Tumors；Advanced Malignant Solid Tumor
干预: TAS0953/HM06
地点: United States，Japan，South Korea
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04691817 / NCI-2023-06008

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

AI 简述这是一项I/II期试验，研究Tocilizumab联合Atezolizumab用于一线免疫检查点抑制剂治疗后难治的局部晚期或转移性非小细胞肺癌，在美国开展。

?

适用疾病: Lung Cancer, Nonsmall Cell；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Atezolizumab，Tocilizumab
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04696575 / NCI-2020-13169

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究拉米夫定联合化学免疫治疗用于广泛期小细胞肺癌，在美国开展。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Extensive Stage Small Cell Lung Cancer
干预: Atezolizumab，Carboplatin，Etoposide，Lamivudine
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04699838 / NCI-2021-01125

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究化疗免疫治疗后Durvalumab和Ceralasertib用于初治广泛期小细胞肺癌。

?

适用疾病: Extensive Stage Small Cell Lung Cancer
干预: Cisplatin，Carboplatin，Etoposide，Durvalumab
地点: United States
申办方: Muhammad Furqan

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04701476 / NCI-2021-11336

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

AI 简述这是一项II期试验，研究TATE联合Pembrolizumab用于转移性结直肠癌和非小细胞肺癌，在美国和台湾开展。

?

适用疾病: Colorectal Cancer; Lung Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage IVA Colorectal (Colon or Rectal) Cancer
干预: TATE and pembrolizumab，TAS-102 pill，Regorafenib Pill
地点: United States，Taiwan
申办方: Teclison Ltd.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Cancer；Solid Tumor；Melanoma
干预: ST-067，Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]，pembrolizumab
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04789486 / NCI-2021-06084

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

AI 简述这是一项I/II期试验，在美国研究AGuIX纳米颗粒联合MR引导SBRT用于中央型肺癌和胰腺癌。

?

适用疾病: Non-small Cell Lung Cancer；Advanced Pancreatic Adenocarcinoma；Unresectable Pancreatic Cancer
干预: AGuIX，Radiotherapy
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04865250

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

AI 简述这是一项II期试验，研究Atezolizumab联合化疗用于可切除非小细胞肺癌新辅助治疗，在德国开展。

?

适用疾病: NSCLC Stage II；NSCLC, Stage IIIA；NSCLC Stage IIIB
干预: Atezolizumab 1200 mg abs day 1 q22 (iv)
地点: Germany
申办方: University Hospital Heidelberg

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT04875585

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC

AI 简述这是一项II期试验，研究帕博利珠单抗/乐伐替尼新辅助治疗联合帕博利珠单抗辅助治疗用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: neoadjuvant therapy with Pembrolizumab/Lenvatinib，Surgery，Adjuvant Treatment Phase
地点: Austria
申办方: Medical University Innsbruck

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04895709 / NCI-2021-06088

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT04919382 / NCI-2022-07297

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Temozolomide联合Atezolizumab用于转移性或复发性小细胞肺癌的后线治疗。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Metastatic Lung Small Cell Carcinoma；Recurrent Lung Small Cell Carcinoma
干预: Atezolizumab，Temozolomide
地点: United States
申办方: Dwight Owen

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04933903

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

AI 简述这是一项II期试验，研究低剂量立体定向放疗联合Ipilimumab和Nivolumab用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Ipilimumab，Nivolumab，SBRT
地点: United States
申办方: Brown University

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT04952480

Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer

AI 简述这是一项2期试验，研究剂量递增适应性放疗联合化疗用于小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: Dose-escalated adaptive radiotherapy，Chemotherapy
地点: Canada
申办方: AHS Cancer Control Alberta

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT04966663

Using ctDNA to Determine Therapies for Lung Cancer

AI 简述这是一项II期试验，基于ctDNA指导Nivolumab、顺铂等用于非小细胞肺癌完全切除术后，在加拿大开展。

?

适用疾病: Non Small Cell Lung Cancer；Complete Surgical Resection；Circulating Tumor DNA
干预: Nivolumab，Pemetrexed，Gemcitabine，Cisplatin
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04969315 / NCI-2023-03874

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

AI 简述这是一项I/II期试验，研究TT-10和TT-4单药或联合用于多种晚期实体瘤，在美国开展。

?

适用疾病: Renal Cell Cancer；Castrate Resistant Prostate Cancer；Non Small Cell Lung Cancer
干预: TT-10，TT-4
地点: United States
申办方: Portage Biotech

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04977453

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GI-101单药或联合Pembrolizumab、Lenvatinib用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Cervical Cancer
干预: GI-101，Pembrolizumab (KEYTRUDA®)，Lenvatinib，GI-101A
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT04992780

Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，比较大分割与常规分割调强放疗联合化疗免疫治疗用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer Stage
干预: Hypo-Fractionation，Standard-Fractionation
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05061550 / NCI-2022-01113

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

AI 简述这是一项2期试验，研究Durvalumab等药物用于可切除非小细胞肺癌的术前和术后治疗，在美国、比利时、加拿大、法国开展。

?

适用疾病: Non-small Cell Lung Cancer；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: Durvalumab，Oleclumab，Monalizumab，Dato-DXd
地点: United States，Belgium，Canada，France 等 8 个
申办方: AstraZeneca

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT05068232 / NCI-2023-02387

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

AI 简述这是一项2期试验，研究Durvalumab联合消融放疗用于广泛期小细胞肺癌，在美国开展。

?

适用疾病: Small-cell Lung Cancer；Extensive-stage Small-cell Lung Cancer；Lung Cancer
干预: Ablative Radiation，Durvalumab，Etoposide，Carboplatin
地点: United States
申办方: University of Chicago

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05098132 / NCI-2022-00633

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

AI 简述这是一项I/II期试验，研究STK-012单药及联合其他药物用于晚期肺癌等实体瘤，在美国、格鲁吉亚、爱尔兰、西班牙等地开展。

?

适用疾病: Advanced Solid Tumor；Non Small Cell Lung Cancer；Untreated Advanced NSCLC
干预: STK-012，pembrolizumab KEYTRUDA®，pemetrexed，carboplatin
地点: United States，Georgia，Ireland，Spain
申办方: Synthekine

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT05144698 / NCI-2022-01928

RAPA-201 Therapy of Solid Tumors

AI 简述这是一项I/II期试验，研究RAPA-201用于多种实体瘤。

?

适用疾病: Solid Tumor；Small Cell and Non-small Cell Lung Cancer；Head and Neck Cancer
干预: RAPA-201 Rapamycin Resistant T Cells，Chemotherapy Prior to RAPA-201 Therapy，Pembrolizumab (PD-1 Blocking Antibody)
地点: United States
申办方: Rapa Therapeutics LLC

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05198830 / NCI-2021-14403

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究TRC102联合化疗及放疗用于III期非鳞非小细胞肺癌。在美国开展。

?

适用疾病: Lung Adenocarcinoma；Lung Large Cell Carcinoma；Lung Non-Squamous Non-Small Cell Carcinoma
干预: Carboplatin，Cisplatin，Computed Tomography，Durvalumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05229614

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

AI 简述这是一项II期试验，研究碳离子放疗联合免疫治疗用于非小细胞肺癌、头颈鳞癌等实体瘤。

?

适用疾病: Non Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Melanoma
干预: Carbon Ion Therapy，Immunotherapy (Pembrolizumab)
地点: Germany，Italy
申办方: CNAO National Center of Oncological Hadrontherapy

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05267626 / NCI-2023-07955

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

AI 简述这是一项I/II期试验，研究AU-007单药或联合用于不可切除局部晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Cancer；Cutaneous Melanoma
干预: AU-007，Aldesleukin，Avelumab，Nivolumab
地点: United States，Australia
申办方: Aulos Bioscience, Inc.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05271292 / NCI-2022-09477

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

AI 简述这是一项I/II期试验，研究Chiauranib用于晚期实体瘤及复发性小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer；Advanced Solid Malignant Tumor；Recurrent Malignant Solid Tumor
干预: Chiauranib
地点: United States
申办方: Chipscreen Biosciences, Ltd.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05277844

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

AI 简述这是一项II期试验，比较局部巩固放疗联合TKI与单用TKI用于驱动基因突变寡转移非小细胞肺癌，在印度开展。

?

适用疾病: Oligometastatic Disease；Non-small Cell Lung Cancer；Driver Mutation
干预: Local Consolidative Radiation Therapy，TKI
地点: India
申办方: Tata Memorial Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05281406

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

AI 简述这是一项II期试验，研究奥希替尼一线治疗后血浆ctDNA EGFRm仍阳性患者加用化疗，在德国开展。

?

适用疾病: NSCLC Stage IIIB；NSCLC Stage IV
干预: Osimertinib，Pemetrexed，Cisplatin，Carboplatin
地点: Germany
申办方: Goethe University

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT05296564

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

AI 简述这是一项I/II期试验，研究HBI 0201-ESO TCRT联合环磷酰胺和氟达拉滨用于NY-ESO-1阳性转移性癌症，在以色列开展。

?

适用疾病: Sarcoma, Synovial；Sarcoma,Soft Tissue；Melanoma Stage IV
干预: CYCLOPHOSPHAMIDE and FLUDARABIN，Cyclophosphamide，HBI 0201-ESO TCRT，Aldesleukin
地点: Israel
申办方: Hadassah Medical Organization

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT05344209

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究抗PD-1/PD-L1治疗联合或不联合UV1疫苗用于非小细胞肺癌。

?

适用疾病: Oncology；NSCLC Stage IV；NSCLC, Stage III
干预: UV1，Sagramostim，Anti-PD-1/PD-L1 treatment
地点: Norway
申办方: Vestre Viken Hospital Trust

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05361174 / NCI-2022-07362

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

AI 简述这是一项I/II期试验，研究IOV-4001用于不可切除或转移性黑色素瘤或III/IV期非小细胞肺癌。

?

适用疾病: Unresectable Melanoma；Metastatic Melanoma；Stage III Non-small Cell Lung Cancer
干预: IOV-4001
地点: United States
申办方: Iovance Biotherapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05363280 / NCI-2022-09738

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

AI 简述这是一项II期试验，研究AL8326用于一线治疗后的肺癌或肾细胞癌，在美国、西班牙开展。

?

适用疾病: Small Cell Lung Cancer；Renal Cell Carcinoma (RCC)；Non-Small Cell Lung
干预: AL8326 40 mg，AL8326 60 mg，AL8326 80 mg--stopped
地点: United States，Spain
申办方: Advenchen Pharmaceuticals, LLC.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

AI 简述这是一项I/II期试验，研究RMC-6236用于携带特定RAS突变的晚期实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05394831 / NCI-2022-11032

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

AI 简述这是一项I/II期试验，研究JIN-A02用于EGFR突变晚期非小细胞肺癌。

?

适用疾病: EGFR Mutant Advanced Non-small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: JIN-A02
地点: United States，South Korea，Thailand
申办方: J Ints Bio

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05398094

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

AI 简述这是一项II期试验，研究Sotorasib用于III期不可切除KRAS G12C非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer Stage III；KRAS P.G12C
干预: Sotorasib
地点: Spain
申办方: Fundación GECP

正在招募 Phase 2 手术/操作放疗

ClinicalTrials.gov / NCI NCT05419076 / NCI-2022-05456

A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

AI 简述这是一项2期试验，研究立体定向放射外科用于肺癌脑转移。

?

适用疾病: Lung Cancer；Lung Cancer Metastatic；Brain Metastases
干预: Stereotactic Radiosurgery，Cerebrospinal fluid collection
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05431270 / NCI-2022-06838

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

AI 简述这是一项I/II期试验，研究Mavrostobart单用或联合替雷利珠单抗或化疗用于晚期实体瘤。

?

适用疾病: Non Small Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma；Metastatic Malignant Solid Tumor
干预: Mavrostobart (PT199)，Tislelizumab，Gemcitabine + nab-Paclitaxel，Docetaxel
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05450965 / NCI-2022-08789

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

AI 简述这是一项II期试验，研究PLK1抑制剂Onvansertib用于复发小细胞肺癌。

?

适用疾病: Small-cell Lung Cancer；Small Cell Lung Carcinoma；Recurrent Small Cell Lung Cancer
干预: Onvansertib
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05467748

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究EZH2抑制剂Tulmimetostat联合PD-1阻断用于晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Tulmimetostat
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05469022

Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

AI 简述这是一项II期试验，研究新辅助拉泽替尼用于BALF液体活检检测出EGFR突变的非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Neoadjuvant lazertinib
地点: South Korea
申办方: Konkuk University Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05473156

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

AI 简述这是一项I/II期试验，研究AP203用于局部晚期或转移性实体瘤。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；Non Small Cell Lung Cancer (NSCLC)；Head and Neck Squamous Cell Carcinoma (HNSCC)
干预: AP203，AP203
地点: Taiwan
申办方: AP Biosciences Inc.

正在招募 Phase 1, Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT05501665 / NCI-2022-05101

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

AI 简述这是一项I/II期试验，研究分割适应性放疗联合Pembrolizumab加或不加化疗用于IV期非小细胞肺癌。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage III Lung Cancer
干预: Biospecimen Collection，Carboplatin，Computed Tomography，Fludeoxyglucose F-18
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05525338

Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

AI 简述这是一项IV期试验，比较标准剂量和根据血药浓度调整剂量的阿来替尼用于ALK阳性非小细胞肺癌。

?

适用疾病: Drug Monitoring；Carcinoma, Non-Small-Cell Lung；Lung Cancer
干预: Alectinib
地点: France，Netherlands
申办方: University Medical Center Groningen

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05532696

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

AI 简述这是一项I/II期试验，研究ABT-101用于实体瘤和肺癌。

?

适用疾病: Advanced Solid Tumor；Non Small Cell Lung Cancer；HER2 Mutations
干预: ABT-101
地点: Taiwan
申办方: Anbogen Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05568212

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

AI 简述这是一项II期试验，比较标准治疗与免疫联合方案用于经放化疗和度伐利尤单抗治疗的复发III期非小细胞肺癌。

?

适用疾病: Non-small-cell Lung Cancer Patients
干预: Durvalumab，Olaparib tablet，Single-agent chemotherapy，Platinum doublet chemotherapy
地点: Italy
申办方: Fondazione Ricerca Traslazionale

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05570825 / NCI-2022-07428

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究SX-682联合帕博利珠单抗用于转移性或复发性IIIC/IV期非小细胞肺癌。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma；Stage IIIC Lung Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，CXCR1/2 Inhibitor SX-682
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05578326 / NCI-2022-07798

Study of Trilaciclib and Lurbinectidin

AI 简述这是一项2期试验，研究Trilaciclib联合Lurbinectedin用于广泛期小细胞肺癌。

?

适用疾病: Lung Cancer；Small-cell Lung Cancer；Extensive Stage Small Cell Lung Cancer
干预: Trilaciclib，Lurbinectedin
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05588388 / NCI-2024-05748

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

AI 简述这是一项II期试验，研究贝伐珠单抗联合化疗免疫及Atezolizumab用于广泛期小细胞肺癌伴肝转移。

?

适用疾病: Extensive-stage Small-cell Lung Cancer；Liver Metastases；Metastatic Malignant Neoplasm to the Liver
干预: Bevacizumab
地点: United States
申办方: Kamya Sankar

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05589818

Pembrolizumab for Advanced NSCLC and PS 2-3

AI 简述这是一项II期试验，研究Pembrolizumab用于体能状态2-3的晚期非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer (NSCLC)
干预: Pembrolizumab
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05613413

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

AI 简述这是一项II期试验，研究卡博替尼联合帕博利珠单抗维持治疗转移性鳞状非小细胞肺癌。

?

适用疾病: Metastatic Squamous Non-Small Cell Lung Carcinoma
干预: Pacliltaxel or Nab-paclitaxel，Carboplatin or Cisplatin，Pembrolizumab，Cabozantinib
地点: United States
申办方: University of Illinois at Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05623319

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

AI 简述这是一项II期试验，研究Pembrolizumab联合Olaparib用于广泛期小细胞肺癌，在意大利开展。

?

适用疾病: SCLC,Extensive Stage
干预: Pembrolizumab/Olaparib
地点: Italy
申办方: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05631249

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

AI 简述这是一项II期试验，研究Sotorasib用于既往治疗过的KRAS G12C突变局部晚期或转移性非小细胞肺癌。

?

适用疾病: KRAS P.G12C；Non Small Cell Lung Cancer
干预: Sotorasib 120Mg Tab
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05642572 / NCI-2022-09254

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

AI 简述这是一项II期试验，比较多种靶向药物组合用于EGFR和MET基因改变的晚期非小细胞肺癌，在美国开展。

?

适用疾病: Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IV Lung Cancer
干预: Biospecimen Collection，Capmatinib，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05652686 / NCI-2023-04193

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

AI 简述这是一项I/II期试验，Peluntamig (PT217) 用于表达DLL3的神经内分泌癌（包括SCLC、LCNEC、NEPC、GEP-NEC等）。

?

适用疾病: Small Cell Lung Cancer (SCLC)；Large Cell Neuroendocrine Cancer (LCNEC)；Neuroendocrine Prostate Cancer (NEPC)
干预: Peluntamig (PT217)，Carboplatin + Etoposide，Paclitaxel.，Atezolizumab
地点: United States
申办方: Phanes Therapeutics

正在招募 Phase 2 生物制剂药物放疗

ClinicalTrials.gov / NCI NCT05657873 / NCI-2023-00405

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，研究L-SABR联合免疫治疗和化疗用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Non Small Cell Lung Cancer Metastatic；Non-small Cell Carcinoma
干预: L-SABR，Anti-PD-(L)1 based immunotherapy，Platinum based chemotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05669430 / NCI-2023-06313

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究GV20-0251单药或联合Pembrolizumab用于多种晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Refractory Cancer；Endometrial Carcinoma (EC)
干预: GV20-0251，GV20-0251 and Pembrolizumab [KEYTRUDA®]
地点: United States
申办方: GV20 Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05669846 / NCI-2025-04863

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

AI 简述这是一项II期试验，研究健康供体粪菌移植联合Pembrolizumab用于PD-L1阳性复发/难治性非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Stage IV Lung Cancer；Refractory Non-Small Cell Lung Cancer
干预: Healthy Donor Fecal Microbiota Transplant (hdFMT)，Pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 2 器械药物手术/操作

ClinicalTrials.gov / NCI NCT05672108 / NCI-2022-10436

Phase II Trial of Lung Chemoemobolization

AI 简述这是一项II期试验，研究肺化疗栓塞术用于非小细胞肺癌等胸部肿瘤。

?

适用疾病: Lung Non-Small Cell Carcinoma；Mediastinal Neoplasm；Pleural Neoplasm
干预: Computed Tomography，Ethiodized Oil，Mitomycin，Transarterial Chemoembolization
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05703971 / NCI-2024-02213

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

AI 简述这是一项I/II期试验，在美国研究Quaratusugene Ozeplasmid联合Atezolizumab用于广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer Extensive Stage；Extensive Stage Small Cell Lung Cancer
干预: quaratusugene ozeplasmid，atezolizumab
地点: United States
申办方: Genprex, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05706129

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究[68Ga]Ga-DPI-4452和[177Lu]Lu-DPI-4452用于多种晚期实体瘤。在澳大利亚、法国等地开展。

?

适用疾病: Clear Cell Renal Cell Cancer (ccRCC)；Pancreatic Ductal Adenocarcinoma (PDAC)；Colorectal Cancer (CRC)
干预: [68Ga]Ga-DPI-4452，[177Lu]Lu-DPI-4452
地点: Australia，France
申办方: ITM Oncologics GmbH

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05713006

Alectinib Pharmacokinetic in Patients With NSCLC

AI 简述这是一项I/II期试验，研究Alectinib用于ALK突变非小细胞肺癌IIIB期。

?

适用疾病: Non-small Cell Lung Cancer Stage IIIB；ALK Gene Mutation
干预: Alectinib Oral Product
地点: Mexico
申办方: Instituto Nacional de Cancerologia de Mexico

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05715229 / NCI-2024-03771

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

AI 简述这是一项II期试验，研究Nivolumab联合Ipilimumab加化疗用于晚期非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Nivolumab，Ipilimumab，Carboplatin，Paclitaxel
地点: United States
申办方: Hackensack Meridian Health

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05718323

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

AI 简述这是一项II期试验，在法国等地研究Niraparib联合抗PD-L1抗体维持治疗用于SLFN11阳性广泛期小细胞肺癌。

?

适用疾病: SCLC,Extensive Stage；SLFN11-positive
干预: Niraparib
地点: France，Germany，Italy，Spain 等 1 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05742607 / NCI-2023-10573

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

AI 简述这是一项II期试验，在美国、法国、希腊、匈牙利等地研究IPH5201联合Durvalumab用于可切除非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: IPH5201 + durvalumab + standard chemotherapy
地点: United States，France，Greece，Hungary 等 1 个
申办方: Innate Pharma

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05748093

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat

AI 简述这是一项IV期试验，研究考比司他提高奥希替尼暴露量和成本效益，用于非小细胞肺癌，在荷兰开展。

?

适用疾病: Non-small Cell Lung Cancer
干预: Cobicistat
地点: Netherlands
申办方: Maastricht University Medical Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05751798

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

AI 简述这是一项I/II期试验，研究OSE-279用于晚期实体瘤或淋巴瘤。

?

适用疾病: Solid Advanced Tumor；Lymphoma；NSCLC (Non-small Cell Lung Cancer)
干预: Part A: OSE-279 100mg，Part A: OSE-279 300mg，Part A: OSE-279 600mg，Part B: OSE-279 600 mg and OSE2101
地点: Belgium，France，Spain
申办方: OSE Immunotherapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05786924 / NCI-2023-03966

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

AI 简述这是一项I/II期试验，研究S241656用于RAS/MAPK突变阳性恶性肿瘤。在美、丹、港、日等地开展。

?

适用疾病: Non-small Cell Lung Cancer；Histiocytic Neoplasm；Histiocytosis
干预: S241656，FOLFOX6/FOLFOX7，FOLFIRI，Cetuximab
地点: United States，Denmark，Hong Kong，Japan 等 1 个
申办方: Institut de Recherches Internationales Servier

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05800587 / NCI-2023-02682

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

AI 简述这是一项II期试验，研究减量化疗用于体弱肺癌患者，在美国开展。

?

适用疾病: Lung Cancer；Small-cell Lung Cancer；Non Small Cell Lung Cancer
干预: Carboplatin，Pemetrexed，Paclitaxel，Nab paclitaxel
地点: United States
申办方: Fox Chase Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05841472

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，在韩国开展，研究卡瑞利珠单抗联合培美曲塞和卡铂一线治疗晚期或转移性非鳞非小细胞肺癌。

?

适用疾病: Non Squamous Non Small Cell Lung Cancer
干预: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
地点: South Korea
申办方: CrystalGenomics, Inc.

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05874401

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

AI 简述这是一项IV期试验，比较Trilaciclib与安慰剂用于广泛期小细胞肺癌患者接受Topotecan治疗。

?

适用疾病: Extensive-stage Small-cell Lung Cancer
干预: Trilaciclib，Placebo，Topotecan
地点: Spain
申办方: Pharmacosmos A/S

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05902988 / NCI-2023-08591

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

AI 简述这是一项I/II期试验，研究VLS-1488用于晚期实体瘤，包括卵巢癌、肺癌、乳腺癌等，在美国开展。

?

适用疾病: Advanced Solid Tumor；High Grade Serous Adenocarcinoma of Ovary；Squamous Non-small-cell Lung Cancer
干预: VLS-1488
地点: United States
申办方: Volastra Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05903092 / NCI-2023-05121

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Monalizumab联合Durvalumab及化疗用于小细胞肺癌，在美国开展。

?

适用疾病: Small Cell Lung Cancer；SCLC；Extensive Stage Small Cell Lung Cancer
干预: Durvalumab，Monalizumab，Carboplatin or Cisplatin，Etoposide
地点: United States
申办方: Hirva Mamdani

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05910827

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

AI 简述这是一项I/II期试验，在澳洲等地研究HMBD-001联合Cetuximab±Docetaxel用于晚期鳞状细胞癌。

?

适用疾病: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Esophageal Squamous Cell Carcinoma
干预: HMBD-001，Docetaxel，Cetuximab
地点: Australia，Moldova，Singapore，South Korea 等 1 个
申办方: Hummingbird Bioscience

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05937906

Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

AI 简述这是一项I/II期试验，研究Mirdametinib联合化免用于PD-L1<50%的非鳞非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Phase I - Mirdametinib - Level 1，Phase II - Mirdametinib，Phase I - Mirdametinib - Level 2，Phase I - Mirdametinib - Level 3
地点: France
申办方: Centre Georges Francois Leclerc

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT05950139 / NCI-2024-09873

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

AI 简述这是一项1/2期试验，研究肽疫苗用于预防晚期ALK阳性非小细胞肺癌获得性耐药，在美国开展。

?

适用疾病: NSCLC Stage IV；ALK Fusion Protein Expression；Stage IV Lung Cancer
干预: Peptide vaccine
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05967689 / NCI-2023-10904

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

AI 简述这是一项II期试验，研究Zipalertinib用于EGFR外显子20插入突变的晚期非小细胞肺癌。

?

适用疾病: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations；Stage III Lung Cancer；Stage IV Lung Cancer
干预: TAS6417，CYP Cocktail，Transporter Cocktail
地点: United States，Australia，Canada，France 等 8 个
申办方: Taiho Oncology, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05985655 / NCI-2026-01491

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GTAEXS617用于多种晚期实体瘤。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预: GTAEXS617，SoC
地点: United States，Belgium，United Kingdom
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06007937 / NCI-2023-06778

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

AI 简述这是一项I/II期试验，研究Lorlatinib联合Ramucirumab用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Metastatic；Recurrent
干预: Lorlatinib，Ramucirumab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 其他手术/操作放疗

ClinicalTrials.gov / NCI NCT06008730 / NCI-2023-02941

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究质子束放疗用于切除后N2非小细胞肺癌。

?

适用疾病: Resectable Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Proton Beam Radiation Therapy，Radiology, Treatment Planning
地点: United States
申办方: Emory University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06010329 / NCI-2023-10529

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

AI 简述这是一项II期试验，研究Sutetinib Maleate Capsule用于局部晚期或转移性非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Sutetinib Maleate Capsule
地点: United States
申办方: Teligene US

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06031688 / NCI-2023-04727

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

AI 简述这是一项II期试验，研究靶向治疗用于美国晚期MET外显子14跳跃突变非小细胞肺癌。

?

适用疾病: Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IV Lung Cancer
干预: Biospecimen Collection，Computed Tomography，Lymphoscintigraphy，Magnetic Resonance Imaging
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06043817 / NCI-2023-07625

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

AI 简述这是一项I/II期试验，研究STX-721/PFL-721用于EGFR或HER2外显子20插入突变非小细胞肺癌。在美国、法国等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；NSCLC；EGFR/HER2 Exon 20 Insertion Mutation
干预: STX-721/PFL-721 (Escalated)，STX-721/PFL-721 (3 dose levels)，STX-721/PFL-721 (RP2D)
地点: United States，France，Germany，Netherlands 等 3 个
申办方: Pierre Fabre Medicament

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06047379 / NCI-2024-08760

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

AI 简述这是一项1/2期试验，研究NEO212用于星形细胞瘤、胶质母细胞瘤或脑转移瘤。在美国开展。

?

适用疾病: Diffuse Astrocytoma, IDH-Mutant；Glioblastoma, IDH-wildtype；Brain Metastases, Adult
干预: NEO212 Oral Capsule，Ipilimumab，Pembrolizumab，Nivolumab
地点: United States
申办方: Neonc Technologies, Inc.

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06051695 / NCI-2024-01620

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，在美国开展，研究间皮素靶向逻辑门控CAR-T细胞用于表达MSLN且失去HLA-A*02表达的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；NSCLC
干预: A2B694，A2B543，xT CDx with HLA-LOH Assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06060613 / NCI-2024-02051

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究OBX-115用于晚期实体瘤，在美国和澳大利亚等地开展。

?

适用疾病: Tumor Skin；Metastatic Melanoma；Melanoma
干预: OBX-115
地点: United States，Australia
申办方: Obsidian Therapeutics, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06088771 / NCI-2023-10539

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

AI 简述这是一项I/II期试验，研究Dupilumab联合Cemiplimab用于早期可切除非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage IA2 Lung Cancer；Stage IA3 Lung Cancer
干预: Dupilumab，Cemiplimab
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06090266

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

AI 简述这是一项I/II期试验，研究OR502单药及联合抗癌药用于晚期实体瘤。

?

适用疾病: Cancer；Tumor, Solid；Malignant Neoplasm
干预: OR502，Cemiplimab
地点: United States
申办方: OncoResponse, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06095505 / NCI-2023-10166

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Alisertib用于广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: Alisertib
地点: United States
申办方: Puma Biotechnology, Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06102057

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

AI 简述这是一项II期试验，研究免疫化疗联合放疗用于局部晚期不可切除非小细胞肺癌，在德国和瑞士等地开展。

?

适用疾病: Stage III Non-small Cell Lung Cancer；Locally Advanced；Unresectable
干预: standard Radiotherapy，Chemotherapy，Immunotherapy，Experimental Radiotherapy
地点: Germany，Switzerland
申办方: TheraOp

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06106802

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

AI 简述这是一项II期试验，研究Lazertinib联合Tepotinib用于EGFR突变非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer Metastatic
干预: Lazertinib，Tepotinib
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06110572 / NCI-2023-08550

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

AI 简述这是一项I/II期试验，研究Atezolizumab联合化疗和全身照射用于广泛期小细胞肺癌。在美国开展。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Stage IV Lung Cancer；Extensive Stage Small Cell Lung Cancer
干预: Carboplatin，Atezolizumab，Etoposide，Total Body Irradiation
地点: United States
申办方: Vanderbilt-Ingram Cancer Center

正在招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06116682 / NCI-2023-07072

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

AI 简述这是一项II期试验，研究Amivantamab用于MET基因扩增的晚期非小细胞肺癌。在美国开展。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer；Non-Small Cell Lung Cancer
干预: Amivantamab，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06128551 / NCI-2024-02114

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

AI 简述这是一项1/2期试验，研究Elironrasib和Daraxonrasib单药或联合用于KRAS G12C突变实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer (NSCLC)；Colorectal Cancer；Pancreatic Ductal Adenocarcinoma
干预: Elironrasib，Daraxonrasib
地点: United States，France，Germany，Italy 等 3 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06162221 / NCI-2024-02382

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

AI 简述这是一项I/II期试验，研究RAS抑制剂RMC-6291和RMC-6236用于RAS突变非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer, NSCLC；KRAS, NRAS, HRAS-mutated NSCLC；KRAS G12C-mutated Solid Tumors, Lung Cancer
干预: RMC-6291，RMC-6236，Pembrolizumab，Cisplatin
地点: United States，Australia，Austria，Czechia 等 9 个
申办方: Revolution Medicines, Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06223711

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

AI 简述这是一项II期试验，研究Durvalumab联合放化疗和立体定向放疗用于广泛期小细胞肺癌。

?

适用疾病: Extensive-stage Small-cell Lung Cancer
干预: Thoracic Radiochemotherapy，durvalumab，Stereotactic radiotherapy of further tumor locations，Chemotherapy
地点: Germany
申办方: Universität des Saarlandes

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06228326 / NCI-2024-03666

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

AI 简述这是一项I/II期试验，研究KB707用于晚期非小细胞肺癌和实体瘤。

?

适用疾病: Lung Cancer, Non-small Cell；Lung Cancer Metastatic；Solid Tumor, Adult
干预: KB707，Pembrolizumab (KEYTRUDA®)，Chemotherapy，Docetaxel
地点: United States
申办方: Krystal Biotech, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究MDX2001用于晚期实体瘤，包括胆管癌、乳腺癌等。

?

适用疾病: Biliary Tract Cancer；Breast Cancer；Cervical Cancer
干预: MDX2001
地点: United States
申办方: ModeX Therapeutics, An OPKO Health Company

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06244771

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究FMC-376用于KRAS G12C突变的晚期实体瘤。

?

适用疾病: Advanced Solid Tumors With KRAS G12C Mutations；Solid Tumor, Adult；Unresectable Solid Tumor
干预: FMC-376
地点: United States，Australia，South Korea
申办方: Frontier Medicines Corporation

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06248606 / NCI-2024-06546

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

AI 简述这是一项II期试验，研究Adagrasib联合立体定向放疗用于KRAS G12C突变非小细胞肺癌脑转移，在美国开展。

?

适用疾病: Non Small Cell Lung Cancer；NSCLC；KRAS G12C
干预: Adagrasib，Stereotactic Radiosurgery
地点: United States
申办方: Ryan Gentzler, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06249854

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究Bojungikki-tang联合Pembrolizumab用于晚期非小细胞肺癌，在韩国开展。

?

适用疾病: Non-small Cell Lung Cancer
干预: Bojungikki-tang(BJIKT)，Pembrolizumab
地点: South Korea
申办方: Korea Institute of Oriental Medicine

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT06262321 / NCI-2025-05815

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

AI 简述这是一项II期试验，在美国研究预防性姑息放疗用于IV期非小细胞肺癌。

?

适用疾病: Stage 4 NSCLC；Radiotherapy；Stage IV Lung Cancer
干预: Prophylactic Palliative Radiotherapy
地点: United States
申办方: University of Rochester

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06275360

Repositioning Immunotherapy in VetArans With Lung Cancer

AI 简述这是一项II期试验，研究Nivolumab用于非小细胞肺癌，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Nivolumab
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06281678

A Study of IBI363 in Subjects with Advanced Solid Malignancies

AI 简述这是一项II期试验，研究IBI363用于晚期黑色素瘤、非小细胞肺癌、结直肠癌、肾癌。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Colorectal Cancer
干预: IBI363
地点: United States
申办方: Innovent Biologics (Suzhou) Co. Ltd.

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06287775 / NCI-2024-01398

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究Iadademstat联合Atezolizumab或Durvalumab用于小细胞肺癌。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IV Lung Cancer
干预: Atezolizumab，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06303505 / NCI-2024-07935

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

AI 简述这是一项I/II期试验，研究NaPi2b ADC TUB-040用于铂耐药卵巢癌或复发难治肺腺癌。

?

适用疾病: Ovarian Cancer；Non-small Cell Lung Cancer；Platinum-Resistant Ovarian Cancer
干预: TUB-040
地点: United States，Belgium，Germany，Romania 等 3 个
申办方: Tubulis GmbH

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT06305715

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

AI 简述这是一项II期试验，研究TKI靶向治疗前使用放疗用于晚期驱动基因突变非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Radiation Therapy，Targeted TKI therapy
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06315010

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

AI 简述一项II期试验，研究Repotrectinib用于ROS1阳性非小细胞肺癌伴活动性脑转移，在奥地利、德国、西班牙开展。

?

适用疾病: NSCLC；Brain Metastases；ROS1 Gene Rearrangement
干预: Repotrectinib
地点: Austria，Germany，Spain
申办方: MedSIR

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06331455

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

AI 简述这是一项II期试验，研究度伐利尤单抗联合非消融寡分割放疗用于肺上沟瘤、肺尖和胸壁非小细胞肺癌，在加拿大开展。

?

适用疾病: Lung Cancer Patients；Non-small Cell Lung Cancer (NSCLC)
干预: Durvalumab，Non-ablative oligofractionated radiation (NORT)
地点: Canada
申办方: Marc de Perrot

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06362252 / NCI-2024-06081

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

AI 简述这是一项I/II期试验，研究I-DXd联合Atezolizumab用于广泛期小细胞肺癌。

?

适用疾病: Extensive Stage-small Cell Lung Cancer；Extensive Stage Small Cell Lung Cancer
干预: Ifinatamab deruxtecan，Atezolizumab，Carboplatin
地点: United States，France，Japan，Spain
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06362369 / NCI-2024-03436

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

AI 简述这是一项I/II期试验，研究Alintegimod联合Ipilimumab及Nivolumab用于晚期实体瘤。

?

适用疾病: Advanced Cancer；Advanced Solid Tumor；Melanoma
干预: Alintegimod，Ipilimumab，Nivolumab
地点: United States
申办方: 7 Hills Pharma, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06364917 / NCI-2025-07478

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

AI 简述这是一项II期试验，比较双免疫与单免疫联合化疗用于PD-L1阴性非小细胞肺癌，在美国开展。

?

适用疾病: Non Small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Pembrolizumab，Carboplatin，Paclitaxel，Pemetrexed
地点: United States
申办方: University of Alabama at Birmingham

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06378892

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

AI 简述这是一项II期试验，研究铂类培美曲塞联合Lorlatinib用于ALK阳性非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer Metastatic；ALK Gene Mutation
干预: Lorlatinib
地点: Italy
申办方: Centro di Riferimento Oncologico - Aviano

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06401824

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

AI 简述这是一项II期试验，研究Sacituzumab Govitecan联合贝伐珠单抗用于非小细胞肺癌脑转移。

?

适用疾病: NSCLC Stage IV；Brain Metastases, Adult
干预: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
地点: Netherlands
申办方: Maastricht University Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

AI 简述这是一项II期试验，研究减少免疫检查点抑制剂给药频率用于晚期癌症。在新加坡开展。

?

适用疾病: Carcinoma, Hepatocellular；Gastric Adenocarcinoma；GastroEsophageal Cancer
干预: Extended Dosing Interval - A，Extended Dosing Interval - B，Extended Dosing Interval - C，Standard of Care - A
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06424067 / NCI-2025-03533

Phase 2 Study of Fingolimod in Lung Cancers

AI 简述这是一项II期试验，在美国研究Fingolimod用于肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Small-cell Lung Cancer；Stage III Lung Cancer
干预: Fingolimod 0.5 milligram (mg) [Gilenya]
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06448572

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

AI 简述这是一项I/II期试验，研究EXL01联合Nivolumab用于免疫治疗难治的晚期非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: EXL01
地点: France
申办方: University Hospital, Lille

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06449313 / NCI-2025-08552

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

AI 简述这是一项II期试验，研究Cemiplimab-Rwlc联合化疗用于局部晚期N3淋巴结非小细胞肺癌的术前治疗。

?

适用疾病: Non-small Cell Lung Cancer Stage III；Stage IIIB Lung Cancer；Stage IIIC Lung Cancer
干预: Cemiplimab-Rwlc
地点: United States
申办方: Georgetown University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06455917

TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

AI 简述这是一项II期试验，在瑞士研究TIL疗法用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Lung Cancer (NSCLC)
干预: TILs（Tumor Infiltrating Lymphocytes）
地点: Switzerland
申办方: University Hospital, Basel, Switzerland

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06463665 / NCI-2025-00598

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

AI 简述这是一项II期试验，在美国开展，比较Olvimulogene nanivacirepvec联合铂类化疗和免疫检查点抑制剂与多西他赛用于晚期非小细胞肺癌。

?

适用疾病: Advanced Non-squamous Non-small-cell Lung Cancer；Advanced Squamous Non-Small Cell Lung Carcinoma；Metastatic Non-squamous Non Small Cell Lung Cancer
干预: Olvimulogene nanivacirepvec，Platinum chemotherapy: carboplatin or cisplatin，Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC，Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab
地点: United States
申办方: Genelux Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06465329 / NCI-2024-09845

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，在美国、巴西、法国、德国等地开展，比较西米普利单抗加化疗与西米普利单抗加化疗加其他药物治疗可手术非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: Cemiplimab，Platinum-based chemotherapy，REGN7075
地点: United States，Brazil，France，Germany 等 2 个
申办方: Regeneron Pharmaceuticals

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06495125 / NCI-2024-04302

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Defactinib、Avutometinib和Nivolumab用于抗PD1难治性LKB1突变晚期非小细胞肺癌。

?

适用疾病: Advanced Lung Adenocarcinoma；Refractory Lung Adenocarcinoma；Stage III Lung Cancer AJCC v8
干预: Avutometinib，Biopsy，Biospecimen Collection，Computed Tomography
地点: United States
申办方: Emory University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06552234

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

AI 简述这是一项II期试验，研究瑞普替尼用于虚弱或老年ROS1重排晚期NSCLC患者，在法国开展。

?

适用疾病: NSCLC Stage IV；NSCLC, Stage III
干预: Repotrectinib
地点: France
申办方: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06579196 / NCI-2025-01866

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

AI 简述这是一项I/II期试验，研究Trabedersen联合帕博利珠单抗用于PD-L1阳性晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Trabedersen，Pembrolizumab
地点: United States
申办方: University of Nebraska

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06582771 / NCI-2024-07528

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Sotorasib用于非小细胞肺癌。在美国开展。

?

适用疾病: Non Small Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Sotorasib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06616766

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

AI 简述这是一项I/II期试验，研究YH42946用于非小细胞肺癌和实体瘤。

?

适用疾病: NSCLC (Non-small Cell Lung Cancer)；Solid Tumor
干预: YH42946
地点: United States，South Korea
申办方: Yuhan Corporation

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06618287 / NCI-2024-09548

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986507联合奥希替尼或帕博利珠单抗或纳武利尤单抗用于晚期实体瘤，在多国开展。

?

适用疾病: Lung Cancer；Breast Cancer；Advanced Malignant Solid Tumor
干预: BMS-986507，Osimertinib，Pembrolizumab，Nivolumab
地点: United States，Australia，Canada，Chile 等 5 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT06620835

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

AI 简述这是一项II期试验，在法国评估局部消融治疗优化用于ALK重排的晚期非小细胞肺癌患者，使用Brigatinib治疗。

?

适用疾病: NSCLC
干预: Blood samples for Hematology，Blood samples for Chemistry，Blood sample for liver function tests，Pregnancy test
地点: France
申办方: Groupe Francais De Pneumo-Cancerologie

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT06630611

Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)

AI 简述这是一项II期试验，评估肿瘤浸润淋巴细胞（TIL）治疗后使用IL-2类似物（ANV419）对比高剂量IL-2，用于黑色素瘤、非小细胞肺癌和宫颈癌。

?

适用疾病: Melanoma；Non Small Cell Lung Cancer；Cervical Cancer
干预: NMA-LD regimen，Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion，High dose IL-2，IL-2 analog
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06634056

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

AI 简述这是一项II期试验，在加拿大研究己酮可可碱与α-生育酚用于III期非小细胞肺癌放化疗患者的肺部预防。

?

适用疾病: Non-Small Cell Lung Cancer；Radiation Induced Lung Injury (RILI)
干预: Pentoxifylline，Placebo，α-Tocopherol
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06656598

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

AI 简述这是一项II期试验，研究辅助化疗加或不加Cemiplimab及序贯放疗用于III期肺癌不适合或老年患者。在法国开展。

?

适用疾病: Stage III NSCLC
干预: Carboplatin，Paclitaxel，Cemiplimab，Curative hypofractionated radiotherapy
地点: France
申办方: Intergroupe Francophone de Cancerologie Thoracique

正在招募 Phase 2 其他手术/操作放疗

ClinicalTrials.gov / NCI NCT06660407 / NCI-2024-08757

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

AI 简述这是一项2期试验，研究网格放疗联合免疫治疗用于IV期非小细胞肺癌，在美国开展。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IV Lung Cancer
干预: Biospecimen Collection，Computed Tomography，Immunotherapy，Palliative Radiation Therapy
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06663098

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

AI 简述这是一项II期试验，研究Atezolizumab联合化疗再挑战用于复发广泛期小细胞肺癌。

?

适用疾病: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
干预: Atezolizumab，Carboplatin，Etoposide
地点: Italy
申办方: Gruppo Oncologico Italiano di Ricerca Clinica

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06667076 / NCI-2025-00167

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，在美国、比利时、芬兰、法国等地研究Amivantamab联合Lazertinib或联合含铂化疗用于EGFR突变局部晚期或转移性非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Amivantamab，Lazertinib，Chemotherapy: Pemetrexed，Chemotherapy: Carboplatin
地点: United States，Belgium，Finland，France 等 9 个
申办方: Janssen Research & Development, LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06667154

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

AI 简述这是一项II期试验，在巴西研究低剂量纳武利尤单抗联合含铂双药化疗用于非小细胞肺癌新辅助治疗。

?

适用疾病: Lung Cancer, Nonsmall Cell；Non-Small Cell Lung Cancer NSCLC
干预: Low-dose nivolumab combined with platinum-based doublet chemotherapy
地点: Brazil
申办方: Aline Fusco Fares, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06667167

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

AI 简述这是一项II期试验，在以色列研究卡铂诱导化疗后帕博利珠单抗联合Sacituzumab Govitecan用于广泛期小细胞肺癌。

?

适用疾病: NSCLC (non-small Cell Lung Cancer)
干预: Induction Carboplatin
地点: Israel
申办方: Nir Peled

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06680050

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

AI 简述一项II期试验，放疗后使用Durvalumab和Ceralasertib用于III期NSCLC胸部复发±寡转移。

?

适用疾病: Non Small Cell Lung Cancer NSCLC
干预: Durvalumab (MEDI4736)，Ceralasertib，radiotherapy
地点: Italy，Switzerland
申办方: Mario Negri Institute for Pharmacological Research

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov NCT06681220

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

AI 简述一项I/II期试验，替莫唑胺和Stenoparib用于复发小细胞肺癌的生物标志物指导治疗。

?

适用疾病: Relapsed Small Cell Lung Cancer；Recurrent Small Cell Lung Cancer
干预: Stenoparib/Temozolomide，Lurbinectedin，Stenoparib/Temozolomide
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06682793 / NCI-2025-01614

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，研究A2B395（一种CAR-T）用于表达EGFR且HLA-A*02缺失的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；Non-Small Cell Lung
干预: A2B395，xT CDx with HLA-LOH assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06693336 / NCI-2026-00835

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究SMS001辅助治疗非小细胞肺癌，在美国、加拿大开展。

?

适用疾病: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)；Stage IB Lung Cancer；Stage IIA Lung Cancer
干预: SMS001
地点: United States，Canada
申办方: ToLymph Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06694454 / NCI-2024-09774

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项1/2期试验，研究吸入阿扎胞苷联合铂类化疗和度伐利尤单抗用于早期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Carcinoma, Non-Small Cell Lung；Non-Small Cell Lung Carcinoma
干预: azacytidine，carboplatin，paclitaxel，durvalumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06695845

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

AI 简述这是一项2期试验，研究Zanidatamab用于HER2表达肿瘤，在美国、韩国、西班牙等地开展。

?

适用疾病: Breast Cancer；Gastric Cancer；Esophageal Cancer
干预: Zanidatamab
地点: United States，South Korea，Spain
申办方: Jazz Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06706076 / NCI-2025-01958

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

AI 简述这是一项I/II期试验，研究BH-30643用于EGFR/HER2突变的局部晚期或转移性非小细胞肺癌，在美国等地开展。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；Stage III Lung Cancer；Stage IV Lung Cancer
干预: BH-30643
地点: United States，Australia，Canada，Hong Kong 等 5 个
申办方: BlossomHill Therapeutics

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT06731270 / NCI-2024-07760

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

AI 简述这是一项II期试验，研究双氯芬酸联合免疫单药用于转移性非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Stage III Lung Cancer AJCC v8
干预: Atezolizumab，Biospecimen Collection，Cemiplimab，Computed Tomography
地点: United States
申办方: Emory University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06731413 / NCI-2025-00893

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，研究减量化疗联合抗PD-1用于老年晚期非小细胞肺癌（PD-L1<50%）。

?

适用疾病: Non-Small Cell Lung Cancer；NSCLC；Advanced Non-Small Cell Lung Cancer
干预: Reduced Dose of Chemotherapy and Immunotherapy
地点: United States
申办方: Virginia Commonwealth University

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06731907 / NCI-2025-06350

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

AI 简述这是一项II期试验，研究帕博利珠单抗联合化疗及其他药物用于晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage IV Lung Cancer；Advanced Non-Squamous Non-Small Cell Lung Cancer
干预: Pembrolizumab，Carboplatin，Paclitaxel，Nab-paclitaxel
地点: United States，Chile，Greece，Hungary 等 7 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06741085 / NCI-2024-10479

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

AI 简述这是一项II期试验，研究osimertinib与立体定向放射外科用于肺癌脑转移。

?

适用疾病: Non Small Cell Lung Cancer Metastatic；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: osimertinib，stereotactic radiosurgery (SRS)
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06745882 / NCI-2025-00831

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

AI 简述这是一项II期试验，评估帕博利珠单抗联合化疗在非小细胞肺癌黑人患者中的真实世界结局。

?

适用疾病: Non-small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Cisplatin，Carboplatin，Pemetrexed，Pembrolizumab
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06747585 / NCI-2025-03675

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

AI 简述这是一项I/II期试验，研究ALE.P02用于CLDN1阳性实体瘤，在美国、法国等地开展。

?

适用疾病: Squamous Non-small-cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Cervical Squamous Cell Carcinoma
干预: ALE.P02
地点: United States，France，Hong Kong，Italy 等 4 个
申办方: Alentis Therapeutics AG

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06769126 / NCI-2024-10080

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

AI 简述这是一项II期试验，使用生物标志物选择个性化治疗用于广泛期小细胞肺癌。在美国开展。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Lung Small Cell Carcinoma, A Subtype；Lung Small Cell Carcinoma, I Subtype
干预: Biospecimen Collection，Ceralasertib，Computed Tomography，Durvalumab
地点: United States
申办方: SWOG Cancer Research Network

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06771518

Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab

AI 简述这是一项II期试验，研究胸部放疗联合Atezolizumab维持免疫治疗用于小细胞肺癌，在意大利开展。

?

适用疾病: Small Cell Lung Cancer
干预: Thoracic radiotherapy，Atezolizumab 1200 mg e.v. q21
地点: Italy
申办方: Regina Elena Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06773910 / NCI-2026-01730

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

AI 简述这是一项II期试验，比较BMS-986489与Durvalumab用于局限期小细胞肺癌。

?

适用疾病: Limited Stage Small Cell Lung Cancer
干预: BMS-986489，Durvalumab
地点: United States
申办方: SCRI Development Innovations, LLC

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06780085 / NCI-2025-06349

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

AI 简述这是一项II期试验，研究Raludotatug Deruxtecan等用于经治IV期非鳞非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: Raludotatug Deruxtecan，Ifinatamab Deruxtecan，Docetetaxel，5-hydroxytryptamine subtype 3 receptor antagonist
地点: United States，Chile，Germany，Greece 等 6 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06784791

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

AI 简述这是一项II期试验，研究Amivantamab单用或联合化疗用于可手术EGFR突变非小细胞肺癌，在比利时、德国、荷兰开展。

?

适用疾病: Lung Cancer (NSCLC)
干预: Amivantamab Intravenous，Carboplatin/Pemetrexed
地点: Belgium，Germany，Netherlands
申办方: University Hospital, Essen

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06810544 / NCI-2025-02619

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

AI 简述这是一项I/II期试验，研究TNG456单用或联合abemaciclib用于MTAP缺失的实体瘤。

?

适用疾病: Non Small Cell Lung Cancer；Glioma Glioblastoma Multiforme；Glioma, Malignant
干预: TNG456，abemaciclib
地点: United States
申办方: Tango Therapeutics, Inc.

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT06810609

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

AI 简述这是一项II期试验，研究免疫化疗、手术或放化疗联合Durvalumab用于IIIA/B期非小细胞肺癌。

?

适用疾病: Lung Cancer Non-Small Cell Cancer (NSCLC)
干预: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines，Chemoradiotherapy，Immunotherapy
地点: Germany
申办方: University Hospital, Bonn

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06814496 / NCI-2025-05953

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

AI 简述这是一项I/II期试验，研究Tarlatamab联合放疗用于DLL3表达的多种肿瘤，在美国开展。

?

适用疾病: Melanoma；Medullary Thyroid Cancer；Sinonasal Undifferentiated Carcinoma
干预: Tarlatamab，Concurrent Radiation Therapy，Sequential Radiation therapy
地点: United States
申办方: University of Arizona

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06822543

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)

AI 简述这是一项II期试验，在巴西开展，研究Datopotamab Deruxtecan联合卡铂和帕博利珠单抗用于初治非小细胞肺癌脑转移。

?

适用疾病: Lung Cancer；Non Small Cell Lung Cancer；Brain Metastases
干预: Pembrolizumab，Datopotamab deruxtecan，Carboplatin
地点: Brazil
申办方: Latin American Cooperative Oncology Group

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06841055 / NCI-2025-03698

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

AI 简述这是一项II期试验，研究Pumitamig联合化疗用于一线或二线非小细胞肺癌，在美国、澳大利亚、韩国和西班牙等地开展。

?

适用疾病: Non-small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Pumitamig，Docetaxel
地点: United States，Australia，South Korea，Spain 等 2 个
申办方: BioNTech SE

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06865339 / NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究胸部放疗联合PD-1和LAG-3抑制剂用于局部晚期非小细胞肺癌。

?

适用疾病: NSCLC；Locally Advanced；Stage II Lung Cancer
干预: Cemiplimab，Fianlimab，Radiotherapy，Platinum Doublet Chemotherapy (PDC)
地点: United States
申办方: Montefiore Medical Center

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06878274

Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC

AI 简述这是一项II期试验，研究术后放疗用于新辅助化免和手术后III期非小细胞肺癌，在加拿大开展。

?

适用疾病: Non Small Cell Lung Cancer；Stage III Lung Cancer
干预: Post-operative radiotherapy
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06896890

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究吸入干粉顺铂（CIS-DPI）用于IV期非小细胞肺癌，在比利时、法国、西班牙等地开展。

?

适用疾病: NSCLC (advanced Non-small Cell Lung Cancer)；Stage IV Lung Cancer
干预: CIS-DPI
地点: Belgium，France，Spain
申办方: Inhatarget Therapeutics

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT06902272 / NCI-2025-04101

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究ctDNA预测化疗免疫治疗反应和检测非小细胞肺癌微小残留病。

?

适用疾病: Non Small Cell Lung Cancer；Stage IB Lung Cancer；Stage II Lung Cancer
干预: Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay，Pembrolizumab，Platinum Doublet Chemotherapy
地点: United States
申办方: University of Miami

正在招募 Phase 4 药物

ClinicalTrials.gov NCT06908070

Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab

AI 简述这是一项IV期试验，研究同步放化疗后Durvalumab巩固治疗用于III期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer Stage III
干预: Consolidation durvalumab
地点: Netherlands
申办方: Idris Bahce

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06917573

PALACE: Cemiplimab Trial According to ctDNA Levels

AI 简述这是一项II期试验，研究Cemiplimab联合化疗用于转移性非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer Metastatic；Lung Diseases；Stage IV Non-small Cell Lung Cancer
干预: Cemiplimab，Carboplatin，Paclitaxel
地点: Spain
申办方: Fundación GECP

正在招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06918132 / NCI-2025-02153

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Cemiplimab和Fianlimab用于IB-IIIB期非小细胞肺癌术前治疗。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IB Lung Cancer AJCC v8；Stage II Lung Cancer AJCC v8
干预: Biospecimen Collection，Cemiplimab，Fianlimab，Magnetic Resonance Imaging
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06922591 / NCI-2025-04690

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

AI 简述这是一项I/II期试验，研究TNG462联合RMC-9805等用于PDAC和NSCLC，在美国开展。

?

适用疾病: PDAC；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC
干预: TNG462，RMC-9805，RMC-6236，mFOLFIRINOX
地点: United States
申办方: Tango Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Non-small Cell Lung Cancer (NSCLC)；Esophageal Cancer
干预: MT-4561
地点: United States，Japan
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06956690 / NCI-2025-04298

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚研究ENV-501用于HER3表达实体瘤。

?

适用疾病: Melanoma (Skin)；Non Small Cell Lung Cancer；Breast Cancer
干预: ENV-501
地点: United States，Australia
申办方: Hummingbird Bioscience

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06974370

Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial

AI 简述这是一项II期试验，评估主动监测用于非小细胞肺癌脑转移。

?

适用疾病: Brain Metastases, Adult；Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
干预: Active Surveillance
地点: United States
申办方: University of Vermont Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07001618

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

AI 简述这是一项II期试验，在法国研究口服粪便微生物群MaaT033联合Cemiplimab用于因使用抗生素而耐药的晚期非小细胞肺癌。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)
干预: MaaT033 capsule，Cemiplimab，Cisplatin，Carboplatine
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07012031 / NCI-2025-03809

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

AI 简述这是一项I/II期试验，研究Sotorasib联合Trastuzumab Deruxtecan用于KRAS G12C突变非小细胞肺癌，在美国开展。

?

适用疾病: Locally Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Stage III Lung Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Echocardiography Test
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07016230

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

AI 简述这是一项II期试验，研究Tarlatamab用于转移性小细胞肺癌及其他神经内分泌癌，在法国开展。

?

适用疾病: Metastatic/Locally Advanced Small-Cell Lung Cancer；Metastatic/Locally Advanced Poorly Differentiated NEC；Metastatic/Locally Advanced High-grade MTC
干预: Tarlatamab
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT07017829 / NCI-2024-08947

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究GT103联合帕博利珠单抗用于STK11突变晚期非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Stage III Lung Cancer AJCC v8
干预: Anti-CFH Monoclonal Antibody GT103，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07020065

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

AI 简述这是一项II期试验，比较减量卡铂双药化疗联合西米普利单抗与西米普利单抗单药用于老年或体弱转移性NSCLC。

?

适用疾病: Metastatic NSCLC - Non-Small Cell Lung Cancer
干预: Cemiplimab，Carboplatin，Pemetrexed & Gemcitabine，Paclitaxel
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07020221 / NCI-2025-04955

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

AI 简述这是一项I/II期试验，研究VS-7375用于KRAS G12D突变实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non Small Cell Lung Cancer；Colorectal Cancer
干预: VS-7375，Cetuximab，Carboplatin + Pemetrexed + Pembrolizumab，Gemcitabine
地点: United States，Australia
申办方: Verastem, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07030257 / NCI-2025-08127

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项1/2期试验，研究CP-383用于晚期或转移性实体瘤，包括结直肠癌、小细胞肺癌等。

?

适用疾病: Solid Tumor Malignancies；Colorectal Carcinoma；Small Cell Lung Cancer ( SCLC )
干预: CP-383
地点: United States
申办方: Tasca Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

AI 简述这是一项I/II期试验，研究AVZO-1418单药或联合用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Solid Tumor Cancer；Locally Advanced；Metastatic Solid Tumors
干预: AVZO-1418，Combination Agent 1，Combination Agent 2
地点: United States
申办方: Avenzo Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07057791 / NCI-2026-01271

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究铂类/依托泊苷联合Ivonescimab用于广泛期小细胞肺癌。

?

适用疾病: Extensive Stage Lung Small Cell Cancer；Extensive Stage Small Cell Lung Cancer
干预: Ivonescimab 10 mg/kg，Ivonescimab 20 mg/kg
地点: United States
申办方: PrECOG, LLC.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07064018 / NCI-2025-03409

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

AI 简述这是一项I/II期试验，研究Spedox-6用于多种晚期实体瘤，在美国开展。

?

适用疾病: Soft-tissue Sarcoma；Triple Negative Breast Cancer；Non-small Cell Lung Cancer
干预: Spedox-6，Pegfilgrastim，Filgrastim
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07084610

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，在巴西开展，研究代谢标志物预测Nivolumab联合化疗新辅助治疗非小细胞肺癌的响应。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)
地点: Brazil
申办方: Hospital das Clínicas de Ribeirão Preto

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07098988 / NCI-2025-08326

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

AI 简述这是一项2期试验，研究Visugromab联合免疫化疗用于转移性非鳞非小细胞肺癌。

?

适用疾病: Metastatic Non-Squamous Non-Small Cell Lung Cancer；Adult Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: Visugromab，Matching placebo for visugromab，Pembrolizumab 200 mg Q3W，Pemetrexed 500 mg/m^2
地点: United States，Germany，Italy，Poland 等 3 个
申办方: CatalYm GmbH

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

正在招募 Phase 2 联合产品

ClinicalTrials.gov NCT07130032

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

AI 简述这是一项II期试验，在俄罗斯研究抗PD-1/PD-L1抗体联合贝伐珠单抗及低剂量环磷酰胺用于NSCLC和黑色素瘤。

?

适用疾病: Metastatic Non-small Cell Lung Cancer (NSCLC)；Metastatic Cutaneous Melanoma
干预: reICB regimen (NSCLC)，reICB regimen (melanoma)
地点: Russia
申办方: EuroCityClinic LLC

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT07132190

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

AI 简述这是一项II期试验，研究立体定向放疗用于生长或变化的脑转移瘤，在美国开展。

?

适用疾病: Brain Metastases, Adult；Brain Tumor - Metastatic；Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
干预: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
地点: United States
申办方: Ayal A. Aizer, MD

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT07132918 / NCI-2025-06177

HEARTS Trial for Thoracic Cancers

AI 简述这是一项II期试验，研究MRgART或LINAC用于胸部肿瘤，包括非小细胞肺癌、食管癌等，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer (Stage III)；Esophageal Cancer Stage I-III；Esophagogastric Cancer Stage I-III
干预: MRgART，LINAC
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07133425 / NCI-2025-06144

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究SAR445877用于免疫检查点抑制剂难治性非小细胞肺癌，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；ICI-refractory；Stage III Lung Cancer
干预: SAR445877
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07145255 / NCI-2026-00044

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究ADC用于多种晚期难治实体瘤。

?

适用疾病: Prostate Cancer Castration-resistant Prostate Cancer；Breast Cancer；Colo-rectal Cancer
干预: ADC
地点: United States
申办方: MBrace Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07148128

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

AI 简述这是一项1/2a期试验，研究WEF-001用于晚期KRAS突变实体瘤。

?

适用疾病: Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma；Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer；Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
干预: WEF-001
地点: United States，Canada，United Kingdom
申办方: Auricula Biosciences Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07149363 / NCI-2026-02683

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

AI 简述这是一项2期试验，评估化疗联合免疫治疗用于完全切除的小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer (SCLC)；Stage I Lung Cancer；Stage II Lung Cancer
干预: Durvalumab 50 MG/ML
地点: United States
申办方: Alliance Foundation Trials, LLC.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07151040

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，在法国、西班牙、英国等地研究TH9619用于晚期实体瘤。

?

适用疾病: Solid Tumor；Colorectal Cancer (CRC)；Squamous Cell Carcinoma of Head and Neck
干预: TH9619
地点: France，Spain，United Kingdom
申办方: One-carbon Therapeutics AB

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07153055

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究Lurbinectedin联合Osimertinib用于转化型小细胞肺癌。在美国开展。

?

适用疾病: Small Cell Lung Cancer ( SCLC )；Transformed Small Cell Lung Cancer
干预: Lurbinectedin，Osimertinib
地点: United States
申办方: Misty Shields

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07153445

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，研究Atezolizumab新辅助及维持治疗用于III期非小细胞肺癌。在西班牙开展。

?

适用疾病: Non Small Cell Lung Cancer；Stage IIIA Lung Cancer；Stage IIIB Lung Cancer
干预: Atezolizumab，Paclitaxel，Carboplatin
地点: Spain
申办方: Fundación GECP

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07154290 / NCI-2026-03443

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，研究Ubamatamab单用或联合REGN7075用于晚期/转移性非小细胞肺癌。

?

适用疾病: Advanced/Metastatic Non-Small Cell Lung Cancer；Stage IIIB Lung Cancer；Stage IIIC Lung Cancer
干预: Ubamatamab，REGN7075，Sarilumab
地点: United States
申办方: Regeneron Pharmaceuticals

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07155200 / NCI-2025-08749

Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

AI 简述这是一项I/II期试验，研究Cirtuvivint联合伊立替康用于小细胞肺癌。

?

适用疾病: Small-cell Lung Cancer；Small Cell Lung Carcinoma；Small Cell Lung Cancer
干预: Cirtuvivint，Irinotecan
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07169734 / NCI-2025-08325

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

AI 简述这是一项I/II期试验，研究ALE.P03用于CLDN1阳性晚期或转移性实体瘤。

?

适用疾病: Cervical Squamous Cell Carcinoma；Squamous Non-small-cell Lung Cancer；Colorectal Cancer
干预: ALE.P03
地点: United States，France，Hong Kong，Italy 等 4 个
申办方: Alentis Therapeutics AG

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07172802

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究GI-108单药用于晚期或转移性实体瘤，包括非小细胞肺癌、头颈癌、胰腺癌，在韩国开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Non-small Cell Lung Cancer (NSCLC)
干预: GI-108
地点: South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07174583 / NCI-2025-09217

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究IDE849用于表达DLL3的肿瘤，包括小细胞肺癌、神经内分泌癌，在美国开展。

?

适用疾病: Small-cell Lung Cancer；Neuroendocrine Carcinomas；Solid Tumor Show to Express DLL3
干预: IDE849，durvalumab，IDE161，Carboplatin
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07189871 / NCI-2026-03797

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-BetaBart用于复发/难治性局部晚期不可切除或转移性实体瘤。

?

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07192068

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

AI 简述这是一项II期试验，在France等地研究Zanidatamab用于HER2基因改变实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer；Sarcoma；Head &Amp; Neck Cancer
干预: Zanidatamab
地点: France
申办方: UNICANCER

正在招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07202611

DC/NK Cell Therapy

AI 简述这是一项II期试验，研究体外培养的自体树突细胞和自然杀伤细胞用于非小细胞肺癌，在台湾开展。

?

适用疾病: Lung Cancer (NSCLC)
干预: In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer
地点: Taiwan
申办方: National Taiwan University Clinical Trial Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07207395

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

AI 简述这是一项II期试验，研究JBI-802单药或联合Pembrolizumab用于STK11突变非小细胞肺癌。在美国开展。

?

适用疾病: Lung Cancer (NSCLC)
干预: JBI-802，Pembrolizumab
地点: United States
申办方: The Christ Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07219576 / NCI-2026-00810

Retifanlimab and Ruxolitinib In Solid Malignancies

AI 简述这是一项I/II期试验，研究Retifanlimab联合Ruxolitinib用于非小细胞肺癌和肾癌。

?

适用疾病: Non Small Cell Lung Carcinoma；Renal Cell Carcinoma；Stage III Lung Cancer
干预: Ruxolitinib，Retifanlimab
地点: United States
申办方: University of California, San Diego

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07221474 / NCI-2025-08355

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

AI 简述这是一项II期试验，研究Intismeran Autogene联合Pembrolizumab和化疗用于肺鳞癌。

?

适用疾病: Squamous Non-small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Squamous Carcinoma
干预: Intismeran Autogene，Pembrolizumab，Carboplatin，Paclitaxel
地点: United States，Argentina，Australia，Chile 等 7 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07223047

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究BMS-986523单用或联合其他抗癌药物治疗晚期实体瘤。

?

适用疾病: Advanced Solid Malignancies；Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: BMS-986523，Gemcitabine，Nab-Paclitaxel，Cetuximab
地点: United States，Canada，Spain
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07223424

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

AI 简述这是一项II期试验，研究患者对皮下与静脉注射免疫治疗的偏好。在美国开展。

?

适用疾病: Renal Cell Carcinoma；Non Small Cell Lung Cancer；Melanoma
干预: nivolumab，pembrolizumab
地点: United States
申办方: Diwakar Davar

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07224152 / NCI-2025-08155

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究NBTXR3联合放疗用于局部晚期非小细胞肺癌。

?

适用疾病: Locally-Advanced Non-Small Cell Lung Cancer；Stage I Lung Cancer；Stage II Lung Cancer
干预: NBTXR3
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07224971 / NCI-2026-00154

Impact of Circadian Rhythm on Immunotherapy

AI 简述这是一项II期试验，研究昼夜节律对免疫检查点抑制剂的影响用于晚期非小细胞肺癌等实体瘤。

?

适用疾病: Advanced/Metastatic NSCLC；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: Immunotherapy - PD-1 Blocker
地点: United States
申办方: Liza Villaruz, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07242547

Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients

AI 简述这是一项2期试验，研究Tarlatamab用于局限期小细胞肺癌放化疗后的维持治疗，在西班牙开展。

?

适用疾病: Limited-stage Small-cell Lung Cancer；Carcinoma, Small Cell Lung；Respiratory Tract Neoplasms
干预: Tarlatamab
地点: Spain
申办方: Fundación GECP

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT07246863 / NCI-2026-02589

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

AI 简述这是一项II期试验，研究Visugromab联合Nivolumab用于转移性非鳞非小细胞肺癌的二线治疗。

?

适用疾病: Metastatic Non-Squamous Non-Small Cell Lung Cancer；Adult Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: Visugromab RDE (recommended dose for expansion)，Visugromab 6mg/kg，Nivolumab，Placebo Saline Infusion
地点: United States，Germany，Italy，Romania 等 2 个
申办方: CatalYm GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07249372 / NCI-2025-08186

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究DRP-104用于NFE2L2/KEAP1突变的非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: DRP-104
地点: United States
申办方: NYU Langone Health

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07250477 / NCI-2026-00133

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

AI 简述这是一项II期试验，在基于蛋白组学指导的系统治疗与标准治疗用于既往未治疗的晚期非小细胞肺癌，于美国开展。

?

适用疾病: Non-small Cell Lung Cancer Stage IIIC；Non-small Cell Lung Cancer Stage IV；Non Small Cell Lung Cancer
干预: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.，Standard of Care
地点: United States
申办方: University of California, Davis

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov NCT07264647

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项II期试验，在意大利开展，研究Tislelizumab联合放化疗用于III期PD-L1阳性非小细胞肺癌的新辅助治疗。

?

适用疾病: Stage III NSCLC
干预: Tislelizumab，surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines，Chemoradiotherapy
地点: Italy
申办方: Fondazione Ricerca Traslazionale

正在招募 Phase 1, Phase 2 药物其他

ClinicalTrials.gov / NCI NCT07278479 / NCI-2026-01280

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

AI 简述这是一项1/2期试验，研究[212Pb]Pb-MP0712用于小细胞肺癌及其他DLL3阳性实体瘤。在美国开展。

?

适用疾病: Large Cell Neuroendocrine Carcinoma；Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)；Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
干预: [212Pb]Pb-MP0712，[203Pb]Pb-MP0712
地点: United States
申办方: Molecular Partners AG

正在招募 Phase 2 行为干预生物制剂药物

ClinicalTrials.gov / NCI NCT07288034 / NCI-2025-09032

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

AI 简述这是一项II期试验，研究免疫生物标志物预测PD(L)1免疫治疗用于IIIB-IV期非小细胞肺癌。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IIIB Lung Cancer AJCC v8；Stage IV Lung Cancer AJCC v8
干预: Adagrasib，Anti-PD-L1 Monoclonal Antibody，Anti-PD1 Monoclonal Antibody，Bevacizumab
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07292168

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

AI 简述这是一项I/II期试验，在俄罗斯研究FGFR1抗体OM-RCA-01用于表达FGFR1的转移性肿瘤。

?

适用疾病: Renal Cell Carcinoma Metastatic；Prostate Cancer Metastatic；Non-small Cell Lung Cancer Metastatic
干预: humanized monoclonal anti-FGFR1 antibody OM-RCA-01
地点: Russia
申办方: Kidney Cancer Research Bureau

正在招募 Phase 2 药物其他手术/操作

ClinicalTrials.gov / NCI NCT07293247 / NCI-2025-06781

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

AI 简述这是一项II期试验，在美国研究术后放疗与化疗、免疫治疗用于残留淋巴结的非小细胞肺癌。

?

适用疾病: Lung Non-Small Cell Carcinoma；Non-Small Cell Lung Cancer
干预: Chemotherapy，Immunotherapy，Intensity-Modulated Radiation Therapy，Computed Tomography
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07306624

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Nelmastobart联合多西他赛用于非小细胞肺癌。在韩国开展。

?

适用疾病: Non Small Cell Lung Cancer
干预: Nelmastobart and Docetaxel
地点: South Korea
申办方: STCube, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07323732

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

AI 简述这是一项II期试验，研究BIO 300联合胸部放疗用于非小细胞肺癌合并间质性肺病。

?

适用疾病: NSCLC；NSCLC, Stage I；NSCLC Stage II
干预: BIO 300
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07325136 / NCI-2026-01263

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究BMS-986525单药或联合Nivolumab用于复发/难治性小细胞肺癌，在美国、意大利等地开展。

?

适用疾病: Relapsed/Refractory Small Cell Lung Cancer；Refractory Lung Small Cell Carcinoma；Recurrent Small Cell Lung Cancer
干预: BMS-986525，Nivolumab
地点: United States，Italy，Japan，Romania 等 1 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07339059

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Sacituzumab govitecan联合Atezolizumab/Durvalumab维持治疗广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer ( SCLC )；Extensive Stage Small Cell Lung Cancer (ES-SCLC)
干预: Sacituzumab govitecan，Atezolizumab，Durvalumab
地点: United States
申办方: Bindu R Potugari

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07391813

SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究SNB-101用于广泛期小细胞肺癌。

?

适用疾病: Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)
干预: SNB-101
地点: Serbia
申办方: SN BioScience

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07392658

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

AI 简述这是一项II期试验，研究Amivantamab联合单药化疗用于EGFR exon20插入突变的非小细胞肺癌。在意大利开展。

?

适用疾病: Metastatic NSCLC - Non-Small Cell Lung Cancer
干预: Amivantamab
地点: Italy
申办方: Fondazione Ricerca Traslazionale

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07397338 / NCI-2026-01954

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

AI 简述这是一项I/II期试验，在美国研究Daraxonrasib、Elironrasib、Zoldonrasib联合Ivonescimab用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumors；Metastatic Solid Tumors；Non-small Cell Lung Cancer (NSCLC)
干预: Daraxonrasib，Elironrasib，Zoldonrasib，Ivonescimab
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 4 药物手术/操作

ClinicalTrials.gov / NCI NCT07405086 / NCI-2026-00433

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

AI 简述这是一项IV期试验，研究上午与下午给药免疫治疗用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Biliary Tract Carcinoma；Advanced Head and Neck Squamous Cell Carcinoma；Advanced Hepatocellular Carcinoma
干预: Biospecimen Collection，Immune Checkpoint Inhibitor
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07407933

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究YL201联合Atezolizumab用于晚期实体瘤，在美国、比利时等地开展。

?

适用疾病: Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
干预: YL201，Atezolizumab
地点: United States，Belgium，Italy，Poland 等 3 个
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07415005 / NCI-2026-01061

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究lorlatinib联合局部巩固治疗用于ALK阳性晚期非小细胞肺癌，在美国开展。

?

适用疾病: Advanced Non-Small Cell Lung Cancer；Stage IV Lung Cancer；Advanced Lung Non-Small Cell Carcinoma
干预: Lorlatinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07428044 / NCI-2026-01525

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，在美国和加拿大研究Trastuzumab Deruxtecan用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Non-small Cell Lung Cancer Stage II；Non-Small Cell Lung Cancer Stage IIIA
干预: Trastuzumab Deruxtecan
地点: United States，Canada
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07439094 / NCI-2026-04261

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究CKD-703用于晚期实体瘤和非小细胞肺癌。在美国开展。

?

适用疾病: Advanced Solid Tumors；Non-Small Cell Lung Cancer；Advanced Malignant Solid Tumor
干预: CKD-703
地点: United States
申办方: Chong Kun Dang Pharmaceutical

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07468071

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

AI 简述这是一项I/II期滚动研究，Opnurasib单药或联合其他药物用于KRAS G12C突变实体瘤，在韩国开展。

?

适用疾病: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer；Advanced Solid Tumors Harboring the KRAS G12C Mutation
干预: Opnurasib，TNO155，trametinib，cetuximab
地点: South Korea
申办方: Novartis Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07483983

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

AI 简述这是一项II期试验，研究ASP3082用于转移性/局部晚期非小细胞肺癌和胰腺导管腺癌。

?

适用疾病: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer；Metastatic/Locally Pancreatic Ductal Adenocarcinoma
干预: ASP3082
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07485452

Boosting Osimertinib Blood Brain Barrier Penetration

AI 简述这是一项II期试验，研究Osimertinib联合Febuxostat增加血脑屏障穿透用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Osimertinib & febuxostat
地点: Netherlands
申办方: Maastricht University Medical Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT07489066 / NCI-2026-04137

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

AI 简述这是一项II期试验，研究PF-08634404单药或联合化疗用于早期或局部晚期非小细胞肺癌，在美国和波多黎各开展。

?

适用疾病: Carcinoma；Non-Small-Cell Lung；Lung Cancer (NSCLC)
干预: PF-08634404，Chemotherapy Regimen 1，Chemotherapy Regimen 2
地点: United States，Puerto Rico
申办方: Pfizer

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07491497 / NCI-2026-03013

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

AI 简述这是一项1/2期试验，研究TRI-611用于ALK阳性非小细胞肺癌。

?

适用疾病: ALK-positive NSCLC；ALK-Positive Lung Cancer；ALK-positive Non-small Cell Lung Cancer
干预: TRI-611
地点: United States
申办方: TRIANA Biomedicines, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07535437 / NCI-2026-03044

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究Ivonescimab联合Dato-DXd或奥希替尼用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: Ivonescimab，Dato-DXd，Osimertinib
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07535463 / NCI-2026-03045

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究Ivonescimab联合化疗和立体定向放疗用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: Ivonescimab，Stereotactic Radiosurgery
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07563738

A 2-part Phase 1/2 Open-label Trial on ODM-212

AI 简述这是一项1/2期试验，研究ODM-212联合Ipilimumab和nivolumab用于间皮瘤、胰腺癌或非小细胞肺癌等，在美国开展。

?

适用疾病: Mesothelioma；Pancreatic Cancer；NSCLC (Advanced Non-small Cell Lung Cancer)
干预: ODM-212，Ipilimumab and nivolumab，Gemcitabine and nab-paclitaxel，sotorasib
地点: United States
申办方: Orion Corporation, Orion Pharma

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07564401 / NCI-2026-04194

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

AI 简述这是一项1/2期试验，研究DJI136（DLL3靶向CAR-T）用于广泛期小细胞肺癌，在美国和新加坡开展。

?

适用疾病: Extensive-stage Small Cell Lung Cancer (ES-SCLC)；Extensive Stage Small Cell Lung Cancer
干预: DJI136
地点: United States，Singapore
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07594522 / NCI-2026-03944

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究依沃西单抗联合立体定向放疗用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage IA2 Lung Cancer；Stage IA3 Lung Cancer
干预: Photon or Proton standard stereotactic body radiotherapy (SBRT)，Ivonescimab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07603856 / NCI-2026-04858

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究免疫治疗（如帕博利珠单抗）联合放疗用于IV期非小细胞肺癌，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Metastatic Lung Cancer；Stage IV Lung Cancer
干预: Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)，Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)，Ablative Hypofractionated Radiotherapy
地点: United States
申办方: University of Chicago

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

AI 简述这是一项I/II期试验，研究BLU-924用于KRAS突变晚期实体瘤，在美国开展。

?

适用疾病: Advanced Solid Tumor；Non-Small Cell Lung Cancer；Colorectal Neoplasms
干预: BLU-924
地点: United States
申办方: Blueprint Medicines Corporation

即将招募 Phase 2, Phase 3 药物其他

ClinicalTrials.gov NCT07149649

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项2/3期试验，研究镁补充剂用于晚期非小细胞肺癌。

?

适用疾病: Metastatic NSCLC - Non-Small Cell Lung Cancer
干预: Magnesiocard，Magnesium Diasporal，Microcrystalline cellulose，Isotonic saline solution 0.9%
地点: Switzerland
申办方: Swiss Cancer Institute

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT07440290

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

AI 简述这是一项II/III期试验，研究Dabrafenib联合Trametinib用于BRAF V600突变阳性癌症。在英国开展。

?

适用疾病: Haematological Malignancy；Malignant Neoplasm；Lymphoproliferative Disorders
干预: Dabrafenib，Trametinib
地点: United Kingdom
申办方: Cancer Research UK

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05597800

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

AI 简述这是一项II期试验，研究Nivolumab/Ipilimumab联合化疗用于晚期非小细胞肺癌伴HIV等感染，在意大利开展。

?

适用疾病: NSCLC Stage IV；HIV；HBV
干预: Nivolumab and Ipilimumab
地点: Italy
申办方: Universita di Verona

即将招募 Phase 2 Dietary_Supplement药物

ClinicalTrials.gov NCT05703997

FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction

AI 简述这是一项II期试验，研究周期性5天卡路里限制联合Atezolizumab用于广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Carcinoma
干预: Cyclic, 5-day calorie restriction，Atezolizumab
地点: Italy
申办方: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05859217

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)

AI 简述这是一项II期试验，研究Cabozantinib联合Atezolizumab用于晚期/转移性非小细胞肺癌，在美国开展。

?

适用疾病: Lung Cancer；NSCLC Stage IV；Metastatic NSCLC - Non-Small Cell Lung Cancer
干预: Cabozantinib，Atezolizumab
地点: United States
申办方: Jun Zhang, MD, PhD

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT06813664

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

AI 简述这是一项II期试验，在加拿大开展，研究ctDNA引导的放疗用于TKI治疗后寡进展的转移性NSCLC。

?

适用疾病: Metastatic NSCLC - Non-Small Cell Lung Cancer；OligoProgressive Metastatic Disease
干预: Radiotherapy，Radiotherapy
地点: Canada
申办方: University Health Network, Toronto

即将招募 Phase 2 生物制剂其他手术/操作

ClinicalTrials.gov / NCI NCT06943664 / NCI-2025-02417

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究ASP-1929联合Cemiplimab用于难治性IIIB-IV期非小细胞肺癌。

?

适用疾病: Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Refractory Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Cemiplimab，Cetuximab Sarotalocan Sodium，Computed Tomography
地点: United States
申办方: Roswell Park Cancer Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07076914

Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy

AI 简述这是一项II期试验，研究预防性质子泵抑制剂用于肺癌放疗食管保护。在加拿大等地开展。

?

适用疾病: Primary Lung Cancer；Non Small Cell Lung Cancer；Small Cell Lung Cancer
干预: Experimental (Health Canada Approved Proton Pump Inhibitors)
地点: Canada
申办方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07146230

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

AI 简述这是一项II期试验，在美国研究Durvalumab联合放疗用于局部晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer
干预: Durvalumab，Monalizumab，Oleclumab，Radiotherapy
地点: United States
申办方: Montefiore Medical Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07158489

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

AI 简述这是一项II期试验，在瑞士研究Gemcitabine联合Ivonescimab用于克服晚期非小细胞肺癌的免疫治疗耐药。

?

适用疾病: NSCLC；NSCLC (Advanced Non-small Cell Lung Cancer)
干预: Gemcitabine + Ivonescimab
地点: Switzerland
申办方: Swiss Cancer Institute

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07229339

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Zipalertinib联合卡铂和培美曲塞用于可切除的II-IIIB期非小细胞肺癌。

?

适用疾病: Lung Non-Squamous Non-Small Cell Carcinoma
干预: Biospecimen Collection，Carboplatin，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Jonsson Comprehensive Cancer Center

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07234877

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

AI 简述这是一项II期试验，研究放疗联合Ivonescimab/化疗用于非小细胞肺癌脑转移。

?

适用疾病: Non Small Cell Lung Cancer
干预: Ivonescimab，Carboplatin，Pemetrexed，Paclitaxel
地点: Austria，France，Germany，Greece 等 4 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

即将招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07247786

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

AI 简述这是一项II期试验，评估粪便微生物移植联合Durvalumab化疗用于II-III期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Respiratory Tract Neoplasm
干预: Biological: Fecal Microbiota Transplantation，Durvalumab，Paclitaxel，Carboplatin (AUC 6)
地点: Spain
申办方: Fundación GECP

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT07322341

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究SX-682联合Atezolizumab用于晚期或转移性非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma
干预: Atezolizumab，CXCR1/2 Inhibitor SX-682，Biospecimen Collection，Computed Tomography
地点: United States
申办方: University of Washington

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07355205

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究伊匹木单抗联合纳武利尤单抗及N-803一线治疗IV期或复发性非小细胞肺癌，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer Stage IV；Non-small Cell Lung Cancer Recurrent
干预: Ipilimumab，Nivolumab，Nogapendekin alfa inbakicept
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07402343

Tarlatamab for SCLC Brain Metastases

AI 简述这是一项II期试验，研究Tarlatamab用于小细胞肺癌脑转移。在荷兰等地开展。

?

适用疾病: Small Cell Lung Cancer；Brain Metastases, Adult
干预: Tarlatamab
地点: Netherlands
申办方: Maastricht University Medical Center

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07405190 / NCI-2026-03271

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

AI 简述这是一项II期试验，研究Ivonescimab单药或联合卡铂/培美曲塞用于非小细胞肺癌。在美国开展。

?

适用疾病: Lung Cancer (NSCLC)；Lung Cancer Non-Small Cell Cancer (NSCLC)；Lung Cancer (Non-Small Cell)
干预: Ivonescimab，carboplatin，pemetrexed
地点: United States
申办方: Massachusetts General Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07418931

A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

AI 简述这是一项II期试验，在意大利开展，研究西米普利单抗联合化疗用于晚期鳞状非小细胞肺癌。

?

适用疾病: Advanced Squamous Non-Small Cell Lung Cancer
干预: Cemiplimab 350 mg IV，Paclitaxel 200 mg/sqm IV，Carboplatin AUC 5 IVa，Cisplatin 80 mg/sqm IV
地点: Italy
申办方: Gruppo Oncologico Italiano di Ricerca Clinica

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07420439

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

AI 简述这是一项II期试验，在法国开展，研究紫杉醇、贝伐珠单抗等化疗用于晚期非小细胞肺癌合并间质性肺病。

?

适用疾病: Non Small Cell Lung Cancer Metastatic；Interstitial Lung Disease (ILD)
干预: Paclitaxel，Bevacizumab，Carboplatin，Pemetrexed
地点: France
申办方: Intergroupe Francophone de Cancerologie Thoracique

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07450183

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

AI 简述这是一项2期试验，研究围手术期Cemiplimab用于高PD-L1可切除非小细胞肺癌，在美国开展。

?

适用疾病: Lung Cancer (NSCLC)
干预: Cemiplimab，Adjuvant chemotherapy
地点: United States
申办方: Henry Ford Health System

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07459634

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

AI 简述这是一项II期试验，研究卢比替定联合度伐利尤单抗用于广泛期小细胞肺癌。在美国开展。

?

适用疾病: Extensive-stage Small-cell Lung Cancer
干预: Lurbinectedin，Durvalumab
地点: United States
申办方: Jazz Pharmaceuticals

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07500285

Yittrium-90(Y-90) Fibroblast Activation Protein Inhibitor (FAPI) Therapy in Patients With Non-Small Cell Lung Cancer (Phase II)

AI 简述这是一项II期试验，研究Y-90 FAPI用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Metastatic Lung Carcinoma
干预: Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor (Y-90 FAPI)
地点: Turkey (Türkiye)
申办方: Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization

即将招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07543172 / NCI-2026-02049

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

AI 简述这是一项II期试验，研究CIMAvax-EGF联合KRAS G12C抑制剂用于晚期KRAS G12C突变非小细胞肺癌，在美国开展。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Stage III Lung Cancer AJCC v8；Stage IV Lung Cancer AJCC v8
干预: Adagrasib，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Roswell Park Cancer Institute

即将招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07551635 / NCI-2026-03403

SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

AI 简述这是一项II期试验，在美国研究SMARCA4/2抑制剂FHD-286用于POU2F3阳性小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer；Recurrent Extensive Stage Lung Small Cell Carcinoma；Extensive Stage Small Cell Lung Cancer
干预: FHD-286
地点: United States
申办方: Dana-Farber Cancer Institute

即将招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT07576725

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

AI 简述这是一项II期试验，在乌干达研究低剂量减少频率的Nivolumab用于不可切除或转移性癌症。

?

适用疾病: Clinical Stage III Cutaneous Melanoma AJCC v8；Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8
干预: Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging，Nivolumab
地点: Uganda
申办方: Fred Hutchinson Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07579221

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，在美国研究Navlimetostat联合Pumitamig用于MTAP缺失的晚期非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Navlimetostat，Pumitamig
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07602842

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究IDP-001用于晚期或转移性实体瘤。在美国开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Head and Neck Squamous Cell Carcinoma
干预: IDP-001
地点: United States
申办方: InduPro, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07630168

Effects of Infusion Timing on Treatment Response in Solid Tumors

AI 简述这是一项II期试验，在美国研究输注时间对PD-1/PD-L1抑制剂治疗实体瘤的影响。

?

适用疾病: Lung Cancer；Non-small Cell Lung Cancer；Metastatic Lung Cancer
干预: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM，PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM，PD-1 inhibitor monotherapy - 2 cycles before 12:00PM，PD-1 inhibitor monotherapy - 2 cycles after 3 PM
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07636785

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

AI 简述这是一项I/II期试验，研究VMD-102用于肝细胞癌和其他实体瘤，在美国开展。

?

适用疾病: Hepatocellular Carcinoma (HCC)；Metastatic Uveal Melanoma；Renal Cell Carcinoma (RCC)
干预: VMD-102
地点: United States
申办方: VM Discovery, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07639242

Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

AI 简述这是一项II期试验，研究Olomorasib联合Pembrolizumab用于KRAS G12C突变、PD-L1 TPS 1-49%的局部晚期或转移性非小细胞肺癌。

?

适用疾病: Lung Cancer；Lung Cancer (NSCLC)；Locally Advanced NSCLC
干预: Olomorasib，Pembrolizumab
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07640932

Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer

AI 简述这是一项II期试验，在South Korea比较Lurbinectedin联合紫杉醇与紫杉醇用于既往治疗过的小细胞肺癌。

?

适用疾病: Carcinoma, Small Cell Lung
干预: Lurbinectedin，Paclitaxel
地点: South Korea
申办方: Yonsei University

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07670312

Evaluation of XYA02 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XYA02用于晚期实体瘤，包括非小细胞肺癌、卵巢癌等。在澳大利亚开展。

?

适用疾病: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: XYA02
地点: Australia
申办方: XYone Therapeutics, Inc

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT07679607

GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung

AI 简述这是一项II期试验，研究通过保留肺部串行和并行成分改善放疗后呼吸功能。在美国开展。

?

适用疾病: Lung Cancer (NSCLC)；Radiation
干预: SOC Radiation Treatment Planning，INSPIRE Radiation Treatment Planning
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06908304

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

AI 简述这是一项III期试验，比较THIO联合Cemiplimab与化疗用于晚期非小细胞肺癌三线治疗，在波兰、罗马尼亚、台湾、土耳其等地开展。

?

适用疾病: Carcinoma, Non-Small -Cell Lung
干预: 6-Thio-2'-Deoxyguanosine，Cemiplimab，Docetaxel，Vinorelbine
地点: Poland，Romania，Taiwan，Turkey (Türkiye)
申办方: Maia Biotechnology

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov NCT07099898

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

AI 简述这是一项3期试验，研究GSK5764227用于复发小细胞肺癌。

?

适用疾病: Neoplasms, Lung
干预: Ris-Rez，Topotecan
地点: Argentina，Australia，Brazil，Bulgaria 等 20 个
申办方: GlaxoSmithKline

正在招募 Phase 1

NCI NCT03076372 / NCI-2017-01170

A Study Evaluating MM-310 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究MM-310用于多种晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Prostate Adenocarcinoma；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Merrimack Pharmaceuticals

正在招募 Phase 1

NCI NCT03986606 / NCI-2019-05462

A Study of PSB205 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PSB205用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

正在招募 Phase 1

NCI NCT04137900 / NCI-2020-00511

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

AI 简述这是一项I期试验，研究抗BTLA抗体单药或联合抗PD-1抗体用于晚期恶性肿瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: TopAlliance Biosciences

正在招募阶段未标明

NCI NCT04368702 / NCI-2020-04571

Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study

AI 简述这是一项磁共振引导放射治疗的研究，用于多种癌症。

?

适用疾病: Malignant Solid Tumor；Stage I Laryngeal Throat Cancer；Stage II Laryngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04485013 / NCI-2020-07730

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

AI 简述这是一项I期试验，研究TTX-080用于晚期实体瘤，包括头颈鳞癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tizona Therapeutics, Inc

正在招募 Phase 1

NCI NCT05039801 / NCI-2021-09063

IACS-6274 with or without Bevacizumab and Paclitaxel or Capivasertib for the Treatment of Advanced Solid Tumors

AI 简述这是一项I期试验，研究IACS-6274联合或不联合Bevacizumab和Paclitaxel用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT04777994 / NCI-2021-11713

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

AI 简述这是一项I期试验，研究ABBV-CLS-484用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Calico Life Sciences LLC

正在招募 Phase 1

NCI NCT05103683 / NCI-2021-12883

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

AI 简述这是一项I期试验，研究TORL-1-23用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: 未列出
地点: United States
申办方: TORL Biotherapeutics

正在招募 Phase 1

NCI NCT05433142 / NCI-2022-05582

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

AI 简述这是一项I期试验，研究XmAb819用于晚期透明细胞肾细胞癌。

?

适用疾病: Stage III Renal Cell Cancer；Stage IV Renal Cell Cancer；Refractory Colorectal Cancer
干预: 未列出
地点: United States
申办方: Xencor, Inc.

正在招募 Phase 1

NCI NCT05067283 / NCI-2022-06807

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

AI 简述这是一项1期试验，研究Calderasib用于KRAS突变晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1

NCI NCT05483491 / NCI-2022-07699

KK-LC-1 TCR T Cells for the Treatment of Metastatic Gastric, Lung, Breast, and Cervical Cancers

AI 简述这是一项I期试验，研究KK-LC-1 TCR-T细胞用于胃癌、乳腺癌、宫颈癌、肺癌等实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 1

NCI NCT05208762 / NCI-2022-08978

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

AI 简述这是一项I期试验，研究PF-08046054联合pembrolizumab用于晚期实体瘤。

?

适用疾病: Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1

NCI NCT05719558 / NCI-2023-03815

A Study of ASP1002 in Adults for Treatment of Solid Tumors

AI 简述这是一项I期试验，在美国研究ASP1002用于多种晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma BV

正在招募 Phase 1

NCI NCT05785754 / NCI-2023-05513

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DCSZ11单药及联合治疗用于晚期或转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DynamiCure Biotechnology

正在招募 Phase 1

NCI NCT05948865 / NCI-2023-05888

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

AI 简述这是一项1期试验，研究CPO301用于晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Conjupro Biotherapeutics, Inc.

正在招募 Phase 1

NCI NCT06014502 / NCI-2023-06808

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

AI 简述这是一项I期试验，研究IMGS-001用于复发或难治性晚期实体瘤，包括头颈癌、鼻咽癌等。

?

适用疾病: Metastatic Head and Neck Cancer；Malignant Solid Tumor；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: ImmunoGenesis

正在招募阶段未标明

NCI NCT04954625 / NCI-2023-06841

Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

AI 简述这是一项试验，研究自体血补片干预用于非小细胞肺癌术后持续漏气。

?

适用疾病: Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Rush MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06021626 / NCI-2023-06972

A Study of CRD3874-SI in People With Locally Advanced or Metastatic Malignant Solid Tumor

AI 简述这是一项I期试验，研究CRD3874-SI用于局部晚期或转移性恶性实体瘤。

?

适用疾病: Recurrent Merkel Cell Cancer；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT06066424 / NCI-2023-08351

TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors

AI 简述这是一项I期试验，研究TROP2-CAR-NK细胞用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT05848739 / NCI-2023-08892

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

AI 简述这是一项1-2期试验，研究ST316用于晚期不可切除和转移性实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Sapience Therapeutics

正在招募 Phase 1

NCI NCT06225427 / NCI-2023-10639

Gilteritinib for the Treatment of ALK NSCLC

AI 简述这是一项I期试验，研究Gilteritinib用于ALK阳性非小细胞肺癌。在美国开展。

?

适用疾病: Stage IV Lung Cancer；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1

NCI NCT05954312 / NCI-2024-00249

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-130037用于多种晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06080061 / NCI-2024-00696

Accelerated radiation (HART) for the Treatment of Patients with Lung Cancer Receiving Chemotherapy

AI 简述这是一项I期试验，研究加速放疗（HART）用于肺癌患者化疗期间，在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Lung Cancer；Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

正在招募 Phase 1

NCI NCT06108050 / NCI-2024-01130

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究JZP898单药或联合Pembrolizumab用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 1

NCI NCT06240728 / NCI-2024-01335

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

AI 简述这是一项1期试验，研究NPX887用于表达B7-H7的实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06270706 / NCI-2024-01965

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PLN-101095用于晚期或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Pliant Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06311578 / NCI-2024-02940

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究JNJ-87704916单药或联合用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Johnson & Johnson Enterprise Innovation Inc.

正在招募 Phase 1

NCI NCT06244485 / NCI-2024-04787

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究Valemetostat Tosylate联合DXd ADC用于实体瘤患者。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1

NCI NCT06400472 / NCI-2024-05353

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

AI 简述这是一项I期试验，研究LY4170156联合其他药物用于晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT06233942 / NCI-2024-05419

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

AI 简述这是一项1a/1b期试验，研究BG-C9074单独及联合其他抗癌疗法用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 1

NCI NCT06521554 / NCI-2024-06647

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

AI 简述这是一项I期试验，研究NVL-330用于晚期或转移性HER2改变非小细胞肺癌，在美国开展。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Nuvalent Inc.

正在招募 Phase 1

NCI NCT06447662 / NCI-2024-06851

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

AI 简述这是一项I期试验，研究PF-07934040单药或联合其他抗癌药用于具有特定基因突变的晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Pfizer Inc

正在招募 Phase 1

NCI NCT06384352 / NCI-2024-07039

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究YL211用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: MediLink Therapeutics (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06577987 / NCI-2024-07866

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

AI 简述这是一项I期试验，研究CID-078单药用于晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Circle Pharma

正在招募 Phase 1

NCI NCT06507306 / NCI-2024-08353

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究KQB198单药及联合用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Kumquat Biosciences Inc.

正在招募 Phase 1

NCI NCT06475937 / NCI-2024-09195

A Study of DM001 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DM001用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT06644755 / NCI-2025-01102

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DS-2243a用于晚期实体瘤患者。

?

适用疾病: Metastatic Urothelial Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo Inc

正在招募 Phase 1

NCI NCT06816992 / NCI-2025-01110

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

AI 简述这是一项I期试验，研究ORIC-114联合Amivantamab用于EGFR外显子20插入突变NSCLC，在美国开展。

?

适用疾病: Stage III Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Oric Pharmaceuticals

正在招募阶段未标明

NCI NCT06896162 / NCI-2025-02181

A Precision Oncology Navigation and Expert Review Intervention for Improving Referral to Genome Informed Therapy among Patients with Stage IV Lung, Colorectal, Breast or Bladder Cancers, PROGRESS Trial

AI 简述这是一项试验，评估基因组指导治疗转诊改进用于IV期肺癌、结直肠癌、乳腺癌或膀胱癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06710379 / NCI-2025-02183

A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors

AI 简述这是一项I期试验，研究ADRX-0405用于晚期实体瘤。在美国开展。

?

适用疾病: Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Adcentrx Therapeutics

正在招募 Phase 1

NCI NCT06906900 / NCI-2025-02319

Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis

AI 简述这是一项I期试验，研究肿瘤电场治疗用于难治性脊柱转移瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IVB Hepatocellular Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06764771 / NCI-2025-02616

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

AI 简述这是一项I期试验，在美国研究BMS-986488单药或联合用于晚期恶性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1

NCI NCT06771219 / NCI-2025-03137

SLV-154 Treatment of Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SLV-154用于转移性实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Metastatic Thyroid Gland Cancer
干预: 未列出
地点: United States
申办方: Solve Therapeutics

正在招募 Phase 1

NCI NCT06752681 / NCI-2025-03245

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DAY301用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage III Ovarian Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Day One Biopharmaceuticals, Inc.

正在招募 Phase 1

NCI NCT06823167 / NCI-2025-03470

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国开展，研究IM-1021用于多种晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1

NCI NCT06723236 / NCI-2025-03571

A Study of MGC028 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究MGC028用于晚期实体瘤。

?

适用疾病: Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: MacroGenics Inc

正在招募阶段未标明

NCI NCT06979661 / NCI-2025-04128

Circulating Tumor Deoxyribonucleic Acid Testing for the Guided Treatment of Stage II-III Non-small Cell Lung Cancer, MRD-PORT Trial

AI 简述这是一项试验，通过循环肿瘤DNA检测指导II-III期非小细胞肺癌的治疗，在美国开展。

?

适用疾病: Stage II Lung Cancer；Stage III Lung Cancer；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 1

NCI NCT06804824 / NCI-2025-04592

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究VVD-159642用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Vividion Therapeutics, Inc.

正在招募 Phase 1

NCI NCT06756035 / NCI-2025-04725

CT-95 in Advanced Cancers Associated With Mesothelin Expression

AI 简述这是一项I期试验，研究CT-95用于间皮素表达的晚期实体瘤，包括卵巢癌、间皮瘤和胰腺癌。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Context Therapeutics Inc.

正在招募 Phase 1

NCI NCT07015697 / NCI-2025-05451

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究皮下注射Trastuzumab Deruxtecan用于转移性实体瘤患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募阶段未标明

NCI NCT03706027 / NCI-2025-05818

Comparing the Safety of a Three- versus Five-Fraction Regimen of Stereotactic Body Radiation Therapy for Treating Early Stage Non-Small Cell Lung Cancer

AI 简述一项比较3次与5次立体定向放疗用于早期非小细胞肺癌的试验，在美国开展。

?

适用疾病: Stage I Lung Cancer；Stage IIA Lung Cancer；Early Stage Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: University of Rochester

正在招募 Phase 1

NCI NCT06874335 / NCI-2025-05820

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

AI 简述这是一项1期试验，研究BHV-1530用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Biohaven Therapeutics Ltd.

正在招募 Phase 1

NCI NCT07027488 / NCI-2025-06053

AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究AB821用于晚期黑色素瘤、默克尔细胞癌等实体瘤。

?

适用疾病: Recurrent Merkel Cell Cancer；Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Yale University

正在招募 Phase 1

NCI NCT06792552 / NCI-2025-06352

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究SIM0505用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: NextCure, Inc.

正在招募 Phase 1

NCI NCT07207707 / NCI-2025-07562

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究KQB548用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Kumquat Biosciences Inc.

正在招募 Phase 1

NCI NCT06959706 / NCI-2025-08169

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究TGW101用于晚期实体瘤，包括转移性及局部晚期实体瘤等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Tagworks Pharmaceuticals BV

正在招募 Phase 1

NCI NCT06809114 / NCI-2026-00164

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AT03-65用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Axcynsis Therapeutics Pte Ltd

正在招募 Phase 1

NCI NCT07252479 / NCI-2026-00268

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

AI 简述这是一项I期试验，研究RAS抑制剂用于携带RAS突变的晚期或转移性实体瘤，于美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Adlai Nortye Biopharma Co., Ltd.

正在招募 Phase 1

NCI NCT07218003 / NCI-2026-00632

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

AI 简述这是一项I期试验，研究RNDO-564单药或联合Pembrolizumab用于Nectin-4阳性实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Rondo Therapeutics

正在招募 Phase 1

NCI NCT05872295 / NCI-2026-00679

IKS014 in Advanced Solid Tumors That Express HER2

AI 简述这是一项I期试验，研究IKS014用于HER2阳性晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Iksuda Therapeutics Ltd.

正在招募 Phase 1

NCI NCT07241039 / NCI-2026-01262

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

AI 简述这是一项I期试验，研究ABBV-711单药及联合Budigalimab用于晚期鳞状肿瘤。在美国开展。

?

适用疾病: Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Abbvie

正在招募 Phase 1

NCI NCT07247110 / NCI-2026-01268

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

AI 简述这是一项I期试验，研究MK-4716用于多种晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 1

NCI NCT07182149 / NCI-2026-01556

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究NRM-823用于晚期难治性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Normunity

正在招募 Phase 1

NCI NCT06960395 / NCI-2026-02255

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究VIR-5525联合帕博利珠单抗用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Stage III Nasopharyngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Vir Biotechnology, Inc.

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募 Phase 1

NCI NCT07525141 / NCI-2026-03281

A Study of JNJ-1761981 in Participants With Solid Tumors

AI 简述这是一项I期试验，研究JNJ-1761981用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Johnson & Johnson Enterprise Innovation Inc.

正在招募 Phase 1

NCI NCT07541573 / NCI-2026-03508

A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy

AI 简述这是一项I期试验，研究GTB-5550用于既往治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Bladder Urothelial Cancer
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT02570815

Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer

AI 简述这是一项I期试验，研究吲哚菁绿引导的机器人肺段切除术用于早期肺癌，在加拿大开展。

?

适用疾病: Non-small Cell Lung Cancer
干预: indocyanine green
地点: Canada
申办方: St. Joseph's Healthcare Hamilton

正在招募 Phase 1 药物

ClinicalTrials.gov NCT03467360

Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

AI 简述这是一项I期试验，研究乙酰唑胺联合放化疗或放射免疫治疗用于小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: acetazolamide in combination with platinum and etoposide-based radiochemotherapy，acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
地点: France，Monaco
申办方: Centre Antoine Lacassagne

正在招募 Phase 1 药物放疗

ClinicalTrials.gov NCT03546829

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究抗菌治疗联合精准放疗用于寡进展非小细胞肺癌。

?

适用疾病: Early Stage Non-Small Cell Lung Cancer
干预: Vancomycin，Precision hypofractionated radiation
地点: United States
申办方: Abramson Cancer Center at Penn Medicine

正在招募阶段未标明放疗

ClinicalTrials.gov NCT03742687

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

AI 简述这是一项试验，研究异质性低分次放疗用于III/IV期非小细胞肺癌，在丹麦开展。

?

适用疾病: Stage III Non-small-cell Lung Cancer；Stage IV Non-small Cell Lung Cancer；Radiotherapy Side Effect
干预: Heterogeneously Hypofractionated Radiotherapy
地点: Denmark
申办方: Danish Lung Cancer Group

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04085315

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

AI 简述这是一项I期试验，研究alisertib联合奥希替尼用于EGFR突变转移性肺癌。

?

适用疾病: Lung Cancer Metastatic；EGFR Gene Mutation
干预: Osimertinib，Alisertib
地点: United States
申办方: Collin Blakely

正在招募 Phase 1 生物制剂联合产品

ClinicalTrials.gov / NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Triple Negative Breast Cancer；Colorectal Cancer
干预: CRX100 suspension for infusion，Fludarabine，Cyclophosphamide
地点: United States
申办方: BioEclipse Therapeutics

正在招募 Phase 1 药物其他

ClinicalTrials.gov / NCI NCT04297605 / NCI-2025-05521

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

AI 简述这是一项I期试验，研究帕博利珠单抗联合单药化疗用于局部晚期或转移性非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Pembrolizumab，Pemetrexed (Chemotherapy)，Nab-paclitaxel (Chemotherapy)
地点: United States
申办方: University of Rochester

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT04342429 / NCI-2019-02577

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

AI 简述这是一项质子束调强放疗用于局限期或广泛期小细胞肺癌的前瞻性研究。

?

适用疾病: Small-cell Lung Cancer；Limited Stage Small Cell Lung Cancer；Extensive Stage Small Cell Lung Cancer
干预: Proton-beam Therapy for Small Cell Lung Cancer
地点: United States
申办方: Emory University

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04389632 / NCI-2020-03931

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Carcinoma, Non-Small Cell Lung；Squamous Cell Carcinoma of Head and Neck；HER2 Negative Breast Neoplasms
干预: sigvotatug vedotin，pembrolizumab，cisplatin，carboplatin
地点: United States，France，South Korea，Spain 等 3 个
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04429087 / NCI-2021-01392

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

AI 简述这是一项I期试验，研究不同剂量Obrixtamig用于DLL3阳性小细胞肺癌和其他神经内分泌肿瘤。

?

适用疾病: Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Obrixtamig - parenteral 1，Obrixtamig - parenteral 2
地点: United States，Germany，Japan，Spain
申办方: Boehringer Ingelheim

正在招募 Phase 1 药物放疗

ClinicalTrials.gov NCT04550104

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

AI 简述这是一项I期试验，研究新型药物联合放疗用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Radiotherapy，Olaparib Oral Tablet [Lynparza]，AZD1390，Ceralasertib
地点: United Kingdom
申办方: University of Leeds

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04762199 / NCI-2020-08392

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究MRX-2843联合Osimertinib用于晚期EGFR突变非小细胞肺癌。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8
干预: Flt3/MerTK Inhibitor MRX-2843，Osimertinib
地点: United States
申办方: Emory University

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT04780568 / NCI-2021-01360

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究奥希替尼联合Tegavivint用于转移性EGFR突变非小细胞肺癌一线治疗，在美国开展。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IVA Lung Cancer AJCC v8
干预: Osimertinib，Tegavivint，Echocardiography Test，Multigated Acquisition Scan
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募阶段未标明放疗

ClinicalTrials.gov NCT04790253

PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)

AI 简述这是一项试验，在比利时、法国、德国等国比较预防性颅脑照射与MRI监测用于小细胞肺癌。

?

适用疾病: Limited Stage Small Cell Lung Cancer；Extensive-stage Small-cell Lung Cancer
干预: Prophylactic cranial irradiation
地点: Austria，Belgium，France，Germany 等 5 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT04852588

Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment

AI 简述这是一项在加拿大开展的试验，研究胸部淋巴结取样用于接受根治性放疗的晚期肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)，Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
地点: Canada
申办方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04999761

AB122 Platform Study

AI 简述这是一项I期试验，研究AB122联合TAS-116、TAS-120、TAS-115用于晚期或转移性实体瘤，在日本开展。

?

适用疾病: Advanced or Metastatic Solid Tumor；Pancreatic Ductal Adenocarcinoma；Colorectal Cancer
干预: AB122，AB122，TAS-116，AB122
地点: Japan
申办方: Taiho Pharmaceutical Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05033691

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

AI 简述这是一项试验，研究奥希替尼联合立体定向放射手术对比单药用于EGFR突变非小细胞肺癌伴无症状脑转移，在以色列开展。

?

适用疾病: NSCLC；EGFR Gene Mutation；EGF-R Positive Non-Small Cell Lung Cancer
干预: Stereotactic surgery
地点: Israel
申办方: Hadassah Medical Organization

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05076760 / NCI-2022-02030

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

AI 简述这是一项I期试验，研究MEM-288溶瘤病毒单用或联合标准治疗用于晚期实体瘤。

?

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05098210 / NCI-2021-10199

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究个体化新抗原肽疫苗联合纳武利尤单抗用于黑色素瘤、乳腺癌或非小细胞肺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8；Locally Advanced Cutaneous Melanoma
干预: Neoantigen Peptide Vaccine，Nivolumab，Poly ICLC，Echocardiography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05104515

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

AI 简述这是一项I期试验，研究OVM-200作为治疗性癌症疫苗用于前列腺癌、非小细胞肺癌、卵巢癌。

?

适用疾病: Prostate Cancer；Non Small Cell Lung Cancer；Ovarian Cancer
干预: OVM-200
地点: United Kingdom
申办方: Oxford Vacmedix UK Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05136846 / NCI-2021-07691

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究罂粟碱联合放化疗用于II-III期非小细胞肺癌，在美国开展。

?

适用疾病: Locally Advanced Lung Non-Small Cell Carcinoma；Stage II Lung Cancer AJCC v8；Stage IIA Lung Cancer AJCC v8
干预: Carboplatin，Durvalumab，Paclitaxel，Papaverine
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05142189 / NCI-2024-10531

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究BNT116单用或联合化疗用于晚期非小细胞肺癌，在美国等多国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Stage II Lung Cancer；Stage III Lung Cancer
干预: BNT116，Cemiplimab，Docetaxel，Carboplatin
地点: United States，Australia，Germany，Hungary 等 4 个
申办方: BioNTech SE

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05176483 / NCI-2022-05617

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

AI 简述这是一项I期试验，研究Zanzalintinib联合免疫药物用于实体瘤，在多国开展。

?

适用疾病: Renal Cell Carcinoma (RCC)；Metastatic Castration-Resistant Prostate Cancer (mCRPC)；Urothelial Carcinoma (UC)
干预: Zanzalintinib，Nivolumab，Ipilimumab，Nivolumab + Relatlimab
地点: United States，Australia，Austria，Belgium 等 9 个
申办方: Exelixis

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05227326 / NCI-2021-14102

AOH1996 for the Treatment of Refractory Solid Tumors

AI 简述这是一项I期试验，研究AOH1996用于多种难治性实体瘤。

?

适用疾病: Refractory Malignant Solid Neoplasm；Osteosarcoma；Leiomyosarcomas
干预: PCNA Inhibitor AOH1996
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05234307 / NCI-2022-00236

PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究PBF-1129联合Nivolumab用于复发或转移性非小细胞肺癌。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8
干预: Adenosine A2B Receptor Antagonist PBF-1129，Biospecimen Collection，Nivolumab
地点: United States
申办方: Dwight Owen

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT05244239 / NCI-2021-12410

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

AI 简述这是一项I期试验，研究Lurbinectedin联合姑息放疗用于广泛期小细胞肺癌。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IV Lung Cancer
干预: Lurbinectedin，Palliative Radiation Therapy
地点: United States
申办方: Emory University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

AI 简述这是一项I期试验，研究MRTX1719用于MTAP缺失的实体瘤，包括间皮瘤、非小细胞肺癌等。

?

适用疾病: Mesothelioma；Non Small Cell Lung Cancer；Malignant Peripheral Nerve Sheath Tumors
干预: MRTX1719
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05254184 / NCI-2025-01424

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

AI 简述这是一项I期试验，研究KRAS靶向疫苗联合免疫化疗用于非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05283330 / NCI-2022-07733

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

AI 简述这是一项I期试验，研究²¹²Pb-DOTAM-GRPR1用于GRPR阳性的复发或转移性实体瘤。

?

适用疾病: Cervical Cancer；Breast Cancer；Colon Cancer
干预: ²¹²Pb-DOTAM-GRPR1
地点: United States
申办方: Orano Med Theranostics, SAS

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT05355701

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

AI 简述这是一项I期试验，研究PF-07799933用于BRAF突变晚期实体瘤，在美国、加拿大、以色列等地开展。

?

适用疾病: Melanoma；Non-Small-Cell Lung Cancer；Thyroid Cancer
干预: PF-07799933，binimetinib，cetuximab，midazolam
地点: United States，Canada，Israel
申办方: Pfizer

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05378633

The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?

AI 简述这是一项研究，比较SRS与全脑放疗用于非小细胞肺癌脑转移患者。在德国开展。

?

适用疾病: Brain Metastases；Nsclc
干预: SRS，Whole Brain Radiotherapy
地点: Germany
申办方: University Hospital Heidelberg

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05401110

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究Osimertinib联合Carotuximab用于晚期EGFR突变非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Lung Cancer
干预: Osimertinib，Carotuximab
地点: United States
申办方: Karen Reckamp, MD, MS

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05403554

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

AI 简述这是一项I期试验，研究NI-1801单药或联合用药用于间皮素表达阳性的实体瘤（卵巢癌、三阴性乳腺癌等），在法国、意大利开展。

?

适用疾病: Epithelial Ovarian Cancer；Triple Negative Breast Cancer；Non-squamous Non-small-cell Lung Cancer
干预: Biological NI-1801，NI-1801 in combination with anti-PD1 (Pembrolizumab)，NI-1801 in combination with paclitaxel，Paclitaxel
地点: France，Italy
申办方: Light Chain Bioscience - Novimmune SA

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05492682

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

AI 简述这是一项I期试验，研究PeptiCRAd-1联合环磷酰胺和Pembrolizumab用于黑色素瘤、三阴性乳腺癌、非小细胞肺癌等。

?

适用疾病: Melanoma (Skin)；Triple-Negative Breast Cancer；Non-Small Cell Lung Cancer
干预: PeptiCRAd-1，Cyclophosphamide，Pembrolizumab
地点: Germany，Italy
申办方: Valo Therapeutics Oy

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05493566 / NCI-2022-00931

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

AI 简述这是一项早期I期试验，研究低剂量白细胞介素-2联合Pembrolizumab用于IV期非小细胞肺癌。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8；Stage IVA Lung Cancer AJCC v8
干预: Aldesleukin，Pembrolizumab
地点: United States
申办方: Emory University

正在招募阶段未标明手术/操作

ClinicalTrials.gov / NCI NCT05502523 / NCI-2022-06111

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

AI 简述这是一项观察性研究，评估手术技术对I-III期非小细胞肺癌ctDNA的影响。

?

适用疾病: Lung Non-Small Cell Carcinoma；Stage I Lung Cancer AJCC v8；Stage II Lung Cancer AJCC v8
干预: Pulmonary Artery-First Surgical Technique，Biospecimen Collection
地点: United States
申办方: Thomas Jefferson University

正在招募 EARLY / Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05620342 / NCI-2023-04525

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

AI 简述这是一项早期I期试验，研究靶向GD2的自体CAR-T细胞用于肺癌。

?

适用疾病: Lung Cancer；Small Cell Lung Carcinoma；Non Small Cell Lung Cancer
干预: iC9.GD2.CAR.IL-15 T Infusion
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05627960 / NCI-2023-01295

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

AI 简述这是一项I期试验，研究AG-01抗体用于晚期实体瘤，包括三阴性乳腺癌、非小细胞肺癌等。

?

适用疾病: Triple Negative Breast Cancer；Hormone-Resistant Breast Cancer；Non Small Cell Lung Cancer
干预: AG-01 Compound
地点: United States
申办方: A&G Pharmaceutical Inc.

正在招募 Phase 1 生物制剂药物其他

ClinicalTrials.gov / NCI NCT05681780 / NCI-2023-00307

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

AI 简述这是一项I期试验，研究CD40L增强TIL用于EGFR、ALK、ROS1或HER2驱动的非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Stage IV Non-small Cell Lung Cancer；Recurrent Non Small Cell Lung Cancer
干预: Tumor-infiltrating Lymphocytes (TIL)，Nivolumab，Cyclophosphamide，Fludarabine
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05724004

Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)

AI 简述这是一项试验，研究Alectinib后巩固放疗用于ALK重排晚期非小细胞肺癌。

?

适用疾病: Radiotherapy Side Effect；Non-small Cell Lung Cancer；ALK Gene Mutation
干预: SBRT/SRS/radiation therapy
地点: Sweden
申办方: Karolinska University Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05752552

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

AI 简述这是一项I期试验，在比利时、法国、荷兰等地研究DO-2用于晚期或难治性实体瘤。

?

适用疾病: Adult Solid Tumor；Advanced Solid Tumor；Refractory Tumor
干预: DO-2
地点: Belgium，France，Netherlands
申办方: DeuterOncology

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT05753722

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

AI 简述这是一项I期试验，在美国研究PRTH-101单药或联合Pembrolizumab用于晚期恶性实体瘤。

?

适用疾病: Advanced or Metastatic Solid Tumors；Non Small Cell Lung Cancer；NSCLC
干预: PRTH-101，Pembrolizumab
地点: United States
申办方: Incendia Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05777603 / NCI-2023-03049

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究雾化抗生素联合帕博利珠单抗用于晚期非小细胞肺癌。

?

适用疾病: Advanced Non Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: aerosolized aztreonam，aerosolized vancomycin，pembrolizumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募阶段未标明其他手术/操作放疗

ClinicalTrials.gov / NCI NCT05802186 / NCI-2023-01822

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

AI 简述这是一项试验，研究人工智能指导的立体定向体部放疗计划用于原发或转移性肺肿瘤。

?

适用疾病: Lung Carcinoma；Lung Non-Small Cell Carcinoma；Metastatic Malignant Neoplasm in the Lung
干预: Computed Tomography，Magnetic Resonance Imaging，Positron Emission Tomography，Quality-of-Life Assessment
地点: United States
申办方: Northwestern University

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05815173

Ladarixin With Sotorasib in Advanced NSCLC

AI 简述这是一项I期试验，研究Ladarixin联合Sotorasib用于KRAS G12C突变晚期非小细胞肺癌。

?

适用疾病: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
干预: Sotorasib，Ladarixin
地点: United States
申办方: NYU Langone Health

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT05837767 / NCI-2023-06276

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

AI 简述这是一项临床试验，研究姑息放疗用于软组织转移的实体瘤。

?

适用疾病: Invasive Ductal Breast Carcinoma；Invasive Ductal Breast Carcinoma Stage IV；Lobular Breast Carcinoma
干预: Palliative radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05856981 / NCI-2023-06437

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

AI 简述这是一项1期试验，研究ADU-1805用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Metastatic Solid Tumor；Refractory Cancer
干预: ADU-1805，Pembrolizumab
地点: United States，Belgium，Spain
申办方: Sairopa B.V.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05873686 / NCI-2023-10501

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

AI 简述这是一项I期试验，研究NXP900用于晚期实体瘤，包括非小细胞肺癌、肾癌等。

?

适用疾病: Advanced Solid Tumor；NSCLC (Non-small Cell Lung Cancer)；Renal Cancer
干预: NXP900
地点: United States，United Kingdom
申办方: Nuvectis Pharma, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05877599 / NCI-2023-04428

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AI 简述这是一项I期试验，研究TP53 R175H靶向T细胞用于HLA-A*02:01阳性晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Colorectal Carcinoma
干预: Autologous, engineered T Cells targeting TP53 R175H
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05963867

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

AI 简述这是一项I期试验，研究BI 764532在小细胞肺癌或神经内分泌癌患者中的肿瘤摄取情况。

?

适用疾病: Small Cell Lung Carcinoma (SCLC)；Neuroendocrine Neoplasms
干预: BI 764532，[89Zr]Zr-BI 764532
地点: Netherlands
申办方: Boehringer Ingelheim

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05983432 / NCI-2023-10398

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

AI 简述这是一项I期试验，研究BL-B01D1用于转移性或不可切除非小细胞肺癌及其他实体瘤，在美国、法国等地开展。

?

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06026410 / NCI-2023-07364

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Darlifarnib联合Cabozantinib或Adagrasib用于晚期实体瘤。在美国、法国等地开展。

?

适用疾病: Solid Tumors With HRAS Alterations；Non Small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)
干预: Darlifarnib，Cabozantinib，Adagrasib
地点: United States，France，Germany，Italy 等 1 个
申办方: Kura Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RMC-9805用于KRAS G12D突变实体瘤。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: RMC-9805，RMC-6236
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06046495 / NCI-2024-06804

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

AI 简述这是一项1期试验，研究口服EGFR抑制剂PLB1004用于非小细胞肺癌。在美国开展。

?

适用疾病: Non-Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: PLB1004
地点: United States
申办方: Avistone Biotechnology Co., Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06066138

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

AI 简述这是一项I期试验，研究基于治疗药物监测的Atezolizumab给药方案用于多种晚期肉瘤和肺癌。在美国开展。

?

适用疾病: Locally Advanced Alveolar Soft Part Sarcoma；Metastatic Alveolar Soft Part Sarcoma；Locally Advanced Non Small Cell Lung Cancer
干预: Atezolizumab
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06069570 / NCI-2024-08465

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

AI 简述这是一项I期试验，研究KB-GDT-01联合低剂量放疗用于局部晚期或转移性非小细胞肺癌或实体瘤骨转移。

?

适用疾病: Carcinoma, Non-Small-Cell Lung Cancer；Bone Metastases From Solid Tumors；Metastatic Malignant Solid Tumor
干预: KB-GDT-01
地点: United States
申办方: Kiromic BioPharma Inc.

正在招募阶段未标明其他放疗

ClinicalTrials.gov NCT06114108

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

AI 简述这是一项试验，比较系统治疗联合局部消融治疗与单纯系统治疗用于IV期非小细胞肺癌。在瑞士开展。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Stage IV
干预: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)，Surgery，Radiotherapy
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT06116786 / NCI-2023-09677

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究JNJ-86974680联合Cetrelimab和放疗用于晚期非小细胞肺癌。

?

适用疾病: Carcinoma, Non-small-Cell Lung；Stage IIIB Lung Cancer；Stage IV Lung Cancer
干预: JNJ-86974680，Cetrelimab，Radiation Therapy
地点: United States，Germany，South Korea，Spain
申办方: Johnson & Johnson Enterprise Innovation Inc.

正在招募 Phase 1 器械药物放疗

ClinicalTrials.gov NCT06124118

Tumor Treating Fields for Locally Advanced NSCLC

AI 简述这是一项I期试验，研究肿瘤治疗电场联合化疗和度伐利尤单抗用于局部晚期非小细胞肺癌，在美国开展。

?

适用疾病: Non Small Cell Lung Cancer
干预: carboplatin chemotherapy，NovoTTF-200T (TTFields) System，Durvalumab
地点: United States
申办方: University of Utah

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06150664 / NCI-2024-04028

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

AI 简述这是一项I期试验，研究CTX-8371用于多种晚期恶性肿瘤。

?

适用疾病: Non Small Cell Lung Cancer；Triple Negative Breast Cancer；Hodgkin Lymphoma
干预: CTX-8371
地点: United States
申办方: Compass Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06171750 / NCI-2023-10926

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Tolododekin Alfa（ANK-101）用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor；Cutaneous Tumor；Subcutaneous Tumor
干预: tolododekin alfa，Cemiplimab
地点: United States，Canada
申办方: Ankyra Therapeutics, Inc

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06218914 / NCI-2024-01226

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究靶向KRAS G12D的T细胞疗法用于不可切除晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Colorectal Carcinoma；Pancreatic Ductal Adenocarcinoma
干预: NT-112: Autologous, engineered T Cells targeting KRAS G12D，AZD0240: Autologous, engineered T Cells targeting KRAS G12D
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06228482 / NCI-2024-00931

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

AI 简述这是一项I期试验，研究靶向整合素αvβ6的放射性核素疗法用于转移性非小细胞肺癌。

?

适用疾病: Metastatic Nonsmall Cell Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
地点: United States
申办方: University of California, Davis

正在招募阶段未标明联合产品

ClinicalTrials.gov NCT06238882

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

AI 简述这是一项试验，在墨西哥研究硝酸甘油联合放疗用于EGFR突变非小细胞肺癌脑转移。

?

适用疾病: Non-small Cell Lung Cancer；Brain Metastases；EGFR Gene Mutation
干预: Nitroglycerin
地点: Mexico
申办方: Instituto Nacional de Cancerologia de Mexico

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT06249282 / NCI-2023-11093

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究Carfilzomib联合Sotorasib用于KRAS G12C突变晚期或转移性非小细胞肺癌，在美国开展。

?

适用疾病: Advanced Lung Non-Small Cell Carcinoma；Metastatic Lung Non-Small Cell Carcinoma；Stage III Lung Cancer AJCC v8
干预: Biopsy，Biospecimen Collection，Carfilzomib，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

AI 简述这是一项I/Ib期试验，研究IAM1363用于HER2相关肿瘤，在美国、法国、爱尔兰、意大利等地开展。

?

适用疾病: HER2 Mutation-Related Tumors；HER2；HER2-positive Breast Cancer
干预: IAM1363
地点: United States，France，Ireland，Italy 等 4 个
申办方: Iambic Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06266299 / NCI-2024-08649

A Study of KK2269 in Adult Participants With Solid Tumors

AI 简述这是一项I期试验，研究KK2269用于晚期实体瘤，在美国和日本开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Gastric Adenocarcinoma
干预: KK2269，Docetaxel
地点: United States，Japan
申办方: Kyowa Kirin Co., Ltd.

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06305962

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

AI 简述这是一项早期I期试验，研究177Lu-抗PD-L1单域抗体用于转移性实体瘤。

?

适用疾病: PDL1 Gene Mutation；Non Small Cell Lung Cancer；Small Cell Lung Cancer ( SCLC )
干预: 177Lu-RAD204
地点: Australia
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06332755

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

AI 简述这是一项I期试验，研究LB-LR1109单药用于实体瘤及联合阿替利珠单抗用于非小细胞肺癌等多种癌症，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer(NSCLC)；Head and Neck Squamous Cell Carcinoma(HNSCC)；Renal Cell Carcinoma(RCC)
干预: Phase 1a: LB-LR1109，Phase 1b: LB-LR1109 and Atezolizumab
地点: United States
申办方: LG Chem

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06343402 / NCI-2024-03040

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究BBO-8520用于KRAS G12C非小细胞肺癌，在美国、澳大利亚、加拿大、丹麦开展。

?

适用疾病: Non-small Cell Lung Cancer；Metastatic Non-Small Cell Lung Cancer；NSCLC
干预: BBO-8520，Pembrolizumab，BBO-10203
地点: United States，Australia，Canada，Denmark 等 1 个
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

AI 简述这是一项I期试验，研究VET3-TGI与Atezolizumab用于多种实体瘤。

?

适用疾病: Solid Tumor, Adult；Microsatellite Stable Colorectal Cancer；Head and Neck Squamous Cell Carcinoma
干预: VET3-TGI，Atezolizumab
地点: United States
申办方: KaliVir Immunotherapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

AI 简述这是一项I期试验，研究BMS-986463用于晚期恶性实体瘤，在美加法等国开展。

?

适用疾病: High-grade Serous Ovarian Carcinoma (HGSOC)；Uterine Serous Carcinoma (USC)；Non-small Cell Lung Cancer (NSCLC)
干预: BMS-986463
地点: United States，Canada，France，Italy 等 1 个
申办方: Bristol-Myers Squibb

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06479811 / NCI-2024-05714

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

AI 简述这是一项I期试验，研究[212Pb]VMT-Alpha-NET用于生长抑素受体阳性的多种癌症，在美国开展。

?

适用疾病: Sinonasal Neuroendocrine Carcinoma；Nasopharyngeal Carcinoma；Esthesioneuroblastoma
干预: 68Ga-DOTATATE，[203Pb]VMT-alpha-NET，[212Pb]VMT-alpha-NET
地点: United States
申办方: National Cancer Institute (NCI)

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06528743

Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER

AI 简述这是一项可行性试验，研究大分割放疗（5次6Gy）用于非小细胞肺癌，在荷兰开展。

?

适用疾病: Patients With Non-small-cell Lung Cancer
干预: RT (5x6 Gy) to the primary tumor and, if indicated, to lymph node and/or distant metastases.
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06529081

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

AI 简述这是一项试验，研究姑息放疗或根治性/消融放疗联合用于小细胞肺癌，在波兰开展。

?

适用疾病: Small Cell Lung Carcinoma
干预: Palliative Radiotherapy，Radical/Ablative Radiotherapy
地点: Poland
申办方: Copernicus Memorial Hospital

正在招募 Phase 1 生物制剂器械药物

ClinicalTrials.gov / NCI NCT06529822 / NCI-2025-00334

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

AI 简述这是一项1期试验，研究个性化癌症疫苗联合Poly ICLC用于实体瘤分子残留病灶阳性患者，在美国开展。

?

适用疾病: Muscle-Invasive Bladder Carcinoma；Gastroesophageal Adenocarcinoma；Melanoma
干预: Synthetic long peptide personalized cancer vaccine，Poly ICLC，Signatera assay
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06545331 / NCI-2024-09409

Study of XB010 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究XB010联合Pembrolizumab用于多种晚期实体瘤。在美国、英国等地开展。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；Esophageal Squamous Cell Cancer；Head and Neck Squamous Cell Cancer
干预: XB010，Pembrolizumab
地点: United States，United Kingdom
申办方: Exelixis

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06561685 / NCI-2024-09084

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究LY4050784联合其他药物用于晚期或转移性实体瘤，包括非小细胞肺癌。

?

适用疾病: Metastatic Solid Tumor；Advanced Solid Tumor；Non-small Cell Lung Cancer
干预: LY4050784，Pembrolizumab，Cisplatin，Carboplatin
地点: United States，France，Germany，Japan 等 2 个
申办方: Eli Lilly and Company

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06562192 / NCI-2024-08464

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

AI 简述这是一项I期试验，研究[177Lu]Lu-NNS309用于胰腺癌、肺癌、乳腺癌和结直肠癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: [68Ga]Ga-NNS309，[177Lu]Lu-NNS309
地点: United States，Belgium，Canada，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募阶段未标明药物

ClinicalTrials.gov NCT06576635

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

AI 简述这是一项试验，研究化疗（多西他赛等）用于转移性非小细胞肺癌患者。

?

适用疾病: NSCLC
干预: Docetaxel，Paclitaxel，Gemcitabine，Pemetrexed
地点: United States
申办方: University of Illinois at Chicago

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06586957 / NCI-2025-00731

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT3964用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Solid Tumor；Advanced Solid Tumor；Solid Tumor, Adult
干预: NKT3964
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06592638 / NCI-2025-04655

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

AI 简述这是一项I期试验，研究ZG006用于小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: ZG006
地点: United States
申办方: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06616623 / NCI-2024-07859

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究Vismodegib联合Atezolizumab用于复发或转移性非小细胞肺癌。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8
干预: Atezolizumab，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: Dwight Owen

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06625775 / NCI-2024-09407

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究BBO-10203用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Metastatic Breast Cancer；Advanced Breast Cancer
干预: BBO-10203，Trastuzumab，Fulvestrant，Ribociclib
地点: United States，Australia，Brazil，France 等 1 个
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06639191

[177Lu]Lu-AKIR001 First-in-human Study

AI 简述这是一项早期I期试验，研究[177Lu]Lu-AKIR001用于甲状腺未分化癌、头颈癌、宫颈癌等。

?

适用疾病: Thyroid Gland Anaplastic Carcinoma；Poorly Differentiated Thyroid Carcinoma；Cancer Head and Neck
干预: [177Lu]Lu-AKIR001
地点: Sweden
申办方: Karolinska University Hospital

正在招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT06732193

AI 简述这是一项观察性研究，评估Fissios应用与现场呼吸理疗对非小细胞肺癌术后并发症的影响（在西班牙开展）。

?

适用疾病: Surgical Procedure, Unspecified；Non Small Cell Lung Cancer；Surgery Scheduled
干预: On-site respiratory physiotherapy，Fissios App
地点: Spain
申办方: Carlos Alfredo Fraile Olivero, MD, PhD.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06774963

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

AI 简述这是一项I期试验，研究LNCB74用于晚期实体瘤，包括卵巢癌、乳腺癌等。

?

适用疾病: Ovarian Cancer；Breast Cancer；Endometrial Cancer
干预: LNCB74
地点: United States
申办方: NextCure, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06784193 / NCI-2025-05945

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究OP-3136用于晚期或转移性实体瘤，包括ER+HER2-乳腺癌、非小细胞肺癌和前列腺癌，在美国和澳大利亚开展。

?

适用疾病: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)；Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)；Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: OP-3136，Fulvestrant，Palazestrant
地点: United States，Australia
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 1 联合产品药物其他

ClinicalTrials.gov / NCI NCT06789172 / NCI-2025-08170

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

AI 简述这是一项I期试验，研究OKN4395联合帕博利珠单抗用于实体瘤，包括肉瘤、头颈癌、非小细胞肺癌。

?

适用疾病: Solid Tumours；Sarcoma；HNSCC
干预: OKN4395，Pembrolizumab，Fasting，Fed
地点: United States，Australia，United Kingdom
申办方: Epkin

正在招募 Phase 1 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT06800339 / NCI-2025-02690

A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究新辅助化疗免疫治疗联合放疗用于可切除的肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Stage II Lung Cancer；Stage IIIA Lung Cancer
干预: Nivolumab，Chemotherapy，SBRT，Surgical Resection
地点: United States
申办方: University of Maryland, Baltimore

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06805825 / NCI-2025-01427

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

AI 简述这是一项I期试验，研究c-Kit特异性抗体药物偶联物NN3201用于表达c-Kit的晚期实体瘤。

?

适用疾病: Gastrointestinal Stromal Tumors；Small-cell Lung Cancer；Adenoid Cystic Carcinoma
干预: NN3201
地点: United States
申办方: Novelty Nobility, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06807632 / NCI-2025-00936

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

AI 简述这是一项I期试验，研究Valemetostat联合Atezolizumab用于肺癌。

?

适用疾病: Extensive-stage Small-cell Lung Cancer；Extensive Stage Small Cell Lung Cancer
干预: Valemetostat，Atezolizumab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06835569

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

AI 简述这是一项I期试验，研究ALTA3263用于KRAS突变的晚期实体瘤，包括胰腺癌、非小细胞肺癌、结直肠癌等，在美国开展。

?

适用疾病: Cancer；PDAC - Pancreatic Ductal Adenocarcinoma；NSCLC (Non-small Cell Lung Cancer)
干预: ALTA3263，cetuximab，mFOLFOX6，Pembrolizumab
地点: United States
申办方: Alterome Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06905197 / NCI-2025-03995

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

AI 简述这是一项I期试验，研究DZD6008用于EGFR突变晚期非小细胞肺癌，在美国、澳大利亚等地开展。

?

适用疾病: Non Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: DZD6008，Sunvozertinib
地点: United States，Australia
申办方: Dizal Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06917079 / NCI-2025-02810

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

AI 简述这是一项I期试验，研究BBO-11818用于KRAS突变实体瘤，在美国和澳大利亚开展。

?

适用疾病: Non-Small Cell Lung Cancer；NSCLC；PDAC - Pancreatic Ductal Adenocarcinoma
干预: BBO-11818，Pembrolizumab，Platinum chemotherapy (cisplatin or carboplatin)，Pemetrexed
地点: United States，Australia
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06922539 / NCI-2025-09451

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

AI 简述这是一项I期试验，研究ST-001 nanoFenretinide用于复发/难治性小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer；Refractory Lung Small Cell Carcinoma；Recurrent Small Cell Lung Cancer
干预: Fenretinide
地点: United States
申办方: SciTech Development, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06931626

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

AI 简述这是一项I期试验，研究NMS-03305293联合替莫唑胺用于复发小细胞肺癌，在美国开展。

?

适用疾病: Small Cell Lung Cancer
干预: NMS-03305293，Temozolomide
地点: United States
申办方: Nerviano Medical Sciences

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07006727 / NCI-2025-07471

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

AI 简述这是一项I期试验，研究225Ac-ETN029用于DLL3阳性晚期实体瘤，在美国、加拿大、韩国等地开展。

?

适用疾病: Small Cell Lung Carcinoma；Large Cell Neuroendocrine Carcinoma of the Lung；Neuroendocrine Prostate Cancer
干预: 225Ac-ETN029，111In-ETN029
地点: United States，Canada，South Korea
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[225Ac]Ac-AKY-1189用于多种晚期实体瘤，在美国开展。

?

适用疾病: Urothelial Carcinoma Bladder；Triple Negative Breast Cancer (TNBC)；Hormone Receptor Positive Breast Adenocarcinoma
干预: [225Ac]Ac-AKY-1189 (therapeutic)，[64Cu]Cu-AKY-1189 (imaging)
地点: United States
申办方: Aktis Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07027514 / NCI-2025-07002

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究Tolododekin Alfa联合Cetrelimab用于晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Stage III Lung Cancer；Stage IV Lung Cancer
干预: tolododekin alfa，Cetrelimab
地点: United States
申办方: Ankyra Therapeutics, Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07037758 / NCI-2025-06049

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

AI 简述这是一项I期试验，研究Tarlatamab联合AB248用于广泛期小细胞肺癌，在美国、韩国、土耳其开展。

?

适用疾病: Extensive Stage Small Cell Lung Cancer；Recurrent Extensive Stage Lung Small Cell Carcinoma
干预: Tarlatamab，AB248
地点: United States，South Korea，Turkey (Türkiye)
申办方: Amgen

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07080242 / NCI-2025-09219

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

AI 简述这是一项I期试验，在美国研究BL-M14D1用于局部晚期或转移性小细胞肺癌和神经内分泌肿瘤。

?

适用疾病: Small Cell Lung Cancer Metastatic or Locally Advanced；Neuroendocrine Cancer；Metastatic Neuroendocrine Prostate Cancer
干预: BL-M14D1
地点: United States
申办方: SystImmune Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07085091 / NCI-2025-05711

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

AI 简述这是一项I期试验，在美国开展，首次研究ALX2004用于晚期或转移性实体瘤。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；HNSCC；CRC (Colorectal Cancer)
干预: ALX2004
地点: United States
申办方: ALX Oncology Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07090499

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PF-08046876用于晚期实体瘤，在美国、加拿大等地开展。

?

适用疾病: Advanced/Metastatic Solid Tumors；Bladder Cancer；Urothelial Carcinoma
干预: PF-08046876
地点: United States，Canada，Puerto Rico，Spain 等 1 个
申办方: Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07094204 / NCI-2025-06344

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

AI 简述这是一项I期试验，研究ASP5834用于实体瘤，在美国、法国等地开展。

?

适用疾病: Solid Tumor；Non-Small-Cell Lung Cancer；Pancreatic Ductal Adenocarcinoma
干预: ASP5834，panitumumab
地点: United States，France，Japan，Spain
申办方: Astellas Pharma Inc

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07107490

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

AI 简述这是一项I期试验，研究ALPS12联合OBINUTUZUMAB用于广泛期小细胞肺癌（中国香港、日本、中国台湾）。

?

适用疾病: Extensive Stage Small Cell Lung Cancer
干预: ALPS12，obinutuzumab
地点: Hong Kong，Japan，Taiwan
申办方: Chugai Pharmaceutical

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT07113691 / NCI-2026-00996

Iadademstat + SBRT With Atezo in ES-SCLC

AI 简述这是一项I期试验，研究Iadademstat联合SBRT和Atezolizumab用于广泛期小细胞肺癌。在美国开展。

?

适用疾病: Extensive Stage Small Cell Lung Cancer (ES-SCLC)；Recurrent Extensive Stage Lung Small Cell Carcinoma；Extensive Stage Small Cell Lung Cancer
干预: Iadademstat，Atezolizumab，SBRT
地点: United States
申办方: Yale University

正在招募 Phase 1 生物制剂器械药物

ClinicalTrials.gov / NCI NCT07116057 / NCI-2025-07462

MOv19-BBz CAR T Cells in FRa+ Cancers

AI 简述这是一项I期试验，研究MOv19-BBz CAR T细胞用于FRα阳性的转移性非小细胞肺癌。在美国开展。

?

适用疾病: Metastatic Non Small Cell Lung Cancer；Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer
干预: MOv19-BBz CAR T cells，Cyclophosphamide/Fludarabine，FRa Expression Testing
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07127874 / NCI-2026-00071

A Study of PHN-012 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究PHN-012用于晚期实体瘤，在美国和西班牙开展。

?

适用疾病: Colon Cancer；Pancreatic Cancer；Lung Cancer (NSCLC)
干预: PHN-012
地点: United States，Spain
申办方: Pheon Therapeutics

正在招募 Phase 1 放疗

ClinicalTrials.gov / NCI NCT07139990 / NCI-2025-08324

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

AI 简述这是一项I期试验，研究个体化立体定向放疗用于广泛期小细胞肺癌、脑转移及实体瘤。

?

适用疾病: Small Cell Lung Cancer Extensive Stage；Brain Metastases；Solid Tumor, Adult
干预: Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)，Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy)
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07140016 / NCI-2025-08161

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项I期试验，在美国、法国、西班牙等地开展，研究Gilteritinib用于ALK阳性晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Anaplastic Lymphoma Kinase (ALK) Positive；Stage III Lung Cancer
干预: gilteritinib
地点: United States，France，Spain
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07140315

DK222 Study at Hopkins

AI 简述这是一项I期试验，研究[18F]DK222放射性示踪剂用于非小细胞肺癌和尿路上皮癌。

?

适用疾病: Non-Small Cell Lung Cancer；Urothelial Cancer
干预: [18F]DK222 radiotracer
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07164313 / NCI-2025-09247

A Study of ZW251 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ZW251用于晚期实体瘤，在美国、爱尔兰、日本、葡萄牙等地开展。

?

适用疾病: Hepatocellular Carcinoma；Squamous Cell Non-Small Cell Lung Cancer；Germ Cell Tumor
干预: ZW251
地点: United States，Ireland，Japan，Portugal 等 2 个
申办方: Zymeworks BC Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07216105

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

AI 简述这是一项1期试验，研究FT836单用或联合化疗/单克隆抗体用于晚期实体瘤。

?

适用疾病: Non-Small Cell Lung Cancer；Colorectal Cancer；Breast Cancer
干预: FT836，Paclitaxel，Cetuximab，Trastuzumab
地点: United States
申办方: Fate Therapeutics

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07225036

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

AI 简述这是一项NA期试验，研究低剂量肝脏放疗联合免疫治疗用于非小细胞肺癌和黑色素瘤肝转移。

?

适用疾病: Low-Dose Liver Radiation (LD-LRT)；Non Small Cell Lung Cancer；Melanoma
干预: LD-LRT
地点: United States
申办方: Jordan Kharofa

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07227168 / NCI-2026-01753

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

AI 简述这是一项I期试验，研究STRO-004联合Pembrolizumab用于难治性/复发性转移性实体瘤，在美国开展。

?

适用疾病: Head and Neck Squamous Cell Carcinoma HNSCC；Non-Small Cell Lung Cancer NSCLC；Esophageal Cancer
干预: STRO-004，Pembrolizumab
地点: United States
申办方: Sutro Biopharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DFC413用于多种实体瘤，在加拿大、丹麦、法国、德国等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-Small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: 68Ga-NNS309，177Lu-DFC413
地点: Canada，Denmark，France，Germany 等 2 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07277413 / NCI-2026-03872

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE892单药或联合IDE397用于MTAP缺失的晚期实体瘤，在美国开展。

?

适用疾病: NSCLC Adenocarcinoma；Gastroesophageal Cancer (GC)；Gastric Adenocarcinoma
干预: IDE892，IDE397
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07284186

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PLX-61639用于局部晚期或转移性实体瘤，包括食管鳞癌、胃腺癌等。

?

适用疾病: Esophageal Squamous Cell Carcinoma；Gastric Adenocarcinoma；Gastric Squamous Cell Carcinoma
干预: PLX-61639
地点: United States
申办方: Plexium, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07300150

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

AI 简述这是一项I期试验，研究PT0511联合西妥昔单抗用于KRAS突变或扩增的晚期实体瘤。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Non-Small Cell Lung Cancer
干预: PT0511，Cetuximab
地点: United States，South Korea
申办方: PAQ Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07315113 / NCI-2026-02918

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究NXP900联合Osimertinib用于晚期EGFR突变非小细胞肺癌。

?

适用疾病: EGFR Mutation Positive Non-small Cell Lung Cancer；EGFR Mutated Non-small Cell Lung Cancer Patients；Stage III Lung Cancer
干预: NXP900，Osimertinib
地点: United States
申办方: Nuvectis Pharma, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07349537

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

AI 简述这是一项I期试验，研究RMC-5127用于KRAS G12V突变实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Adenocarcinoma
干预: RMC-5127，daraxonrasib，cetuximab
地点: United States
申办方: Revolution Medicines, Inc.

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov NCT07358806

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究OCT-598用于晚期实体瘤，在韩国开展。

?

适用疾病: Solid Tumor；Breast Cancer；Head and Neck Cancer
干预: OCT-598，Docetaxel
地点: South Korea
申办方: Oscotec Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07361562 / NCI-2026-00709

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国研究选择性ERBB2抑制剂CGT4255用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor, Adult；ERBB2 Altered Breast Cancer；ERBB2 Gene Amplification
干预: CGT4255
地点: United States
申办方: Cogent Biosciences, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SYS6043用于晚期/转移性实体瘤。

?

适用疾病: Cancer；Solid Tumor Cancer；Advanced Metastatic Cancer
干预: SYS6043
地点: United States
申办方: Conjupro Biotherapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07444814 / NCI-2026-01993

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究HWK-007用于晚期实体瘤。

?

适用疾病: Endometrial Cancer；Ovarian Cancer；Ovarian Cancer Metastatic
干预: HWK-007
地点: United States
申办方: Whitehawk Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07458347 / NCI-2026-03309

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

AI 简述这是一项I期试验，研究KST-6051用于KRAS突变晚期实体瘤，包括非小细胞肺癌、胰腺癌、结直肠癌等。在美国开展。

?

适用疾病: KRAS-mutant Non-small Cell Lung Cancer (NSCLC)；KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)；KRAS-mutant Colorectal Cancer (CRC)
干预: KST-6051
地点: United States
申办方: Kestrel Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

AI 简述这是一项I期试验，研究EPI-326用于EGFR突变非小细胞肺癌和头颈鳞癌。

?

适用疾病: Epidermal Growth Factor；Epidermal Growth Factor Receptor；Epidermal Growth Factor Receptor Gene Mutation
干预: EPI-326
地点: United States
申办方: EpiBiologics

正在招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT07479277

Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC

AI 简述这是一项非随机试验，研究Progel Platinum用于减少NSCLC VATS肺叶切除术后漏气。

?

适用疾病: Non-Small Cell Lung Cancer；Postoperative Air Leak；NSCLC
干预: Progel Platinum，Mechanical Stapling
地点: Italy
申办方: Fondazione del Piemonte per l'Oncologia

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

AI 简述这是一项I期试验，确定EXS74539用于多种实体瘤的剂量。在美国开展。

?

适用疾病: Solid Tumor；Small Cell Lung Cancer (SCLC)；High Grade Neuroendocrine Cancer
干预: EXS74539
地点: United States
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07531095 / NCI-2026-03005

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

AI 简述这是一项I期试验，研究塔拉妥单抗联合ZL-1310用于小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer；Extensive Stage Small Cell Lung Cancer；Recurrent Small Cell Lung Cancer
干预: ZL-1310，Tarlatamab，Durvalumab
地点: United States，Turkey (Türkiye)
申办方: Amgen

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07540572

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE574联合Fulvestrant用于多种晚期实体瘤，在美国开展。

?

适用疾病: ER+, HER 2- Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Castration-resistant Prostate Cancer (CRPC)
干预: IDE574，Fulvestrant injection
地点: United States
申办方: IDEAYA Biosciences

正在招募阶段未标明放疗

ClinicalTrials.gov NCT07565987

A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

AI 简述这是一项试验，研究前期立体定向体部放疗用于III期非小细胞肺癌，在印度开展。

?

适用疾病: Non Small Cell Lung Cancer
干预: SBRT in stage III NSCLC
地点: India
申办方: All India Institute of Medical Sciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07578571

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国研究IM-1617用于多种晚期实体瘤。

?

适用疾病: Colorectal Cancer；Non-Small Cell Lung Cancer；Breast Cancer
干预: IM-1617
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT07594067 / NCI-2026-04690

TCR1188-ABC Cells in KRAS-mutated Cancers

AI 简述这是一项I期试验，在美国开展，研究TCR1188-ABC细胞用于KRAS突变胆管癌、结直肠癌、非小细胞肺癌和胰腺癌。

?

适用疾病: Cholangiocarcinoma；Colorectal Cancer；Non-Small Cell Lung Cancer
干预: TCR1188-ABC cells，Fludarabine + Cyclophosphamide combination，Tocilizumab
地点: United States
申办方: University of Pennsylvania

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07613723

A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

AI 简述这是一项I期试验，研究ZI-MA4-1用于局部晚期或转移性实体瘤，在英国开展。

?

适用疾病: Ovarian Cancer；Squamous Non-Small Cell Lung Cancer (NSCLC)；Synovial Sarcomas
干预: ZI-MA4-1 (TCR-NK cells)，Cyclophosphamide，Fludarabine
地点: United Kingdom
申办方: Zelluna Immunotherapy AS

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07619339 / NCI-2026-04259

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究Tepotinib联合Ivonescimab用于非小细胞肺癌患者。

?

适用疾病: Non-Small Cell Lung Cancer；Stage IIIB Lung Cancer；Stage IIIC Lung Cancer
干预: Tepotinib，Ivonescimab
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07646106

THE-0504 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究THE-0504用于多种实体瘤，在意大利开展。

?

适用疾病: Small Cell Lung Cancer (SCLC)；Colorectal Carcinoma (CRC)；Gastric Cancer (GC)
干预: THE-0504
地点: Italy
申办方: Thena Biotech S.r.l.

正在招募 Phase 1 诊断检测药物

ClinicalTrials.gov NCT07660055

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DWJ155和[68Ga]Ga-DWJ155用于多种实体瘤，在澳大利亚、加拿大、日本等地开展。

?

适用疾病: Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Gastric/Gastroesophageal Junction (GEJ) Cancer
干预: [68Ga]Ga-DWJ155，[177Lu]Lu-DWJ155
地点: Australia，Canada，Japan
申办方: Novartis Pharmaceuticals

正在招募阶段未标明手术/操作放疗

ClinicalTrials.gov NCT02984761

Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy

AI 简述这是一项试验，比较立体定向放疗与手术用于早期肺癌。

?

适用疾病: Lung Neoplasm
干预: Stereotactic Radiotherapy，Anatomic Pulmonary Resection
地点: United States
申办方: VA Office of Research and Development

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05805631

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

AI 简述这是一项II期试验，研究鞘内注射培美曲塞用于EGFR突变非小细胞肺癌伴脑膜转移。

?

适用疾病: Carcinoma, Non-Small-Cell Lung；Epidermal Growth Factor Receptor；Leptomeningeal Metastasis
干预: Pemetrexed
地点: Taiwan
申办方: Taipei Veterans General Hospital, Taiwan

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06156527

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

AI 简述这是一项II期试验，比较Lazertinib单药与Lazertinib联合贝伐珠单抗用于EGFR突变且有吸烟史的非小细胞肺癌，在韩国开展。

?

适用疾病: Lazertinib
干预: Lazertinib，Bevacizumab Injectable Product
地点: South Korea
申办方: National Cancer Center, Korea

正在招募阶段未标明药物放疗

ClinicalTrials.gov NCT06484491

IMPT Dose Escalation for NSCLC (HyDose)

AI 简述这是一项试验，研究剂量递增质子调强放疗用于非小细胞肺癌，在荷兰开展。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: Dose-escalated intensity-modulated proton therapy (IMPT-74)，Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy，Immunotherapy: adjuvant durvalumab
地点: Netherlands
申办方: University Medical Center Groningen

正在招募阶段未标明药物

ClinicalTrials.gov NCT06487078

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

AI 简述这是一项在法国开展的观察性分析，研究Lorlatinib用于未经治疗的ALK阳性非小细胞肺癌患者。

?

适用疾病: ALK+ Non-Small-Cell Lung Carcinoma
干预: Lorlatinib
地点: France
申办方: Pfizer

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06623656

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

AI 简述这是一项II期试验，比较术前放疗免疫与化疗免疫用于非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: Cemiplimab，Platinum based chemotherapy，Stereotactic body radiation therapy
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06627738

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

AI 简述这是一项II期试验，研究立体定向放射治疗（Cyberknife）作为局部晚期非小细胞肺癌放化疗后的加强治疗，在法国开展。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: Cyberknife irradiation
地点: France
申办方: Centre Antoine Lacassagne

正在招募 EARLY / Phase 1 放疗

ClinicalTrials.gov NCT06712745

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

AI 简述这是一项早期I期试验，研究个性化超分割立体定向消融放疗用于中央型肺癌。

?

适用疾病: Cancer, Lung；Metastasis
干预: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT06788912

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

AI 简述这是一项II期试验，研究帕博利珠单抗联合其他药物用于可切除非小细胞肺癌的新辅助治疗。

?

适用疾病: Lung Neoplasm Malignant
干预: Pembrolizumab (neoadjuvant)，Cisplatin，Gemcitabine，Pemetrexed
地点: United States，Chile，Greece，Hungary 等 5 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06830694

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

AI 简述这是一项II期试验，研究Tarlatamab联合依托泊苷、卡铂和阿替利珠单抗用于EGFR-TKI治疗后转化的腺癌来源小细胞肺癌患者。

?

适用疾病: Small Cell Carcinoma of Lung
干预: Atezolizumab, Etoposide, Carboplatin, Tarlatamab
地点: South Korea
申办方: Se-Hoon Lee

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07203053

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

AI 简述这是一项II期试验，研究Tarlatamab用于既往治疗过的广泛期小细胞肺癌，在法国、希腊等地开展。

?

适用疾病: Extensive Stage Lung Small Cell Cancer
干预: Tarlatamab
地点: France，Greece，Italy，Spain 等 1 个
申办方: ETOP IBCSG Partners Foundation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07586202

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

AI 简述这是一项II期试验，在台湾开展，研究Amivantamab联合Lazertinib或化疗用于可切除EGFR突变非小细胞肺癌的新辅助治疗。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: Amivantamab，Lazertinib，Carboplatin，Pemetrexed
地点: Taiwan
申办方: Janssen Research & Development, LLC

暂时不招募 Phase 2, Phase 3

NCI NCT04929041 / NCI-2021-06042

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy with or without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients who are PD-L1 Negative

AI 简述这是一项II/III期试验，研究放疗联合免疫治疗用于PD-L1阴性晚期非小细胞肺癌，在美国开展。

?

适用疾病: Stage IIIB Lung Cancer；Stage IIIC Lung Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

即将招募 Phase 3 药物手术/操作放疗

ClinicalTrials.gov NCT04465968

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

AI 简述这是一项III期试验，研究放化疗、度伐利尤单抗和手术治疗肺上沟瘤。

?

适用疾病: Superior Sulcus Tumor；Non-small Cell Lung Cancer Stage IIB；Non Small Cell Lung Cancer Stage III
干预: Cisplatin，S1，concurrent radiotherapy，Durvalumab
地点: 未列出
申办方: National Cancer Center Hospital East

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06048315

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

AI 简述这是一项III期试验，研究安罗替尼联合派安珠单抗用于EGFR敏感突变且TKI治疗失败的晚期非小细胞肺癌。

?

适用疾病: Lung Cancer；TKI Resistance；EGFR Sensitive Mutation
干预: Anlotinib，Penpulimab
地点: 未列出
申办方: Degan Lu

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06441344

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

AI 简述这是一项III期试验，研究特瑞普利单抗联合安罗替尼用于广泛期小细胞肺癌维持治疗。

?

适用疾病: SCLC；Maintenance Treatment
干预: Toripalimab plus Anlotinib，Toripalimab
地点: 未列出
申办方: Taizhou Hospital

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06485557

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

AI 简述这是一项III期试验，研究Sintilimab联合化疗新辅助治疗可切除非小细胞肺癌。

?

适用疾病: Resectable Non-small Cell Lung Cancer
干预: sintilimab plus platinum-based chemotherapy，sintilimab plus platinum-based chemotherapy，sintilimab plus platinum-based chemotherapy
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06526624

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

AI 简述这是一项III期试验，研究HS-20093对比主动监测用于局限期小细胞肺癌。

?

适用疾病: Limited-stage Small-cell Lung Cancer
干预: HS-20093
地点: 未列出
申办方: Hansoh BioMedical R&D Company

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06581380

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

AI 简述这是一项III期试验，比较JK-1201I与拓扑替康用于复发广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: JK-1201I，Topotecan
地点: 未列出
申办方: JenKem Technology Co., Ltd.

即将招募 Phase 3 药物放疗

ClinicalTrials.gov NCT06719336

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

AI 简述这是一项III期试验，研究高剂量同步推量放疗联合阿替利珠单抗或度伐利尤单抗用于广泛期小细胞肺癌维持治疗。

?

适用疾病: Extensive-stage Small Cell Lung Cancer
干预: High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy，atezolizumab or durvalumab
地点: 未列出
申办方: Anhui Shi, MD

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06789796

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

AI 简述这是一项III期试验，研究QL1706或QL1604用于放化疗后局限期小细胞肺癌。

?

适用疾病: Small-cell Lung Cancer
干预: Iparomlimab and Tuvonralimab (QL1706)，placebo for QL1604，QL1604，placebo for Iparomlimab and Tuvonralimab (QL1706)
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06970782

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

AI 简述这是一项III期试验，比较Vebreltinib联合PLB1004与化疗用于EGFR突变MET阳性非小细胞肺癌。

?

适用疾病: Non-Small-Cell Lung Cancer
干预: Vebreltinib，PLB1004，Pemetrexed plus Carboplatin or Cisplatin
地点: 未列出
申办方: Avistone Biotechnology Co., Ltd.

即将招募 Phase 3 联合产品药物

ClinicalTrials.gov NCT07135882

Primary Radiotherapy In MEtastatic Lung Cancer

AI 简述这是一项III期试验，比较放疗后化疗与标准治疗用于转移性非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung (NSCLC)
干预: Radiotherapy followed by chemotherapy，Standard of Care (SOC)
地点: 未列出
申办方: Trans Tasman Radiation Oncology Group

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07197853

Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial

AI 简述这是一项III期试验，研究微波消融联合槐耳颗粒用于不可手术IA期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Huaier Granules；Microwave Ablation
干预: Huaier Granule
地点: 未列出
申办方: Xin Ye

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07361484

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

AI 简述这是一项III期试验，研究多西他赛联合Plinabulin用于PD-1/PD-L1和铂类化疗后的晚期非鳞非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Non-squamous Non-Small Cell Lung Cance
干预: Plinabulin，Docetaxel，Placebo (matching plinabulin placebo)
地点: 未列出
申办方: BeyondSpring Pharmaceuticals Inc.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07365241

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

AI 简述这是一项III期试验，比较ABBV-706与标准治疗用于复发/难治性小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer
干预: ABBV-706，Topotecan，Topotecan，Lurbinectedin
地点: 未列出
申办方: AbbVie

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07376382

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

AI 简述这是一项III期试验，研究SYS6010联合奥希替尼用于局部晚期或转移性非小细胞肺癌。

?

适用疾病: NSCLC
干预: SYS6010，Osimertinib，platinum-pemetrexed
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07442565

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

AI 简述这是一项III期试验，比较SYS6010与多西他赛用于既往治疗的EGFR野生型非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: SYS6010，Docetaxel
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07464327

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

AI 简述这是一项III期试验，比较HS-20093联合Adebrelimab与多西他赛用于经治的晚期非鳞非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: HS-20093，Docetaxel
地点: 未列出
申办方: Hansoh BioMedical R&D Company

即将招募 Phase 3 药物其他

ClinicalTrials.gov NCT07477808

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

AI 简述这是一项III期试验，研究醋酸甲地孕酮联合PD-1/L1抑制剂用于治疗营养不良的非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer
干预: Nanocrystalline Megestrol Acetate Oral Suspension，PD-1/L1 inhibitor combined with chemotherapy
地点: 未列出
申办方: Hunan Province Tumor Hospital

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07541170

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项III期试验，比较Divarasib与免疫治疗或观察用于II-III期KRAS G12C突变非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer
干预: Divarasib，Pembrolizumab，Nivolumab
地点: 未列出
申办方: Hoffmann-La Roche

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07625644

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

AI 简述这是一项III期试验，比较BL-M14D1联合阿替利珠单抗与标准治疗用于广泛期小细胞肺癌一线治疗。

?

适用疾病: Small Cell Lung Cancer Extensive Stage；Small-cell Lung Cancer；Small Cell Carcinoma
干预: BL-M14D1 and Atezolizumab，Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
地点: 未列出
申办方: SystImmune Inc.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07633873

SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

AI 简述这是一项III期试验，比较SYS6010联合Enlonstobart与免疫加铂类化疗用于PD-L1阳性非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: SYS6010 injection，Enlonstobart injection，Tislelizumab injection，Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07637513

Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

AI 简述这是一项III期试验，比较Tarlatamab联合Durvalumab与Durvalumab单用用于局限期小细胞肺癌。

?

适用疾病: Limited Stage Small-Cell Lung Cancer
干预: Tarlatamab，Durvalumab
地点: 未列出
申办方: PrECOG, LLC.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07672223

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项III期试验，研究SYS6010联合抗PD-(L)-1单抗用于非小细胞肺癌辅助治疗。

?

适用疾病: Non-small Cell Lung Cancer
干预: SYS6010，Enlonstobart，Tislelizumab，Toripalimab ±+platinum-based doublet chemotherapy
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物放疗

ClinicalTrials.gov NCT06672133

Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC

AI 简述这是一项III期试验，研究Adebrelimab联合化疗和放疗用于广泛期小细胞肺癌的一线治疗。

?

适用疾病: Extensive Stage Lung Small Cell Carcinoma
干预: Adebrelimab，Radiation Therapy
地点: 未列出
申办方: Jinming Yu

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07162883

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项3期试验，比较QL2107与Keytruda用于非小细胞肺癌辅助治疗。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: QL2107，Keytruda®
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

暂时不招募 Phase 1

NCI NCT02321501 / NCI-2015-00062

Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究Ceritinib和Everolimus用于局部晚期或转移性实体瘤或IIIB-IV期非小细胞肺癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage IV Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT03392064 / NCI-2018-01009

A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

AI 简述这是一项I期试验，研究AMG 119用于复发难治性小细胞肺癌。

?

适用疾病: Refractory Lung Small Cell Carcinoma；Recurrent Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Amgen, Inc.

暂时不招募 Phase 2

NCI NCT03110978 / NCI-2018-01212

Stereotactic Body Radiation Therapy with or without Nivolumab in Treating Patients with Stage I-IIA or Recurrent Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究立体定向放疗联合或不联合Nivolumab用于早期非小细胞肺癌。

?

适用疾病: Non-Small Cell Squamous Lung Cancer；Stage I Lung Cancer；Stage IA1 Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募 Phase 1

NCI NCT04266730 / NCI-2020-04787

Personalized Vaccine (PANDA-VAC) and Pembrolizumab for the Treatment of Squamous Cell Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

AI 简述这是一项I期试验，研究个体化疫苗PANDA-VAC联合帕博利珠单抗用于鳞状非小细胞肺癌或鳞状头颈癌。

?

适用疾病: Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer；Recurrent Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

暂时不招募 Phase 1

NCI NCT04418167 / NCI-2020-06750

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

AI 简述这是一项I期试验，研究JSI-1187-01单药或联合Dabrafenib用于MAPK通路突变的晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: JS InnoPharm, LLC

暂时不招募 Phase 2

NCI NCT04701307 / NCI-2020-13698

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

AI 简述这是一项II期试验，研究Niraparib和Dostarlimab用于小细胞肺癌及其他高级别神经内分泌癌。

?

适用疾病: Stage III Lung Cancer；Stage IIIA Lung Cancer；Stage IIIB Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT04837716 / NCI-2021-02560

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

AI 简述这是一项I期试验，研究Ensartinib联合化疗用于ALK阳性IIIC期或IV期非小细胞肺癌。

?

适用疾病: Stage IIIC Lung Cancer；Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT04585477 / NCI-2021-03445

Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease

AI 简述这是一项II期试验，研究Durvalumab用于IA2-III期NSCLC伴微小残留病灶，在美国开展。

?

适用疾病: Stage IA2 Lung Cancer；Stage IA3 Lung Cancer；Stage IB Lung Cancer
干预: 未列出
地点: United States
申办方: Stanford Cancer Institute Palo Alto

暂时不招募 Phase 2

NCI NCT05337735 / NCI-2022-02841

Vudalimab for the Treatment of Advanced Rare Cancers

AI 简述这是一项II期试验，研究Vudalimab用于多种晚期罕见癌症。在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT05642195 / NCI-2022-10532

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究癌症裂解物疫苗联合Montanide ISA-51 VG加或不加IL-15超级激动剂N-803，作为PD-L1阴性非小细胞肺癌的辅助治疗，在美国开展。

?

适用疾病: Stage IB Lung Cancer；Stage II Lung Cancer；Stage IIA Lung Cancer
干预: 未列出
地点: United States
申办方: National Cancer Institute

暂时不招募 Phase 1

NCI NCT05958199 / NCI-2023-06569

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

AI 简述这是一项I期试验，研究NPX267用于表达HHLA2/B7-H7的实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT06237881 / NCI-2024-00734

KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

AI 简述这是一项1/2期试验，研究KSQ-001EX用于晚期黑色素瘤、复发非小细胞肺癌或复发头颈部鳞癌。

?

适用疾病: Recurrent Head and Neck Squamous Cell Cancer；Stage IV Cutaneous (Skin) Melanoma；Stage IIIC Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募阶段未标明

NCI NCT07655583 / NCI-2026-04559

Removing Radiation Therapy from the Treatment of Brain Metastases in Patients with Melanoma or Non-small Cell Lung Cancer who are Receiving CNS-Active Systemic Therapy after Resection, OBSERVE Trial

AI 简述这是一项观察性试验，探索在脑转移切除术后取消放疗，用于黑色素瘤或非小细胞肺癌。

?

适用疾病: Stage IV Lung Cancer；Metastatic Lung Non-Small Cell Carcinoma；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

即将招募阶段未标明放疗

ClinicalTrials.gov NCT05998993

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

AI 简述这是一项试验，研究立体定向放射治疗用于EGFR突变非小细胞肺癌患者接受奥希替尼治疗，在哥伦比亚开展。

?

适用疾病: EGF-R Positive Non-Small Cell Lung Cancer；Non Small Cell Lung Cancer；EGFR Exon 19 Deletion
干预: Stereotactic Body Radiation Therapy SBRT
地点: Colombia
申办方: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo

即将招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT06067776

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

AI 简述这是一项I期试验，研究Osimertinib、Cetuximab和Tucatinib用于EGFR突变晚期或复发性非小细胞肺癌。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8
干预: Cetuximab，Osimertinib，Tucatinib
地点: United States
申办方: Jonathan Riess

即将招募 Phase 1 手术/操作

ClinicalTrials.gov NCT06602661

Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy

AI 简述这是一项I期试验，比较加强与非加强钉合线用于无裂肺叶切除术，在加拿大开展。

?

适用疾病: Lung；Lung Adenocarcinoma；Lung Adenosquamous Carcinoma
干预: Fissureless Lobectomy with Reinforced Staple Lines，Fissureless Lobectomy with Non-Reinforced Staple Lines
地点: Canada
申办方: Surrey Thoracic Surgery Group

即将招募 Phase 1 放疗

ClinicalTrials.gov NCT06622174

Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

AI 简述这是一项I期试验，在加拿大研究脉冲放疗用于克服转移性肺癌的免疫逃逸。

?

适用疾病: Non Small Cell Lung Cancer；Metastatic Lung Cancer
干预: Pulse radiotherapy
地点: Canada
申办方: Houda Bahig

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06646770

SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)

AI 简述这是一项NA期试验，比较肺段切除术与肺叶切除术用于T1C非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Segmentectomy，Lobectomy
地点: Turkey (Türkiye)
申办方: Istanbul University - Cerrahpasa

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06679712

Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA

AI 简述一项经支气管光动力疗法肿瘤消融试验，用于非小细胞肺癌或肺转移瘤。

?

适用疾病: Lung Cancer - Non Small Cell；Lung Metastases From Any Primary
干预: Transbronchial PDT lung tumor ablation
地点: Taiwan
申办方: Taoyuan General Hospital

即将招募 Phase 1 其他手术/操作

ClinicalTrials.gov NCT06743555

Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study

AI 简述这是一项I期试验，评估局部晚期可手术肺癌在确认疾病存在后的手术策略。

?

适用疾病: Non-Small Cell Lung Cancer；Immunotherapy；Neoadjuvant Therapy
干预: Observation without surgery，Standard-of-care surgery
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

即将招募阶段未标明药物

ClinicalTrials.gov NCT06743581

Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

AI 简述这是一项I/II期试验，研究新辅助Cemiplimab和Dupilumab用于早期非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；Immunotherapy；Neoadjuvant Therapy
干预: Cemiplimab，Dupilumab
地点: Canada
申办方: Centre hospitalier de l'Université de Montréal (CHUM)

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06934590

Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

AI 简述这是一项I期试验，研究RX001用于KRAS突变晚期非小细胞肺癌，在韩国开展。

?

适用疾病: Non-Small Cell Lung Cancer
干预: RX001
地点: South Korea
申办方: GeneCraft Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07382726

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

AI 简述这是一项I期试验，在美国开展，研究Izalontamab Brengitecan联合Adagrasib用于非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer
干预: Adagrasib，Iza-bren
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募阶段未标明手术/操作放疗

ClinicalTrials.gov NCT07432802

Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer

AI 简述这是一项试验，比较楔形切除与立体定向放疗用于高风险早期肺癌。在丹麦开展。

?

适用疾病: Lung Cancer (NSCLC)
干预: Stereotactic radiation therapy intervention，Surgical intervention
地点: Denmark
申办方: Aarhus University Hospital

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07488923

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

AI 简述这是一项I期试验，研究ML261（CAR-T细胞疗法）用于复发/难治性小细胞肺癌或神经内分泌癌，在美国开展。

?

适用疾病: Small Cell Lung Cancer (SCLC )；Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)；Gastroenteropancreatic NEC (GEP NEC)
干预: ML261
地点: United States
申办方: Moonlight Bio, Inc

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07509034

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

AI 简述这是一项I期试验，研究B7-H3 CAR-T细胞用于复发性或难治性广泛期小细胞肺癌。

?

适用疾病: Extensive-Stage Small Cell Lung Cancer；Extrapulmonary Neuroendocrine Carcinoma；Recurrent or Refractory
干预: Autologous B7-H3 CAR T，Cyclophosphamide，Fludarabine
地点: United States
申办方: National Cancer Institute (NCI)

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07545954

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

AI 简述这是一项I期试验，研究DSP-0390联合Atezolizumab用于广泛期小细胞肺癌。

?

适用疾病: Small-cell Lung Cancer；Small Cell Lung Cancer Extensive Stage
干预: DSP-0390，Atezolizumab
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 1 生物制剂手术/操作放疗

ClinicalTrials.gov NCT07619599

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

AI 简述这是一项I期试验，研究PET显像剂64Cu-DOTA-Pembrolizumab用于评估IV期非小细胞肺癌接受Pembrolizumab的治疗反应。

?

适用疾病: Metastatic Lung Non-Small Cell Carcinoma；Metastatic Malignant Neoplasm in the Brain；Oligoprogressive Lung Non-Small Cell Carcinoma
干预: Computed Tomography，Copper Cu 64-DOTA-pembrolizumab，Low Dose Radiation Therapy，Pembrolizumab
地点: United States
申办方: City of Hope Medical Center

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07631299

Nebulized AER101 in Pre-op NSCLC

AI 简述这是一项早期I期试验，在美国研究雾化AER101用于术前I-II期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer Stage I；Non-small Cell Lung Cancer Stage II
干预: AER101
地点: United States
申办方: University of Oklahoma

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07650357

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

AI 简述这是一项1期试验，研究CLSP-5282用于HLA-A*03:01阳性晚期实体瘤。在美国开展。

?

适用疾病: Advanced Solid Tumor；Non Small Cell Lung Cancer；Pancreatic Carcinoma
干预: CLSP-5282
地点: United States
申办方: Clasp Therapeutics, Inc.

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07675876

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

AI 简述这是一项1期试验，在美国研究Cromolyn Sodium吸入用于局部晚期非小细胞肺癌。

?

适用疾病: Locally Advanced Non-Small Cell Lung Cancer；Lung Adenocarcinoma
干预: Cromolyn Sodium
地点: United States
申办方: Carcinex Inc

即将招募 Phase 2 药物

ClinicalTrials.gov NCT04153734

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

AI 简述这是一项II期试验，研究帕博利珠单抗联合铂类双药治疗PD-L1≥50%的局部晚期非小细胞肺癌。

?

适用疾病: Locally Advanced Non-small Cell Lung Cancer
干预: Pembrolizumab，Cis Platinum，Carboplatin，Pemetrexed
地点: 未列出
申办方: Kobe Minimally Invasive Cancer Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05275374

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

AI 简述这是一项I/II期试验，研究XP-102单药或联合Trametinib用于BRAF V600突变晚期实体瘤。

?

适用疾病: Cancer；BRAF V600 Mutation；Melanoma
干预: XP-102，Trametinib
地点: 未列出
申办方: Xynomic Pharmaceuticals, Inc.

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05393466

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

AI 简述这是一项I/II期试验，研究BPI-361175用于晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Carcinoma
干预: BPI-361175
地点: 未列出
申办方: Xcovery Holdings, Inc.

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05503888

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

AI 简述这是一项Ib/II期试验，研究Almonertinib联合SHR-1701用于复发或晚期非小细胞肺癌。

?

适用疾病: Relapsed or Advanced Non-small Cell Lung Cancer
干预: Almonertinib combined with SHR-1701，Almonertinib
地点: 未列出
申办方: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT05548504

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

AI 简述一项II期试验，研究异构低分割放疗用于局部晚期非小细胞肺癌。

?

适用疾病: Non-small Cell Lung Cancer Stage III；Radiotherapy Side Effect；Frailty
干预: Photon，Proton
地点: 未列出
申办方: Odense University Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06018688

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

AI 简述这是一项II期试验，研究奥希替尼联合阿司匹林新辅助治疗用于可切除EGFR突变非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；EGFR Gene Mutation
干预: Osimertinib，Aspirin
地点: 未列出
申办方: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT06202690

SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC

AI 简述这是一项比较单孔机器人辅助與单孔胸腔鏡肺切除術用于非小细胞肺癌的试验。

?

适用疾病: Robotics；Lung Cancer
干预: Single-port robotic-assisted thoracic surgery，Single-port video-assisted thoracoscopic surgery
地点: 未列出
申办方: Korea University Guro Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06218940

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

AI 简述这是一项I期试验，研究HY1272用于局部晚期或转移性实体瘤或EGFRm+非小细胞肺癌。

?

适用疾病: NSCLC Stage IV
干预: HY1272
地点: 未列出
申办方: Newsoara Biopharma Co., Ltd.

即将招募 Phase 4 药物

ClinicalTrials.gov NCT06276933

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

AI 简述这是一项IV期试验，研究Camrelizumab联合化疗±沙利度胺用于晚期非小细胞肺癌。

?

适用疾病: Lung Cancer；Camrelizumab
干预: Camrelizumab + chemotherapy+Thalidomide，Camrelizumab + chemotherapy+placebo
地点: 未列出
申办方: Tongji University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06299371

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

AI 简述这是一项II期试验，研究阿得贝利单抗联合化疗用于可手术驱动基因突变非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Adebrelimab，paclitaxel for injection (albumin bound)，Cisplatin or Carboplatin
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06319950

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

AI 简述这是一项II期试验，比较高剂量Furmonertinib与Osimertinib用于EGFR突变非小细胞肺癌伴脑转移。

?

适用疾病: Lung Cancer, Nonsmall Cell
干预: Furmonertinib，Osimertinib
地点: 未列出
申办方: Taizhou Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06336954

Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure

AI 简述这是一项II期试验，研究Adibelimab联合法米替尼和化疗用于PD-1抑制剂失败后的晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Adibelimab
地点: 未列出
申办方: Second Affiliated Hospital of Xi'an Jiaotong University

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06434740

A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

AI 简述这是一项II期试验，研究SBRT联合Puterizumab用于非小细胞肺癌肺内转移。

?

适用疾病: Non-Small-Cell Lung Cancer
干预: Stereotactic Body Radiation Therapy，SBRT，Puterizumab
地点: 未列出
申办方: Sir Run Run Shaw Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06436144

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

AI 简述这是一项II期试验，研究奥希替尼联合依托泊苷用于EGFR突变非小细胞肺癌一线治疗。

?

适用疾病: Non Small Cell Lung Cancer；EGFR Gene Mutation；Non Small Cell Lung Cancer Stage IIIB
干预: Osimertinib
地点: 未列出
申办方: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

即将招募阶段未标明药物

ClinicalTrials.gov NCT06462105

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

AI 简述这是一项试验，研究脂质体伊立替康联合方案用于小细胞肺癌一线治疗。

?

适用疾病: Small Cell Lung Cancer
干预: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
地点: 未列出
申办方: Zhou Chengzhi

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06525350

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究Glumetinib联合白蛋白结合型多西他赛对比多西他赛用于MET过表达的非小细胞肺癌。

?

适用疾病: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
干预: Glumetinib tablets，HB1801 (docetaxel, albumin-bound），Docetaxel
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06530719

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

AI 简述这是一项II期试验，评估Osimertinib用于EGFR敏感突变非小细胞肺癌术后辅助靶向治疗后进展的患者。

?

适用疾病: Lung Neoplasms；Lung Cancer, Nonsmall Cell
干预: Osimertinib mesylate
地点: 未列出
申办方: Jin Ying

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06554535

Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Serplulimab联合化疗和阿司匹林用于未经治疗的广泛期小细胞肺癌。

?

适用疾病: Extensive-Stage Small Cell Lung Cancer；Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer；ECOG Performance Status Score of 0 or 1
干预: Serplulimab，Platinum-based Chemotherapy，Aspirin
地点: 未列出
申办方: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06557096

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

AI 简述这是一项早期I期试验，研究脑脊液CTC指导奥希替尼联合贝伐珠单抗用于EGFR突变晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Circulating Tumor Cell；EGF-R Positive Non-Small Cell Lung Cancer
干预: Osimertinib 80 MG，Bevacizumab
地点: 未列出
申办方: Second Affiliated Hospital of Nanchang University

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06597513

Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC

AI 简述这是一项I/II期试验，研究自体干细胞移植支持下剂量密集化疗联合Adebrelimab用于广泛期小细胞肺癌。

?

适用疾病: Extensive Stage Small Cell Lung Cancer
干预: auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab
地点: 未列出
申办方: Zhou Chengzhi

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06614621

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究阿得贝利单抗联合化疗一线治疗广泛期小细胞肺癌。

?

适用疾病: Extensive-Stage Small Cell Lung Cancer
干预: Adebrelimab +Etoposide+Platinum-based drugs，Maintenance treatment period:
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06652529

Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AROG4-01用于晚期实体瘤。

?

适用疾病: Solid Tumors (Phase 1)；Mesothelioma；Colorectal Carcinoma
干预: AROG4-01，AROG4-01
地点: 未列出
申办方: Aromics Therapeutics

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06672068

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

AI 简述这是一项II期试验，研究TY-9591联合化疗一线治疗EGFR突变非小细胞肺癌。

?

适用疾病: NSCLC
干预: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin，TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
地点: 未列出
申办方: TYK Medicines, Inc

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06747169

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

AI 简述这是一项II期试验，研究信迪利单抗联合Nab-PP及重组人血管内皮抑制素用于鳞状非小细胞肺癌。

?

适用疾病: Squamous Non-Small Cell Lung Cancer SqNSCLC
干预: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
地点: 未列出
申办方: Jian-Guo Zhou, MD, PhD

即将招募 Phase 1 药物放疗

ClinicalTrials.gov NCT06760676

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

AI 简述这是一项I期试验，研究QL-1706联合脉冲低剂量放疗用于食管癌、非小细胞肺癌、宫颈癌。

?

适用疾病: Esophageal Cancer；Non Small Cell Lung Cancer；Cervical Cancer
干预: Pulsed low dose rate radiotherapy (PLDR)，Alpaloritovorelli antibodies
地点: 未列出
申办方: Anhui Provincial Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06851169

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

AI 简述这是一项II期试验，研究Benmelstobart单药或联合Anlotinib术前治疗用于非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib)，Cohort 2: Neoadjuvant therapy (benmelstobart only)
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06882174

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

AI 简述这是一项II期试验，比较上午与随机时间输注帕博利珠单抗用于转移性非小细胞肺癌。

?

适用疾病: Metastatic Non Small Cell Lung Cancer
干预: Scheduling of the time of pembrolizumab infusions
地点: 未列出
申办方: AHS Cancer Control Alberta

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06908733

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

AI 简述这是一项II期试验，研究替雷利珠单抗联合化疗转化治疗后整合手术和放疗用于III期N2非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer (Stage III)
干预: 3-4 cycles of Tislelizumab combined with platinum-based chemotherapy, evaluated by MDT and assigned to treatment strategies based on eligibility and patient preference.
地点: 未列出
申办方: Liaoning Cancer Hospital & Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06918782

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

AI 简述这是一项II期试验，观察奥希替尼联合双药化疗用于预后不良的EGFR突变转移性肺腺癌。

?

适用疾病: Lung Cancer (NSCLC)
干预: Osimertinib plus platinum doublet chemotherapy
地点: 未列出
申办方: The University of Hong Kong

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06925048

SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

AI 简述这是一项II期试验，研究SHR0302联合PD-1/PD-L1抑制剂用于NSCLC。

?

适用疾病: Non-Small Cell Lung Cancer；JAK Inhibitor；Immunology
干预: PD-1 inhbitor+SHR0302，PD-L1 inhibitor+SHR0302
地点: 未列出
申办方: Chunxia Su

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06971406

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

AI 简述这是一项II期试验，研究高剂量Firmonertinib联合贝伐珠单抗和鞘内注射培美曲塞用于EGFR突变非小细胞肺癌伴脑膜转移。

?

适用疾病: Non Small Cell Lung Cancer；EGFR Mutation；Leptomeningeal Metastases
干预: Combination therapy prospective cohort
地点: 未列出
申办方: Qiming Wang

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06978153

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Benmelstobart联合化疗加或不加安罗替尼用于可切除局限期小细胞肺癌。

?

适用疾病: Limited Stage Small Cell Lung Cancer
干预: benmelstobart combined with chemotherapy and anlotinib，benmelstobart combined with chemotherapy
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 1 手术/操作放疗

ClinicalTrials.gov NCT06982222

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

AI 简述这是一项I期试验，研究Sn-117m-DTPA用于晚期骨转移癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Positron Emission Tomography
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07014215

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

AI 简述这是一项II期试验，研究信迪利单抗联合贝伐珠单抗和tafolecimab用于抗PD-1/L1治疗后进展的晚期非小细胞肺癌。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；Resistance to Immunotherapy
干预: Sintilimab combined with Bevacizumab and tafolecimab
地点: 未列出
申办方: Anhui Provincial Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07022301

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

AI 简述这是一项II期试验，研究Sintilimab联合Anlotinib用于抗PD-1/L1治疗进展后的广泛期小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer Extensive Stage；Resistance to Immunotherapy
干预: sintilimab combined with anlotinib
地点: 未列出
申办方: First Affiliated Hospital of Wannan Medical College

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07043907

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

AI 简述这是一项II期试验，研究PANK-003细胞注射联合标准辅助化疗用于IIIA期非小细胞肺癌术后。

?

适用疾病: Stage IIIA Non-small Cell Lung Cancer
干预: PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy
地点: 未列出
申办方: Shenzhen Celconta Life Science Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07069270

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

AI 简述这是一项II期试验，研究阿得贝利单抗和Vunakizumab联合化疗用于小细胞肺癌一线治疗。

?

适用疾病: Vunakizumab；Adebrelimab；Small Cell Lung Cancer
干预: Vunakizumab (IL-17A inhibitor)，Adebrelimab，Chemotherapy
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07083687

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

AI 简述这是一项II期试验，研究Lorlatinib用于ROS1阳性非小细胞肺癌伴脑转移。

?

适用疾病: Lung Cancer (NSCLC)
干预: Lorlatinib 100 mg
地点: 未列出
申办方: Hunan Cancer Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07110363

A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer

AI 简述这是一项I期试验，研究BT02用于晚期肺癌等多种实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Advanced Lung Cancer；Non-Small Cell Lung Cancer
干预: BT02
地点: 未列出
申办方: Biotroy Therapeutics

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07139041

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

AI 简述这是一项II期试验，研究Iparomlimab和Tuvonralimab联合化疗用于初始不可切除的III期非小细胞肺癌。

?

适用疾病: NSCLC (Non-small-cell Lung Cancer)
干预: Iparomlimab and tuvonralimab plus chemotherapy
地点: 未列出
申办方: Chang Chen

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07177092

Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究原发灶切除加奥希替尼用于EGFR突变非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer；EGFR
干预: Surgery，Osimertinib
地点: 未列出
申办方: Jianxing He

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07177105

Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC

AI 简述这是一项II期试验，研究原发灶切除联合信迪利单抗和化疗用于晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Cytoreductive surgery，Immunochemotherapy
地点: 未列出
申办方: Jianxing He

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07190027

Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial

AI 简述这是一项I/II期试验，研究免疫动力学指导的个体化免疫化疗用于晚期驱动基因阴性非小细胞肺癌。

?

适用疾病: Advanced Non-Small Cell Lung Cancer (NSCLC)
干预: Arm 1： Standard Synchronous Group，Arm 2：Fixed Delay Group，Arm 3： Individualized Delay Group
地点: 未列出
申办方: First Affiliated Hospital of Wenzhou Medical University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07197008

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

AI 简述这是一项II期试验，研究Sacituzumab Tirumotecan联合贝伐珠单抗用于EGFR突变非小细胞肺癌伴脑转移。

?

适用疾病: Lung Cancer
干预: Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
地点: 未列出
申办方: Li-kun Chen

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07256509

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

AI 简述这是一项2期试验，比较SYS6010联合奥希替尼与奥希替尼单药用于EGFR突变可切除非鳞非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: SYS6010，Osimertinib，Pemetrexed，Cisplatin
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07271602

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

AI 简述这是一项II期试验，研究QL1706联合化疗及Quad Shot用于驱动基因阴性晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer；Immunotherapy；Radiotherapy
干预: Quad shot，Chemotherapy，Immune Checkpoint Inhibitors
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 联合产品药物

ClinicalTrials.gov NCT07274384

Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial

AI 简述这是一项II期试验，研究化疗联合Cemiplimab用于PD-L1≥50%且出现超进展的NSCLC。

?

适用疾病: NSCLC (Non-small Cell Lung Cancer)；Hyperprogression
干预: chemotherapy plus cemiplimab，Cemiplimab
地点: 未列出
申办方: Università Vita-Salute San Raffaele

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07289048

A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression

AI 简述这是一项II期试验，研究IBI363用于广泛期小细胞肺癌免疫治疗进展后。

?

适用疾病: SCLC,Extensive Stage
干预: IBI363（PD-1/IL-2a-bias）
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07327736

Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT

AI 简述这是一项多中心随机对照试验，比较非插管与插管方式用于早期小细胞肺癌手术。

?

适用疾病: Patients With Suspected Non-small Cell Lung Cancer (NSCLC) at Clinical Stage T1
干预: Non-intubated video-assisted thoracic surgery with spontaneous breathing (NIVATS)
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07349225

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Iparomlimab和Tuvonralimab联合化疗及放疗用于广泛期小细胞肺癌。

?

适用疾病: ES-SCLC
干预: Iparomlimab and Tuvonralimab Injection，Etoposide，Cisplatin，Targeted Radiation Therapy
地点: 未列出
申办方: The Second Affiliated Hospital of Dalian Medical University

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07351565

Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究化疗联合Pitavastatin用于难治性非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: Pitavastatin 1 mg daily or 4 mg daily
地点: 未列出
申办方: Chang Chen

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07358884

First in Human Study of QLS5316 in Solid Tumors

AI 简述这是一项I期试验，研究QLS5316用于多种实体瘤。

?

适用疾病: Solid Tumors；Colorectal Cancer；Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
干预: QLS5316
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07360743

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

AI 简述这是一项II期试验，研究帕博利珠单抗或西米普利单抗单药用于高PD-L1表达的晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer (Squamous or Non Squamous)
干预: Pembrolizumab，Cemiplimab
地点: 未列出
申办方: UNICANCER

即将招募 Phase 2 生物制剂手术/操作

ClinicalTrials.gov NCT07393555

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

AI 简述这是一项II期试验，研究Ivonescimab用于晚期非小细胞肺癌。

?

适用疾病: Recurrent Lung Non-Small Cell Carcinoma；Stage IV Lung Cancer AJCC v8
干预: Biospecimen Collection，Computed Tomography，Ivonescimab，Magnetic Resonance Imaging
地点: 未列出
申办方: SWOG Cancer Research Network

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07423117

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

AI 简述这是一项I期试验，研究ITC-6146RO用于标准治疗失败的晚期或转移性实体瘤。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Non-small Cell Lung Cancer；Triple Negative Breast Cancer
干预: ITC-6146RO
地点: 未列出
申办方: IntoCell, Inc

即将招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT07432984

Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC

AI 简述这是一项II期试验，研究粪菌移植联合Tislelizumab用于晚期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Tislelizumab，Fecal Microbiota Transplant(FMT)
地点: 未列出
申办方: Se-Hoon Lee

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07435038

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

AI 简述这是一项I/II期试验，研究BPI-572270用于RAS突变晚期实体瘤，包括非小细胞肺癌、结直肠癌等。

?

适用疾病: Non-small Cell Lung Cancer (NSCLC)；Colorectal Cancer (CRC)；Pancreatic Ductal Adenocarcinoma (PDAC)
干预: BPI-572270
地点: 未列出
申办方: Betta Pharmaceuticals Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07452224

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究ILKN421H联合Pembrolizumab用于晚期非小细胞肺癌。

?

适用疾病: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
干预: ILKN421H，Pembrolizumab
地点: 未列出
申办方: iLeukon Therapeutics, Inc.

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07453394

QLS5132 Combination Therapy in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究QLS5132联合治疗用于多种晚期实体瘤。

?

适用疾病: Gastric Cancer (GC)；Non-small Cell Lung Cancer (NSCLC)；Endometrial Cancer
干预: QLS5132; Bevacizumab，QLS5132; Platinum; Bevacizumab，QLS5132; Olaparib; Bevacizumab，QLS5132; QL1706; QL2107
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT07458919

Therapy for Advanced NSCLC With EGFR 19delins Mutation

AI 简述这是一项早期I期试验，研究埃克替尼或吉非替尼用于EGFR 19delins突变晚期肺癌。

?

适用疾病: Lung Cancer
干预: Icotinib/Gefitinib
地点: 未列出
申办方: Fuzhou General Hospital

即将招募阶段未标明放疗

ClinicalTrials.gov NCT07462728

Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer

AI 简述这是一项III期试验，研究三维放疗用于非寡转移IV期非小细胞肺癌。

?

适用疾病: Non Small Cell Lung Cancer Metastatic；Radiotherapy
干预: Three-Dimensional Radiotherapy for Primary lungTumors
地点: 未列出
申办方: Guizhou Medical University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07465757

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

AI 简述这是一项II期试验，研究Alisertib联合Paclitaxel用于小细胞肺癌。

?

适用疾病: Small Cell Lung Cancer ( SCLC )
干预: Alisertib，Alisertib，Alisertib，Alisertib
地点: 未列出
申办方: Puma Biotechnology, Inc.

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07482605

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

AI 简述这是一项II期试验，研究Furmonertinib联合胸部放疗用于EGFR+非小细胞肺癌伴恶性胸腔积液。

?

适用疾病: Lung Cancer (NSCLC)；Malignant Pleural Effusions (Mpe)- Pleurodesis
干预: Furmonertinib，Thoracic Radiotherapy (TRT)
地点: 未列出
申办方: Jiangmen Central Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07495098

Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer

AI 简述这是一项I期试验，研究瘤内注射cisplatin用于IV期肺癌。

?

适用疾病: Lung Cancer Metastatic；Lung Cancer (NSCLC)
干预: cisplatin (cis-diamminedichloroplatinum(II) (CDDP))
地点: 未列出
申办方: University of Vermont

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07507188

Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

AI 简述这是一项II期试验，研究Amivantamab联合Lazertinib或化疗用于EGFR突变肺癌。

?

适用疾病: Non Small Cell Lung Cancer
干预: Amivantamab SC + Lazertinib PO，Amivantamab SC + Chemotherapy (Carboplatin IV & Pemetrexed IV)
地点: 未列出
申办方: Yonsei University

即将招募 Phase 1 放疗

ClinicalTrials.gov NCT07523464

Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC

AI 简述这是一项I期试验，研究中央限制性8Gy/1f放疗后同步放化疗用于不可切除的III期非小细胞肺癌。

?

适用疾病: Locally-Advanced Non-Small Cell Lung Cancer；Radiotherapy
干预: Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent Chemoradiotherapy
地点: 未列出
申办方: Anhui Provincial Hospital

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07538258

Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Benmelstobart联合安罗替尼、化疗和胸部放疗用于局限期小细胞肺癌。

?

适用疾病: Limited-stage Small Cell Lung Cancer (LS-SCLC)
干预: Benmelstobart，Anlotinib，Cisplatin or carboplatin，Etoposide
地点: 未列出
申办方: Yayi He

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07538271

A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究Benmelstobart、安罗替尼、化疗和胸部放疗用于广泛期小细胞肺癌。

?

适用疾病: SCLC, Extensive Stage
干预: benmelstobart，Anlotinib，Carboplatin or cisplatin，Etoposide
地点: 未列出
申办方: Yayi He

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07542704

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究KQB368单药用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumors；Colorectal Cancer (CRC)；Non-Small Cell Lung Cancer
干预: KQB368
地点: 未列出
申办方: Kumquat Biosciences Inc.

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07551778

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究异体NK细胞联合标准维持治疗用于晚期非小细胞肺癌、结直肠癌等实体瘤。

?

适用疾病: NSCLC (Advanced Non-small Cell Lung Cancer)；Colorectal Cancer；Advanced Solid Tumors
干预: NK Cells，NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy，NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
地点: 未列出
申办方: BOE Technology Group Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07573696

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

AI 简述这是一项II期试验，研究新辅助阿来替尼联合化疗后多学科决策用于III期ALK+非小细胞肺癌。

?

适用疾病: Nonsmall Cell Lung Cancer Stage III
干预: After neoadjuvant alpelisib combined with chemotherapy, a multidisciplinary decision was made
地点: 未列出
申办方: Wen-zhao ZHONG

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07574684

Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC

AI 简述这是一项II期试验，研究Alpha Lipoic Acid用于晚期非小细胞肺癌。

?

适用疾病: Advanced Non Small Cell Lung Cancer (NSCLC)
干预: Alpha Lipoic Acid 600mg
地点: 未列出
申办方: Ain Shams University

即将招募 Phase 2 生物制剂

ClinicalTrials.gov NCT07597070

Universal Immunization to Fortify Immunotherapy Efficacy and Response

AI 简述这是一项II期试验，研究Pfizer mRNA新冠疫苗用于IV期非小细胞肺癌。

?

适用疾病: Stage 4 NSCLC
干预: Pfizer-BioNTech mRNA COVID-19 vaccine
地点: 未列出
申办方: University of Florida

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07617337

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究AQUA07用于ALK阳性非小细胞肺癌。

?

适用疾病: ALK Positive Non-small Cell Lung Cancer
干预: AQUA07，Lorlatinib
地点: 未列出
申办方: Chugai Pharmaceutical

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07623369

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究HH160用于晚期实体瘤。

?

适用疾病: Solid Tumor；Non-small Cell Lung Cancer；Hepatocellular Carcinoma
干预: HH160
地点: 未列出
申办方: Huahui Health

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07631884

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

AI 简述这是一项II期试验，研究Trastuzumab Rezetecan用于HER2表达晚期实体瘤。

?

适用疾病: Solid Tumors；Neoplasms (Cancer / Tumors)；Advanced Malignant Solid Neoplasm
干预: Trastuzumab Rezetecan
地点: 未列出
申办方: Haihua Yuan

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07632209

Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment

AI 简述这是一项II期试验，研究Lomustine联合Anlotinib用于二线以上耐药的广泛期小细胞肺癌。

?

适用疾病: SCLC, Extensive Stage
干预: Lomustine，Anlotinib
地点: 未列出
申办方: Yayi He

即将招募 Phase 4 生物制剂手术/操作

ClinicalTrials.gov NCT07633613

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

AI 简述这是一项IV期试验，研究Pembrolizumab对非小细胞肺癌和头颈鳞癌患者免疫及肿瘤微环境的影响。

?

适用疾病: Non-Small Cell Lung Carcinoma (NSCLC)；Metastatic Head and Neck Squamous Cell Carcinoma
干预: Blood sampling，Tumor biopsies for biobank establishment (optional)
地点: 未列出
申办方: Centre Antoine Lacassagne

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07659782

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

AI 简述这是一项II期试验，研究VS-7375用于KRAS G12D突变非小细胞肺癌。

?

适用疾病: Non-Small Cell Lung Cancer
干预: VS-7375
地点: 未列出
申办方: Verastem, Inc.

即将招募 Phase 4 药物

ClinicalTrials.gov NCT07671560

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

AI 简述这是一项IV期试验，研究恩沙替尼联合安罗替尼用于洛拉替尼耐药ALK阳性非小细胞肺癌。

?

适用疾病: ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
干预: Combined group of ensatinib and arotinib
地点: 未列出
申办方: Qiming Wang

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07688577

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX501用于转移性非小细胞肺癌和晚期实体瘤。

?

适用疾病: Metastatic NSCLC - Non-Small Cell Lung Cancer；Advanced Solid Tumor
干预: XTX501
地点: 未列出
申办方: Xilio Development, Inc.

暂时不招募 Phase 1

NCI NCT05403723 / NCI-2023-03171

Stereotactic Body Radiotherapy in Combination with Durvalumab, Cisplatin or Carboplatin, and Etoposide for Treatment of Refractory Extensive Stage Small Cell Lung Cancer

AI 简述这是一项I期试验，研究立体定向放疗联合Durvalumab、顺铂/卡铂和依托泊苷用于难治性广泛期小细胞肺癌。

?

适用疾病: Refractory Extensive Stage Lung Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06221462

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究信迪利单抗联合安罗替尼用于IB-IIIB期可切除非小细胞肺癌。

?

适用疾病: Carcinoma, Non-Small-Cell Lung
干预: Sintilimab，Anlotinib
地点: 未列出
申办方: Ningbo No.2 Hospital

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07583550

Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer

AI 简述这是一项II期试验，研究低剂量胸部放疗联合Adebrelimab和化疗用于广泛期小细胞肺癌。

?

适用疾病: Lung；Radiotherapy
干预: Etoposide，Cisplatin，Carboplatin，Adebrelimab
地点: 未列出
申办方: Jiangmen Central Hospital

术语	中文意思	对找临床试验有什么用
非小细胞肺癌 / Non-small cell lung cancer / NSCLC	肺癌中最常见的一大类，和小细胞肺癌在治疗方式、常见基因突变和试验设计上不同。	很多试验会明确只招 NSCLC 患者，或进一步限定 EGFR、ALK、KRAS 等突变状态。
小细胞肺癌 / Small cell lung cancer / SCLC	一种生长较快、治疗路径和非小细胞肺癌不同的肺癌类型。	搜索时通常要单独使用 SCLC 或 small cell lung cancer，不要只搜 lung cancer。
EGFR mutation	EGFR 基因突变是肺癌常见驱动基因之一，常见于部分非小细胞肺癌患者。	可以找 EGFR 靶向药、耐药后治疗、exon 19 deletion、L858R、exon 20 insertion 等相关试验。
ALK rearrangement	ALK 融合或重排是一类肺癌驱动基因改变。	可以找 ALK 抑制剂、耐药后治疗、新一代 ALK 药物等相关试验。
KRAS G12C	KRAS 基因的一种具体突变类型，在部分非小细胞肺癌中出现。	可以找 KRAS G12C 抑制剂、联合治疗或耐药后治疗相关试验。
PD-L1	一种和免疫治疗选择有关的生物标志物，通常由病理或检测报告给出表达水平。	很多免疫治疗试验会要求 PD-L1 表达水平，或按表达水平分层。
转移性肺癌 / metastatic lung cancer	癌症已经扩散到肺以外的远处器官，比如脑、骨、肝、肾上腺等。	很多海外试验会限定 metastatic 或 advanced 患者，需要和影像报告一起确认。
First line	一线治疗，通常指晚期或转移后第一次系统治疗方案。	试验可能要求患者尚未接受过晚期一线治疗，或只接受过特定治疗。
Second line	二线治疗，通常指一线治疗失败、进展或不能耐受后更换的下一套方案。	很多试验会写 after progression on first-line therapy，需要准备既往治疗记录。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

肺癌

当前同步到的治疗类试验